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 i 
Abstract 
 
The liver has a unique connection with the immune system; harbouring vast numbers of 
lymphocytes, able to instigate secondary lymphoid organ-independent naive T cell 
activation, and promoting potent immune tolerance. We set out to determine the effect of 
this unique microenvironment on the biology of CD4+ T cells at three key interaction 
points: following migration into the parenchyma, after short-term hepatocyte contact, and 
at long-term tissue-residency. Modelling transmigration through hepatocytes revealed 
intrinsic, disease-specific cytokine responses in blood-derived CD4+ T cells, not 
discernible through static co-culture. However, short-term co-culture did induce 
activation-independent CD69 upregulation, reliant upon cell-cell contact. This phenotype 
mimicked the similar hepatic CD4+ CD69INT cells that we discovered in liver tissue. Unlike 
CD69HI cells which represented the tissue-resident memory T cells (TRM) of the liver, 
CD69INT cells were the most activated population, likely able to migrate to many liver and 
gut niches, and singularly able to produce IL-4 and IL-10. By contrast, CD69HI TRM 
displayed a resting phenotype, marked for more restricted movement, and produced the 
best multifunctional TH1 responses following stimulation. These data demonstrate the 
importance of studying migration, and provide detailed characterisation of CD69HI TRM 
and novel CD69INT cells, along with their proposed roles and generation pathways. 
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Chapter 1 – Introduction 
  
 2 
1.1 The Biology of T cell responses 
 
Human immunity has evolved as a fluid, dynamic, multifaceted system to cope with a 
seemingly endless array of diverse pathogens1, 2. With effective defence against 
pathogens so intimately linked to survival, development of a highly functional and efficient 
immune system was a critical selection factor. Constant improvements and upgrades 
have been added over the millennia as we co-evolve with pathogens in the constant battle 
for supremacy3. 
 
In principle, immunity of all jawed vertebrates can be split into two main parts: the innate 
and adaptive immune systems. The innate system exists as a series of simple barriers; 
antimicrobial proteins; and cells that recognise conserved pathogenic motifs that will lead 
to the engulfment (phagocytosis) of the pathogen, direct attack of the invader, and/or 
recruitment of further immune cells through the initiation of inflammation. Within this 
response, pathogens are taken up, degraded and transported to lymphoid organs where 
adaptive immunity can be triggered. Adaptive immune cells comprise T and B 
lymphocytes, with the astounding ability to recognise almost any imaginable constituent 
of pathogens in a highly specific manner. Rare antigen-specific T and B cells will respond, 
expand, and traffic to infected areas to provide a potent, focussed response. B cells 
produce antibodies that both mark pathogens for destruction and neutralize toxins; while 
T cells can kill pathogens directly and augment many other vital arms of the immune 
response. Crucially, only adaptive lymphocytes can generate long-term immune memory 
that provides much faster and stronger responses upon future pathogen reencounter, the 
main goal of vaccination. 
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This study focusses on the T cell arm of the immune response, specifically examining 
CD4+ T cells – the so-called orchestrators of adaptive immunity. In the following sections, 
the development of T cells will be briefly discussed, followed by walkthroughs of primary 
and secondary immune responses, alongside the stringent regulatory steps put in place 
at each and every stage. 
 
1.1.1 T cell Development 
 
Following haematopoiesis in the bone marrow, thymic seeding progenitor cells (TSPs) 
traffic to the thymus to begin the maturation process. These multipotent precursors 
express neither CD8 nor CD4 (CD – cluster of differentiation), and are thus referred to as 
double negative (DN). DN cells destined to become conventional T cells upregulate 
recombination-activating genes (RAG) -1 and -2 to allow rearrangements of the T cell 
receptor (TCR)-b chain as they migrate through the thymic cortex4. Productive 
rearrangements are then tested with an invariant TCR-a partner and CD3 signalling 
machinery. Passing this test allows a T cell to survive, proliferate and the daughter cells 
to upregulate both CD8 and CD4 to become double positive (DP) cells. Here T cells use 
the RAG enzymes to rearrange their TCRa genes. DP cells can then test their fully 
rearranged TCR through interactions with cortical thymic epithelial cells (cTECs) 
expressing self-peptide held in major histocompatibility complex (MHC) molecules, in 
what is called the positive selection process4, 5. The ability of a DP cell to successfully 
recognise antigen-MHC complexes leads to simultaneous downregulation of either CD4 
or CD8 to become a single positive cell (SP). DP cells that recognise antigen held in MHC 
class I become CD8 SP cells; while those that recognize antigen-MHC class II complexes 
become CD4 SP cells6, 7. All cells that fail to bind peptide-MHC die by apoptosis. Surviving 
 4 
SP cells then enter the final stage of thymocyte development – negative selection. This 
process occurs in both the cortex, and medulla, where cTEC, medullary thymic epithelial 
cells (mTEC), as well as dendritic cell (DC) populations display a vast array of self-
peptides (derived from proteins that are expressed all over the body) held in MHC 
complexes. Any SP cells with too high an affinity for self-antigen are either deleted, or 
differentiate into thymus-derived regulatory T cells (tTREGS), a vital inhibitory population7, 
8. This mechanism is termed central tolerance, and is vital for preventing the release of 
potentially autoreactive T cell clones into the periphery. All remaining, now mature, naïve 
T cells then leave the thymus and continually recirculate between the blood and lymphoid 
tissue in search of cognate antigen. 
 
1.1.2 Naïve T cell Activation & Differentiation 
 
Naïve T cell activation (T cell priming) takes place in secondary lymphoid organs (SLOs), 
such as lymph nodes (LNs) and the spleen. Here naïve T cells interact with DCs that have 
engulfed and processed pathogens in the periphery, and display resulting antigens on 
their surface, held in MHC molecules. CD8+ and CD4+ T cells recognise antigens in the 
context of MHC class I, and class II molecules respectively. In order for the linked 
processes of activation, proliferation, and differentiation to occur, a naïve T cell must 
receive three signals - antigen recognition, co-stimulation and cytokine modulation (Fig. 
1.1.1.). Importantly, the nature of the three signal types is principally dependent on the 
type of infection present. All signals are integrated to determine not only the level of 
activation, but the differentiation pathway chosen. This ensures that the output effector 
cell population is best suited to eliminate the pathogen9-13. Following priming, activated 
effector T cells (TEFF) migrate into the periphery and traffic to the site of infection where 
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they either kill the pathogen directly, or use their arsenal of effector cytokines to augment 
other arms of the immune response. 
 
Signal 1 describes the specific recognition of cognate peptide-MHC complexes by the 
TCR. Alongside providing precise specificity to the response, TCR signal strength is also 
an important initial determinant of the magnitude of the response, and the eventual 
differentiation path chosen14, 15. Signal 2 comes from the binding of T cell co-stimulatory 
receptors to co-stimulatory ligands on the DC. CD28 ligation with CD80 and/or CD86 is 
essential in the activation process11, 16-18; yet ligation of many other co-stimulatory 
receptors can also supplement T cell signalling, promote T cell activation and imbue 
differentiation pathway preferences. These include CD2, CD27, and inducible T-cell 
costimulator (ICOS)9, 19. Conversely, negative co-stimulation (co-inhibition) exists to 
regulate these responses. Co-inhibitory receptors such as cytotoxic T-lymphocyte-
associated protein 4 (CTLA-4), programmed cell death protein 1 (PD-1), or lymphocyte 
activation gene 3 (LAG-3) work to dampen or prevent the activation process. It is the net 
sum of these positive costimulatory and negative co-inhibitory signals that determines 
whether a T cell becomes activated or not, and how this balance changes over time 
affects the length and quality of the activation event9. Antigen recognition in the absence 
of sufficient co-stimulation leads to either cell death, or T cell anergy – a functional and 
prolonged state of hyporesponsiveness that requires a supernormal stimulus to reverse20. 
Because only DCs that have encountered pathogens (through innate pattern recognition 
receptors - PRRs) should have upregulated co-stimulatory ligands, signal 2 also acts as 
a barrier to autoantigen responses, and anergy reduces the likelihood of autoreactive T 
cells being activated in future. Finally, signal 3 is provided by the cytokine milieu. DC-
derived cytokines not only promote T cell survival and proliferation, but are instrumental  
! %!
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Figure 1.1.1 -  The three signal model of T cell activation. In order for full activation and differentiation 
to occur, T cells must receive three signals from the antigen-presenting cell (APC). The first is received 
through specific recognition of cognate peptide held in MHC molecules (MHC class I for CD8+ T cells, class 
II for CD4+ T cells). The second is through co-stimulatory molecule binding. The example here shows CD80 
and/or CD86 binding CD28 to give a positive stimulatory signal (+); but many other costimulatory ligand-
receptor pairs exist, including CD70 - CD27, ICOS ligand - ICOS, and CD58 - CD2. Co-inhibitory molecules 
serve to inhibit T cell activation (-) - shown here by CTLA-4 competing for CD80/86 ligation (other ligand-
receptor pairs include PD-L1/2 - PD-1, and putatively MHC class II binding LAG-39). The balance of these 
positive and negative signals determines whether a T cell is activated, or enters a state of 
hyporesponsiveness known as anergy. Last, signal 3 is through cytokine ligation. Cytokines enable T cell 
survival and proliferation (IL-2), or the skewing towards different lineages (see Fig. 1.1.2). IL-12 and IL-4  
promote differentiation into TH1 and TH2  cells respectively. IL-12R - IL-12 receptor, IL-4R - IL-4 receptor. 
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in providing instructional differentiation cues21. Alongside the three signals, priming 
location plays a key role in instructing the final effector cell phenotype, a concept 
discussed further in section 3.1. 
 
Having received sufficient activation signals, T cells proliferate extensively, such that a 
single clone can produce tens of thousands of heterogenous progeny22, 23. Concomitantly, 
T cells undergo characteristic changes in their phenotype, reflective of their activated 
status. Many such activation markers have been described, and among the most 
commonly used are CD69, CD25, CD38 and Human leukocyte antigen – antigen D 
related (HLA-DR)24-26. CD69 is the earliest known activation marker – upregulated within 
2 hours of stimulation27, 28. This molecule is not only likely involved in the inhibition of 
further, excessive, activation29, 30, but in modulation of the LN dwell time in order to allow 
the T cell more time to become fully activated31. CCL19 and CCL21 attract CCR7+ naïve 
T cells to SLOs, whereas sphingosine-1-phosphate (S1P) concentration gradients draw 
these cells back out to the blood through their sphingosine-1-phosphate receptor 1 
(S1PR1) expressions23, 32. Receptor desensitisation of both CCR7 and S1PR1 ensures 
the continued recirculation of naïve T cells through blood and SLOs in the steady state. 
However, this equilibrium is skewed towards longer SLO dwell time by CD69, which 
directly causes the degradation of S1PR131, 33, 34. T cell antigen affinity increases with 
longer LN dwell times, as the higher affinity T cells outcompete the rest to remain in the 
LN for the longest35. With CD69 so critical to our studies, this molecule is discussed in far 
more detail later (sections 1.2, 4.1, & 5.1). Meanwhile, expression of intermediate-term 
activation marker CD25 is seen later – typically beginning at 6-12 hours post-stimulation24, 
36. CD25 is the high-affinity a-chain of the IL (interleukin)-2 receptor. CD25 expression 
endows the activated T cell with enhanced sensitivity to IL-2, a cytokine key in T cell 
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survival and proliferation37. CD38 is an interesting multifunctional activation marker, 
upregulated in response to both antigenic and cytokine stimulation. Also expressed in the 
intermediate timeframe25, this ectoenzyme also has roles in T cell migration, proliferation 
and regulatory function [reviewed in ref 38]. Last, HLA-DR is an MHC class II molecule 
expressed late in the T cell activation process24. This enables T cells to present antigen 
to other T cells, though interestingly some data suggests the outcome of this is tolerance 
in the form of anergy or deletion39. 
 
CD4+ T cells (helper T cells) are often named the master orchestrators of the immune 
system due to their ability to amplify and regulate many different aspects of the immune 
response. This is made possible by the multiple T-helper (TH) subsets within the CD4+ T 
cell compartment, each with specific impacts on immunity (Fig. 1.1.2). TH1 cells are 
induced by IL-12 that promotes the expression of lineage-specific transcription factor (TF) 
T-box expressed in T cells (T-bet). TH1 cells are defined by production of Interferon (IFN)-
g and tumour necrosis factor (TNF)-a that combat intracellular pathogens by increasing 
macrophage activation and inhibiting viral replication11, 12, 15. The TH2 differentiation 
programme is controlled by GATA-binding protein 3 (GATA-3); which is both promoted 
by, and drives expression of, the TH2 prototypic cytokine IL-4. These cells can also 
secrete IL-5 and IL-13. TH2 cells promote antibody class switching (to immunoglobulin 
[Ig] E and IgA) in B cells; and activate granular mast cells, eosinophils and basophils. 
This is important in the clearance of parasites and other extracellular pathogens, but also 
in allergic and atopic responses11. Highly pro-inflammatory TH17 cells and anti-
inflammatory peripheral TREGS (pTREGS) – induced from conventional T cells in the 
periphery as opposed to generated in the thymus) seem diametrically opposed in 
function, yet share inducing signals. IL-6 alone induces RAR-related orphan receptor C  
! &!
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Subset Reported role(s) Refs. 
TH1 Intracellular pathogens, autoimmunity 11 
TH2 Parasites, allergy/atopy, fibrosis 11  
TH17 Extracellular pathogens, autoimmunity, allergy, tumour suppression 
11, 13, 15  
TFH B cell class switching/affinity maturation: extracellular pathogens  11,15  
TH9 Parasites, allergy/atopy, mucosal autoimmune disease, tumour suppression 
11,15, 40, 41  
TH22 Barrier tissue immunity & autoimmunity, allergy 42  
iTREG General immune suppression, tumour progression 11, 43  
TR1 Local immune regulation, tumour progression 44  
TH3 General immune suppression (specifically oral tolerance) 45, 46  
 
(legend on next page)  
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Figure 1.1.2 - CD4+ T cell subsets: differentiation requirements and roles in immunity. A - 
Differentiation requirements for each identified CD4+ T cell subset. Cytokines (shown along arrows) in the 
SLO environment direct a naïve CD4+ T cell towards different fates. Cytokines in parentheses are thought 
to be secondary/less important in each differentiation pathway, or have not been heavily reported in the 
literature. Each lineage is defined by a master regulator - a transcription factor (shown within each 
differentiated cell) that is crucial for driving development and re-enforcement of each subset. For many of 
the subsets, multiple transcription factors cooperate to regulate subset differentiation and stability14, so only 
the main one is shown here (except TR1 cells where a main factor is not currently known, but c-MAF, AHR, 
IRF4 and Blimp1 are the best candidates44; and TH3 cells that do not yet have an identified master 
regulator). Cytokines shown in looped arrows are not required for initial formation of each subset, but are 
important in propagation of the phenotype/additional acquisition of lineage-specific effector functions. Each 
subset is defined by its function - the complement of effector cytokines it produces that will feed into the 
immune response. The main prototypic cytokines for each subset are shown adjacent to the cells (in 
parentheses are non-prototypic cytokines, but that are commonly associated with the subset(s)). Part A 
influenced from similar figures in sources 11, 14, 47, while additional information came from refs 10, 12, 13, 44, 45, 
48-54. AHR - Aryl hydrocarbon receptor, Bcl-6 - B-cell lymphoma 6, Blimp1 - B-lymphocyte-induced 
maturation protein 1, c-MAF - cellular homolog of the avian virus oncogene musculoaponeurotic 
fibrosarcoma (c-MAF), IRF4 - interferon regulatory factor 4, PU-1 - purine-rich box 1). B - Table showing 
reported general roles for each subset in pathogen clearance, autoimmune/autoinflammatory disorders, 
allergies and cancer.  Extracellular pathogens include extracellular bacteria, fungi; intracellular pathogens 
include intracellular bacteria, viruses. 
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(RORc) expression and TH17 lineage differentiation, while IL-6 and transforming growth 
factor-b (TGF-b) together instead favour Forkhead box P3 (FoxP3) expression and pTREG 
generation13. TH17 cells produce IL-17A, IL-17F, IL-21, and IL-22, and are involved in 
neutrophil activation, recruitment, and clearance of extracellular bacterial and fungal 
infections11, 13; whereas TREGS produce anti-inflammatory cytokines such as IL-10 and 
TGF-b, and express high levels of inhibitory molecules like CTLA-4 in order to suppress 
excessive immune responses55. Other CD4+ T cell types also exist, including follicular 
helper T cells (TFH) that are essential for B cell affinity maturation in germinal centre (GC) 
reactions; TH9 cells that produce IL-9; TH22 cells that produce IL-22; and TH3 and type-1 
regulatory (TR1) regulatory cell types that produce TGF-b and IL-10 respectively (Fig. 
1.1.2)14, 42, 44, 48, 52, 56-58. 
 
Briefly, CD8+ T cells, also known as cytotoxic T cells (TC) due do their direct killing ability, 
are generally assumed to have a more linear differentiation path than their CD4+ 
counterparts. IL-12 together with type-1 IFNs promotes differentiation into effector T cells 
with high cytotoxic potential11. However, like CD4+ T cells, polarising cytokines can drive 
different CD8+ T cell fates too. These TC designations (TC1, TC2, TC17 etc.) broadly 
correspond to T-helper subsets in both induction requirements, and output cytokine 
profiles [Reviewed in ref 59]. 
 
T cell differentiation is a plastic and dynamic process. Differentiation into a certain subset 
is not necessarily final or irreversible, adding flexibility into immune responses. Numerous 
instances of interconversion between various subsets have been documented in both 
mice and humans; and these range from simple acquisition of one effector cytokine 
associated with a different lineage (as evidenced by the debate as to whether TH9 cells 
 12 
as a separate lineage, or simply an IL-9+ TH2 cell) to full-blown adoption of a new, 
unrecognisable cellular identity15, 47, 60. The stability of a subset is currently thought to 
depend on cytokine and co-stimulatory conditions upon secondary antigen encounter, 
TCR signal strength, TF networks, T cell clonality, and epigenetic modifications [reviewed 
in  refs 15, 60]. Based on these factors, a stability hierarchy appears to exist with pTREGS 
and TH17 cells more plastic than TH1 and TH2 subsets [reviewed in ref 60]. Benefits of 
plasticity include the ability of effector cells to adapt to pathogens that have moved into a 
different niche, skewing to a less inflammatory subset (immune deviation) to prevent 
tissue damage, and upregulation of effector cell-specific TFs and associated homing 
molecules in TREGS that allows each subset to be closely followed and regulated61, 62. 
Conversely, a dangerous situation could be envisaged where self-specific TREGS convert 
to pathogenic TEFF cells, as has been shown in mice63-68. Therefore, whatever the 
implications of plasticity, the CD4+ T cell compartment can be viewed as a fluid and 
malleable multi-dimensional spectrum allowing for highly complex adaptations to best 
eliminate pathogens. 
 
1.1.3 T cell memory 
 
Following the effector response and clearance of pathogen comes a contraction phase 
where most effector T cells die by apoptosis. A small proportion survive and become long 
lived memory cells that are capable of dealing with pathogen re-exposure with heightened 
response times and effector functions69. The generation of these cells is the basis of 
vaccination strategies, and accordingly is a major cornerstone of much immunological 
research. 
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Memory cells can be broadly split into three subsets – central memory (TCM), effector 
memory (TEM) and tissue-resident memory (TRM) T cells. By convention, TCM recirculate 
throughout blood and lymphoid organs, have a high proliferative potential, and produce 
abundant IL-2; but do not exhibit high effector functions (Fig. 1.1.3). By contrast, TEM 
mostly recirculate through blood and non-lymphoid tissues (NLTs), are less proliferative 
and produce little IL-2; but are highly responsive with robust effector function70. 
Contrastingly, TRM only reside within NLTs, providing robust frontline effector functions 
(see section 1.2 for extensive TRM discussion). It is clear that a division of labour exists 
between these three subsets, with TEM and TRM important in limiting the spread of 
pathogens in infected tissues, while TCM provide delayed back up – responding to antigen 
in SLOs and differentiating into a second wave of new, effector-ready TEM31, 71. 
 
For CD8+ T cells, the required cellular phenotypes and factors involved in the conversion 
to memory are relatively well understood. Memory precursor effector cells (MPECs) have 
been identified and show several key differences in surface phenotype, transcriptional 
activity, and metabolic requirements from short-lived effector cells (SLECs)72, 73. 
Moreover, the integration of combined signal strength from signals 1-3 in T cell priming 
impacts these fate decisions; with lower strength stimulations (beyond a certain activation 
threshold) favouring memory cell generation, and higher strength stimulations 
preferentially inducing SLEC cells; even if the precise precursor-product relationships 
have not yet been defined72. Conversely, CD4+ memory T cell generation appears to be 
a more flexible process. CD4+ equivalents of SLEC and MPECs have not been defined, 
with evidence instead suggesting that memory cells can form from multiple precursors73. 
As such, specific antigen signal strengths (again beyond a certain initial survival 
threshold); co-stimulation inputs; and signals from cytokines such as IL-2,  
! '(!
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Figure 1.1.3 - Recirculation patterns of naïve and memory T cell subsets. Naïve and TCM cells 
recirculate through blood and T cell zones (TCZ) of secondary lymphoid organs (SLOs) via the lymphatic 
vessels. TEM are mainly found in blood and non-lymphoid tissues (NLTs) but also recirculate through the 
lymphatics (via sinuses of SLOs) to drain back into the blood. TRM are confined to individual NLTs. Placing 
these migratory restraints on different subsets allows for an effective division of labour system whereby TEM 
and TRM patrol frontline tissues for immediate responses to re-encountered pathogens, while TCM with their 
increased proliferative potential, provide back up later on from their SLO garrisons. Image adapted from 
Schenkel & Masopust, 2014 – ref 71. 
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IL-12, and IL-21 are not absolutely required for CD4+ T cell memory cell generation; 
although modifying these parameters does lead to variations in the efficiency of memory 
cell production69, 73, 74. However, exposure to the homeostatic cytokine IL-7, may be an 
absolute requirement for memory generation and maintenance69, 74-76. 
 
Just like their primary CD4+ effector cell counterparts, memory CD4+ T cells exhibit 
remarkable heterogeneity and plasticity. TEM cells can become TCM in order to generate 
more stable long-lived memory cells77; or switch to different secondary effector types, for 
instance allowing a memory cell generated from a TH1 effector precursor to switch to a 
TH2 type in the correct conditions73, 78-81. These changes are imparted by different tissue 
niches, which are in turn informed by the nature of the infectious agent73. Thus, the 
secondary CD4+ T cell immune response allows the flexibility to adjust and adapt to 
returning pathogens as required, and promote immune tolerance by only unleashing 
effector function when and where instructed. 
 
Most studies on human memory T cells have been carried out using peripheral blood 
samples, which do not accurately reflect the rich array of distinct tissue-specific memory 
cell phenotypes present in peripheral organs82. Additionally, generation and maintenance 
mechanisms may be completely different for tissue T cells when compared to those 
isolated from blood and lymph83. Key to furthering our understanding of T cell memory 
are TRM cells. The existence and introduction of TRM as such a major component of T cell 
memory has already begun to make researchers aware of the increased complexity and 
heterogeneity of the memory pool; as well as the importance of tissue-specific immunity. 
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1.2 Tissue Resident Memory T cells 
 
In the old, two-subset model of anamnestic immune responses, central memory cells 
garrison the forts (SLOs), providing back up to the frontline where needed, while effector 
memory cells patrol through the blood and tissues constantly searching for antigen and 
responding with robust effector function. While a logical system, what if the body could 
supercharge this response by providing specialised local troops to every site of the body, 
ready to ambush any invading pathogen as soon as they infiltrate? Well, it turns out that 
evolution has already provided, arming us with a third memory T cell type – tissue resident 
memory T cells (TRM). 
 
As their name suggests, TRM are retained in peripheral tissues, providing rapid frontline 
recall immunity. Developing within the infected/inflamed tissue during effector responses, 
TRM will take up residence in peripheral niches and remain for what seemingly can be the 
lifetime of the host84. Their location makes them ideal for rapid responses to pathogens 
as there is no need for antigen trafficking to nearby lymphoid organs85. Furthermore, not 
only have they been shown to be crucial players in mouse models of infection, but recent 
data is also revealing their importance in multiple human inflammatory diseases23, 86. 
These properties have earned TRM their place at the forefront of immunology research. 
One recent study used novel quantitative immunofluorescence microscopy to adduce that 
there are between 50- and 70-fold more CD8+ TRM in mouse peripheral tissues than 
previously appreciated, and as many as 91% of total mouse T cells are actually tissue-
resident87! Similarly, human TRM have been shown to outnumber circulating memory 
cells88  – the lungs contain approximately 10 billion T cells, the same as in the entire 
circulation, while the skin surface contains double this number23, 89. Coupled with the fact 
that it is thought the vast majority of tissue-associated cells are resident87, 88, 90, 91, it is 
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Box 1.1 – The discovery and history of tissue-resident memory T cells 
astounding that these cells were only recently discovered (Box 1.1). Finally, it is important 
to note that the majority of studies in mice and humans have only investigated CD8+ TRM 
residence, leaving CD4+ TRM as a relatively unknown quantity. This section will discuss 
the characterisation, development and maintenance, function of TRM in mice and humans 
(examining the CD8+ lineage unless otherwise specified); before focussing on CD4+ TRM 
specifically. 
 
Discovery & History of TRM 
 
Before the idea of TRM cells was postulated, the dogma stated that following resolution of 
an infection, remaining effector T cells in NLTs either returned to the blood and SLO, or 
underwent apoptosis86. Moreover, in the absence of infection, it was thought that any T 
cells found in NLTs must be TEM cells trafficking through the organ as part of continuous 
recirculation. 
 
These ideas began to be questioned when researchers noticed antigen-specific CD8+ T 
cell populations persisted long-term following viral infection of the lungs and brain in 
mouse models92-96. The pioneering work of David Masopust and his team uncovered 
long-lived CD8+ T cells within a whole array of different NLTs in mice, and crucially, first 
hypothesised that these cells are permanent tissue-residents97. The next key discovery 
came from Gebhardt et al., who showed that ‘passenger’ lymphocytes carried in sensory 
ganglia grafts stayed resident in the donor graft98. In proving this, the authors officially† 
coined the term ‘tissue-resident memory T cells’98. The final nail in the coffin of the old 
memory T cell dogma came via numerous parabiosis experiments that definitively proved 
tissue-associated T cell populations did not equilibrate between surgically conjoined 
congenic mice, instead remaining at their original tissue sites99-102. 
 
True TRM have proved more difficult to identify in humans (see Box 1.2). Studies began 
in human skin. Grafting skin from psoriasis patients into immunodeficient mice revealed 
the presence of a resident, disease-linked T cell population103. These findings were built 
upon by the work of Rachel Clark – a key player in human TRM biology. Her body of work 
uncovered the vast reservoir of skin-associated T cells, with distinct homing receptor 
phenotypes and diverse TCR repertoires that heavily implied at tissue-residence89, 104, 105. 
 
 
† - Similar nomenclature has been used in the literature long before this, with resident memory106, resident-
memory T cells107, and tissue-resident memory93 all evident. The self-explanatory nature of these terms 
make it difficult to pinpoint the first researchers to use these terms. 
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1.2.1 Characterising Tissue Resident Memory T cells 
 
Tissue resident memory cells represent a completely distinct population to their 
circulating effector memory counterparts. Although TRM are principally defined by their 
long term peripheral location; differences in surface phenotype108, 109, TF expression84, 
110, maintenance requirements111, functionality98, 100, 102, 112, sensitivity to stimuli113, and 
even metabolism114 have all been described. Mouse TRM have now been characterised 
in a plethora of different NLTs85, 100-102, 109, 110, 115-130. Breakthroughs in mouse TRM 
characterisation subsequently led to the discovery of human TRM in the gut88, 90, lungs131-
135, stomach136, peritoneum137, pancreas138, 139, adipose tissue140, female genital 
mucosa141-145, salivary glands91, conjunctiva146, bone marrow147, and liver82, 148, 149; as 
well as in the skin143, 150-152. 
 
Here, I will first discuss the different phenotypic signatures associated with TRM in mice, 
before moving onto the characterisation of human TRM. 
 
1.2.1.1 Characterising Mouse TRM 
 
Just as TRM are defined by their location, the markers used to characterise them are 
largely associated with tissue retention. The expression of surface markers CD69, 
integrin a1 (CD49a), integrin ae (CD103); alongside the lack the of lymph node homing 
markers CCR7 and CD62L, as well as tissue egress marker S1PR1 all act to keep T cells 
localised in the tissue. Each of these putative TRM markers is discussed in detail below. 
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The first phenotypic criteria that a TRM cell must meet is to be CD45RA-, CCR7-, and 
CD62L-. The absence of expression of the latter two molecules prevents TRM returning to 
SLOs23. 
 
CD69 is the closest surface molecule to a universal TRM marker109, 153, 154. To date, TRM 
from all NLTs studied expressed CD6971, 92, 109, 110, 153, 155-157, and genetic deletion of CD69 
abolished TRM populations in skin and lungs110, 156, 158, 159. Despite also being an activation 
marker, CD69 clearly has another role in tissue retention as most TRM in tissues have not 
been recently activated by antigen109, although maintenance of CD69 expression may be 
cytokine-mediated23. The dominant role of CD69 in tissue retention is thought to be due 
to its reciprocal interaction with S1PR1, whereby CD69 directly downregulates S1PR1153, 
158, 160, and thus prevents migration towards S1P that encourages tissue egress23, 32, 161-
164. Fittingly, forced S1PR1 expression led to a failure to establish TRM153, emphasising 
the importance of this marker pair for TRM biology. Lastly it is worth noting that despite its 
merits, CD69 is not the perfect murine TRM marker as some TRM in the pancreas, salivary 
tract, and female reproductive tract (FRT) were CD69- 87; while some CD69+ cells in the 
thymus were not truly resident130. 
 
CD103 expression has been strongly linked to TRM in a number of NLTs where it plays 
important roles in TRM maintenance post-seeding109, 110, 115, 156, 165. CD103 upregulation 
appears to depend on upstream TCR signalling in a tissue-dependent manner115, 121. 
CD103 makes up half of the aeb7 integrin complex. This integrin is able to bind E-
cadherin on epithelial cells expressed in barrier tissues166. Therefore, it has been 
speculated that physical tethering to epithelial cells directly contributes to tissue 
retention31, 101, 109, 167. Yet, not all TRM cells express CD103109, 157. Furthermore, this 
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interaction is not strictly required for tissue residence as CD103+ T cells have been found 
in the dermis168, and in the brains of mice115, despite the absence of E-cadherin in these 
locations169. Additionally, CD103 is a poor marker of CD4+ TRM (see 1.2.4). Instead, 
CD103 may act as a differentiation marker for TRM23, and may promote survival in NLTs110, 
115. 
 
Similarly, CD49a is highly expressed on TRM from skin, small intestine, lung and brain98, 
110, 133, 170, 171, but like CD103, its expression is not an absolute requirement for tissue 
residency in all organs172. CD49a forms half of integrin a1b1 and may promote retention 
by binding tissue laminins and collagens71. However, a1b1 integrin expression was 
required for maintenance in the lungs173.  
 
Alongside retention markers, some other common TRM characteristics include elevated 
expression of co-inhibitory markers such as PD-1 and CTLA-4109, 174, and enhanced 
expression of quiescence marker nuclear receptor subfamily group A member 1 
(NR4A1)170, 174-176. Downregulation of the tissue egress receptor sphingosine-1-
phosphate receptor-5 (S1PR5) may also be important at some sites71, while the aryl 
hydrocarbon receptor (AHR) is seemingly important in TRM persistence in the skin and 
gut177. There are undoubtedly many tissue-specific adaptations of TRM, beyond the scope 
of this report, although expression of CXCR3 and CXCR6 on TRM is of particular 
importance in many tissues128, 174, 178-181.  
 
Multiple studies have shown differential TF changes in murine TRM cells (Fig. 1.2.1)109-111, 
130, 153, 170, 174. The seminal work of Mackay et al. identified a core transcriptional signature 
for murine TRM cells comprising of 37 key transcripts and their products that distinguish 
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TRM from both traditional circulating memory subsets110. In a follow up study, the TF 
Homolog of B lymphocyte-induced maturation protein 1 (Blimp1) in T cells (Hobit) was 
identified from these transcripts as a key transcriptional regulator of TRM cells174. Hobit 
operates in conjunction with Blimp1 itself to precisely coordinate the TRM differentiation 
programme84, 174. Blimp1 is a transcriptional repressor broadly expressed in many effector 
cell lineages, promoting T cell effector function and terminal differentiation pathways174, 
182-184. By contrast, Hobit is specifically upregulated in CD8+ T cells from different NLTs 
including the skin, gut, kidneys and liver174. Deletion of either factor led to a reduction in 
resident CD8+ T cell numbers, but knockout of both led to a complete block of residency 
across multiple organs174. Hobit-1 and Blimp-1 together repressed the genes for CCR7, 
S1PR1 and Krüppel-like factor 2 (KLF-2), as well as T-cell factor-1 (TCF-1 - a key 
determinant of circulating memory cells)174. Thus, these two master regulators promote 
the residency programme while simultaneously repressing other fates84. Interestingly, 
both Blimp-1 and Hobit bind many of the same target sites, but yet both are required for 
the full residency programme. Mackay and Kallies suggest that perhaps there is a division 
of labour amongst the two TFs whereby Blimp-1 is induced early and then Hobit induced 
later allowing sequential gene regulation, and/or different tissue environments rely more 
on either factor due to differential induction of upstream Blimp-1 or Hobit binding 
partners84. 
 
Other TFs such as KLF-2 are downregulated in multiple tissue-resident cell types130, 153, 
174. KLF-2 directly promotes S1PR1 expression, prevention of which is critical for TRM 
formation; and indirectly supports CD69 expression through the lack of competition with 
S1PR1153, 158. TFs T-bet and eomesodermin (Eomes) are also repressed in skin, gut, lung 
and brain-resident T cells110, 170. T-bet and Eomes are expressed in short-lived effector 
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cells, and long-lived memory cells respectively72. Downregulation of the pair in TRM 
promotes responsiveness to TRM-promoting cytokines, and allows Hobit expression to 
emerge84, 111, 178. 
 
1.2.1.2 Characterising human TRM 
 
Many of the surface markers used to characterise mouse TRM are transferrable to 
humans. CD69 is widely considered the best marker of human TRM, having been 
observed on memory CD8+ and CD4+ T cells from every peripheral tissue studied86, 88, 90, 
131, 136, 185, 186. In support of this, it was very recently shown that CD69 expression alone 
delineates cells with transcriptionally distinct tissue-resident programmes that share core 
features with mouse TRM cells91. Additionally, CD103 is often associated with human 
CD8+ TRM, particularly in mucosal sites and skin91, 132, 133, 136, 147, 152, 185, 187, while CD49a 
has been heavily associated with lung and skin TRM131, 151, 188. As in mouse, these two 
molecules are not absolutely required for residence. For instance, many describe CD103- 
cells as a separate resident subset – distinct from CD103+ cells in their anatomical 
location, function, phenotype, and transcriptional profiles91, 132, 146, 152, 187. Similar 
suggestions have now been made about CD49a as a TRM subset discriminator rather than 
a bone-fide universal marker82, 188. 
 
A number of excellent studies coming out of the Farber lab and others have assessed 
tissue residency profiles across a number of lymphoid, and non-lymphoid tissues82, 88, 90, 
91. These types of studies provide the field with invaluable maps of body-wide T cell 
trafficking patterns, phenotypes and function. For resident T cell biology, these 
investigations have recently been taken one step further – through the transcriptomic 
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profiling of resident T cells from lung and spleen91, 134. First off, TRM populations from 
different tissues consistently showed more genetic similarities to each other, than to 
circulating TEM cells91, 134. TRM show a strong association with the genes for CD49a and 
CD103, as well the downregulation of the genes coding for tissue egress receptors 
S1PR1 (and its associated TF KLF-2), and CD62L91, 134. Other key hallmarks of TRM 
included an upregulation of mRNA for inhibitory receptors such as PD-1, CTLA-4, LAG-
3, CD39, NKG2A, and CD101; and the chemokine receptors CXCR6 and CX3CR1, which 
showed up-, and down-regulation respectively91, 134. Hombrink et al. reported additional 
changes in metabolic pathways, including an enhanced glucose-deprivation signature, 
and increases in hypoxia-related genes134. Importantly, Kumar et al. demonstrated the 
majority of these properties are similar to previously identified mouse TRM transcriptional 
profiles, helping to validate mouse models in the study of TRM91, 110, 170, 174. An obvious 
caveat of these studies is that the only NLT investigated in both was lung tissue. However, 
Kumar et al. did show that spleen and lung NLT cells were very similar genetically; and 
went on to verify many of the key identified molecules that associated with lung/spleen 
TRM across intestine, LN and tonsil tissue at the protein level91. Together these profiles 
go towards identifying a universal tissue programme that clearly has a lot of shared 
features across different tissue types. 
 
Within these studies, clues into the transcriptional regulation of human TRM were 
investigated. Like their mouse counterparts, human TRM appear to have diminished 
expression of the genes coding for T-bet and Eomes134, 149. However, unlike mouse TRM, 
Hobit is not a key differentiator of human TRM134, as it can be expressed following both 
CD8+ and CD4+ T cell activation189, 190. Furthermore, Hobit is not appreciably expressed 
in TRM from liver, lung, or spleen91, 148. Thus, although a great many characteristics of 
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mouse TRM translate well to human TRM, a master TF for the human lineage has yet to be 
identified. 
 
1.2.2 Development and Maintenance of Tissue Resident Memory T cells 
 
The development of TRM cell populations requires a combination of intrinsic cellular and 
tissue specific factors. This process requires multiple checkpoints including tissue entry, 
antigen recognition and sensitivity to specific tissue cues71. The great majority of our 
knowledge on this topic comes from mouse models, again discussed first. 
 
1.2.2.1 Mouse TRM development & maintenance 
 
Given the phenotypic similarities of TRM and TEM, it was initially assumed that the former 
developed from the latter. However, largely only effector, not memory, cells can enter 
NLTs in mice115-117, 191. So, it is likely TRM develop directly from effector cells in the tissues 
following an immune response71. Second, TRM develop from killer cell lectin-like receptor 
G1 (KLRG-1)-negative precursors110, 116, 157. This is akin to circulating long lived CD8+ 
memory T cells that develop from CD127hiKLRG-1- cells, as opposed to short-lived 
effector populations that arise from the CD127loKLRG-1+ pool192, 193. KLRG-1 
downregulation may also be caused or increased by TGF-b signalling194, and may be 
important in allowing CD103-mediated adhesion as both KLRG-1 and CD103 can bind to 
E-cadherin108, 195. Further, Gaide et al. demonstrated that the generation of skin TRM led 
to parallel generation of TCM in lymph nodes, suggestive of a shared common 
precursor196. The TCM pool could even replenish the TRM population following activation196. 
Additionally, like TCM cells, TRM are more quiescent than TEM31, and are not terminally 
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differentiated, as adoptive transfer of TRM to the circulation caused switching to the TCM 
phenotype155. Lastly, the mechanistic target of rapamycin (mTOR) signalling pathway 
may be important in this cell fate decision, as mTOR signalling pushes precursor cells 
down the TRM route197. Collating all the available evidence, it is likely that TRM develop 
from a common central memory precursor due to shared longevity properties, but 
following differentiation adopt a more effector memory-like phenotype with the ability to 
rapidly carry out effector functions following stimulation. 
 
The first important step in becoming a TRM cell is tissue entry. Effector cells upregulate 
homing receptors upon activation in SLO, and these determine specific tissue migration 
capabilities (see 3.1). Following entry, the tissue microenvironment imprints susceptible 
T cells with a residence phenotype as key TRM signatures such as CD69 and CD103 are 
only acquired following tissue entry116, 155. CD4+ T cells can aid the entry of CD8+ TRM into 
the skin, lungs and FRT through IFN-g production, and Laidlaw et al. demonstrated CD4+ 
T cell help is essential for CD8+ TRM formation in the lungs178, 198, 199. Therefore, just as 
the process of circulating memory CD8+ T cell formation depends on CD4+ T cell help200, 
so too might the generation of CD8+ TRM108, at least at certain tissue sites. 
 
Intriguingly, it appears that TRM do not absolutely require antigen recognition to form.  
Antigen-independent TRM development has been observed in the mouse airways, FRT, 
and skin epithelium100, 121, 124, 201, 202. However, brain TRM formation was antigen-
dependent109, 121. Perhaps then non-cognate inflammatory signals are sufficient to drive 
TRM production in many tissues? Casey at al. dispute even this hypothesis, demonstrating 
that naïve T cells transferred into lymphopaenic hosts seed many NLTs and are able to 
adopt the phenotype of TRM cells in the absence of either antigen or inflammation109. 
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However, while it appears often neither antigen-mediated or inflammatory signals are 
absolutely required, the combination of both has shown to be necessary for optimum TRM 
generation as illustrated particularly elegantly by so-called ‘prime and pull’ vaccination 
strategies (immunisation followed by local chemokine application to ‘pull’ effector T cells 
into desired tissue)121, 124, 202, 203. Notably, repeated antigen exposures increased TRM 
dissemination throughout the entire skin surface or whole FRT, far beyond the local 
infected area100, 124, 202. Interestingly, it now seems that weaker TCR stimulations are 
better at establishing fully functional TRM in brain tissue204.  
 
Having established TRM do not always require antigen to form, others asked whether TRM 
maintenance depends on cognate signals. It appears that while resident T cells in the 
brain and dorsal root ganglia require antigen stimulation for persistence109, 115, 121, 129, the 
general consensus is that TRM in most other NLTs seem to be antigen independent109, 110, 
117, 121, 126, 127, 176, albeit with some contradicting evidence in lung tissue156. Moreover, 
chronic antigen stimulation actually skewed cells away from the TRM phenotype109, 171. 
This could represent a similar situation to the prevailing model in circulating memory CD8+ 
T cell differentiation where increased antigen signal strength preferentially generates 
SLECs72. 
 
Once TRM progenitors have entered the tissue, the cytokine milieu appears to have a 
profound impact on the development and maintenance of the tissue residency 
programme (Fig. 1.2.1). The cytokine most implicated in this process is TGF-b, 
consistently being associated with TRM development at a variety of sites, including skin, 
gut, and lungs109-111, 156, 157, 171, 205. TGF-b promotes the development of TRM cells through 
four known mechanisms. First, TGF-b signalling promotes CD103 upregulation. These 
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findings fit nicely with the model of KLRG-1- cells being TRM precursors, as KLRG-1- cells 
express more TGF-bRII than their KLRG-1+ counterparts110, 157, and TGF-b is only able 
to induce CD103 upregulation on effector, not resting memory cells109. In addition, CD49a 
expression can be driven by TGF-b171. Third, TGF-b signalling enabled KLF-2 
downregulation and the acquisition of the residency programme, effects that were 
augmented by the cumulative addition of first IL-33, then TNF-a153. Lastly, the competitive 
interaction between TGF-b signalling and T-bet promotes residence. TGF-b drives 
downregulation of both Eomes and T-bet, which indirectly enhances surface TGF-b 
receptor expression, creating a positive feedback loop, as both these TFs are negative 
regulators of TGF-b receptor gene expressions111, 178. However, residual T-bet is needed 
to promote CD122 expression (the b-subunit shared by IL-2 and IL-15 receptors) that 
allows subsequent IL-15 signalling111. IL-15 is another cytokine commonly cited in TRM 
development110, and long term TRM survival111, 206. IL-15 is also thought important in the 
upregulation of CD103110, 126. Whereas TRM regulator Hobit is induced following tissue 
entry in a T-bet and IL-15 –dependent manner174, Blimp-1 does not require either factor, 
instead being induced in the early effector phase by IL-2 and IL-12 signalling207. This 
supports the theory that first Blimp-1, then Hobit are induced in TRM development, playing 
different temporal roles84. Lastly, CD4+ T cell-derived IFN-g has also been implicated in 
the establishment of residence via suppressing T-bet on CD8+ T cells, and promoting 
subsequent CD103 expression and settling in lung tissue178. 
 
Although we have come far in understanding a lot of the cytokine signals that trigger TRM 
development and maintenance, there is no one factor that is ubiquitously required for this 
programme. For example, some studies have reported a TGF-b independent 
development programme in the gut, and nasal epithelium201, 208, while others showed it  
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Figure41.2.1 - Signals and transcription factors required for the development of TRM in mice. 
Following activation and migration into NLTs, TRM precursors that are putatively KLRG-1
- Blimp1+ CXCR3+ 
can develop into TRM due to influences from the tissue microenvironment. The two cytokines most 
implicated are TGF-$ and IL-15. TGF-$ can promote expressions of TRM-associated integrins CD49a and 
CD103; and repress both Eomes and T-bet - resulting in enhanced sensitivity to further TGF-$.  Retention 
of low/intermediate T-bet levels is required for IL-15 responsiveness however. IL-15 can also promote 
CD103 upregulation (not shown); and induce Hobit expression alongside residual T-bet. Together, Hobit 
and Blimp1 coordinate the downregulation of genes associated with tissue egress such as KLF2, S1PR1, 
CCR7 and TCF1.  KLF2 and S1PR1 allows the upregulation of CD69 (not shown) and establishment of 
residency. Additionally IFN-" can contribute to this circuit, through its suppression of T-bet, and promotion 
of CD103 expression. 
 
Mechanisms shown summarise current knowledge on CD8+ T cells across mouse NLTs. While this is a 
general paradigm, TRM formation in some tissues has shown to be TGF-$ or IL-15-independent208, 209, 
suggestive of tissue-specific influences. Figure adapted from Mackay & Kallies 2016 - ref 84. Additional 
references: 110, 111, 153, 171, 174, 178. 
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was not required for long-term population maintenance in the salivary glands126.  
Comparably, although skin and lung CD8+ TRM depend on IL-15 for their maintenance, 
resident cells in many other tissue sites such as gut and FRT, are not reliant on it to 
persist125. Furthermore, different subsets of TRM require different signals to form. 
Bergsbaken et al. found that CD103- TRM in the small intestines of mice require pro-
inflammatory IL-12 and IFN-b, which suppresses TGF-b-mediated CD103 expression 
required by the more appreciated CD103+ subset210. It is therefore likely that different 
NLTs impose their own residency requirements based on their distinct cytokine 
microenvironments, and favoured ‘in-house’ cell subtype(s) they choose to dwell there. 
Illustrating this, some have found a universal requirement for IL-33 for maintenance of all 
lymphocyte tissue residency in adipose tissues84, 211, 212. 
 
Finally, Notch1 signalling may contribute to the maintenance of TRM. Hombrink et al. 
showed that Notch1 signalling was important in the persistence of lung CD8+CD103+ TRM 
cells, promoting metabolic programmes that allow tissue retention. Notch1 signalling 
interconnects with the TGF-b signalling pathway through common downstream signalling 
mediators, and the induction of Notch1 ligand expression in epithelial cells; thus providing 
an integrated mechanism to maintain TRM cells, at least in lung tissue134. 
 
1.2.2.2 Human TRM development & maintenance 
 
There is precious little data on human TRM development so many of our assumptions 
must come from mouse models (see Box 1.2 for problems associated with studying 
human TRM). Human lung TRM have been found to express low KLRG-1 mRNA134. One 
likely possibility is that, akin to mouse, human CD8+ TRM also share a KLRG-1- TCM  
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Box 1.2 – Complications in the study of human TRM 
 
Complications in the study of human TRM 
 
Tools for studying mouse TRM such as parabiosis, in vivo imaging, and tissue grafting are 
generally not possible in humans. Furthermore, determining phenotype and function of 
target cells through multi-parametric flow cytometry requires tissue digestion and cell 
isolation which introduces a number of potential problems. These include the admixing of 
different tissue microenvironments; sampling bias due to inefficient removal of blood 
contaminants, inefficient tissue-associated cell extraction (neither mechanical nor 
enzymatic digestion can remove 100% of tissue lymphocytes), or the inclusion of tissue-
associated lymphoid structures; and this methodology gives no architectural 
information71. On top of this, lymphocyte yields from NLTs are often low, thus 
investigators require a large amount of starting material, and TRM are not thought to 
survive well in culture71, 170. Even in mouse models, total body TRM were vastly 
underestimated in number until recent in vivo imaging corrected this87. It is worth noting 
these complications because as the human TRM field explodes, so too will the need for 
scrutiny and careful research. This is not to say that excellent studies do not exist. As a 
positive, CD69 has proven to be a robust marker and key distinguisher of TRM in every 
human tissue studied91, 186, although not perfect in mice87, 213, perhaps due to the specific 
pathogen free conditions in which they are housed214. Until new technologies develop for 
improved isolation, or visualisation of ex vivo TRM, the field must take great care to 
minimise the associated risks with studying human TRM. 
 
 
 
 
 
 
precursor that maintains low KLRG-1- expression once differentiated into a resident cell 
type. Alternatively, the tissue environment could directly downregulate KLRG-1 
expression, as has been shown for TGF-b194. Furthermore, clues to the long-term 
persistence of human TRM may lie in their phenotype, with the quiescent, inhibited, resting 
phenotype of these cells being shown in multiple studies91, 134, 140, 175. 
 
Cytokines are indisputably important in human TRM cell generation too. To our knowledge, 
Pallett et al. were the first to generate CD8+ T cells with TRM phenotypes (CD103+CD69+) 
from peripheral blood mononuclear cells (PBMCs). Optimal TRM induction was achieved 
through either IL-15, or anti-CD3 stimulation; followed by TGF-b exposure148. IL-15 was 
also implicated in retention in the human tonsil through downregulating KLF2 and 
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S1PR1187. Thus, while studies of human development are still in their infancy, key 
similarities to mice gives confidence that in the future, clear hypothesis-driven research 
can be tested effectively. 
 
1.2.2.3 Longevity of mouse and human TRM 
 
Having discussed known maintenance requirements for TRM, an important question is 
how long can these cells persist? Unfortunately, data is lacking on the longevity of human 
memory T cells, even in peripheral blood71. However, studies in mice and rhesus 
monkeys noted TRM persistence for up to 700 days97, 100, 215. This is complemented by 
circumstantial evidence of human skin T cell numbers remaining stable even in patients 
in their 90s86, 216. Nonetheless, none of these studies exclude the possibility that 
circulating memory T cells are constantly replenishing the TRM pool, a phenomenon 
observed for CD8+ T cells in murine lung tissue, but not skin100, 159, 217. The situation is 
likely even more complex, as murine dermal-dwelling CD4+ TRM were far more transiently 
resident compared to CD8+ TRM retained in the epidermis218. Finally, competition for 
space, antigen, and other local signals can shape the TRM repertoire108, 177, 219. So, it 
appears that the cytokine signals, cumulative antigen exposure history, and tissue niche 
properties all control the length of stay of TRM. 
 
An alternative explanation suggests tissue residence is a continuum - ranging from true 
TEM that merely pass through the tissue, up to true life-long resident memory T cells, and 
every possibility in between. Research over the coming decade, including both 
longitudinal studies and advanced phenotypic analyses will help us address this 
possibility. 
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1.2.3 Function of Tissue Resident Memory T cells 
 
TRM are superior to their circulating counterparts in terms of cytokine responses, and 
anamnestic immunity. TRM from many different mouse NLTs been proven to be better at 
clearance of a variety of infections, including those in the lungs102, 112, 113, 201, 220-223, FRT98, 
99, 124, 218, 224, 225, and skin100, 121, 199, 226-228. A pertinent example of this superior protection 
includes the 99.99% impairment in vaccinia virus clearance in the absence of TRM in 
mice100. Crucially, TRM-mediated protection is often critical for pathogen clearance99, 102, 
121, 128, 220, 229. Analogous findings have since been made for human TRM. For example, 
respiratory syncytial virus-specific TRM numbers correlate strongly with reduced 
symptoms and reduced viral load230. Similarly, lung TRM cells contain more influenza-
specific clones, and respond better than blood T cells to this pathogen131, 132. Mouse, 
followed by human, TRM functions are covered below. 
 
1.2.3.1 Mouse TRM function 
 
TRM have a number of key advantages over circulating memory T cell subsets, allowing 
them to assert functional superiority. TRM respond rapidly to antigen, and can do so 
entirely within the tissue microenvironment85, 113, 115, 226. Furthermore, TRM appear to need 
only peptide recognition, not costimulatory signals, to become activated231; and may 
actually function better after receiving lower strength TCR stimulation204. The specific 
types of antigen-presenting cells (APCs) needed to prime TRM in the tissues are now 
starting to be uncovered232, 233. Third, resting skin TRM in mice appear to adopt a dendritic 
morphology; and move in slow, deliberate Lévy walks, both of which enhance their 
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antigen scanning capabilities31, 108, 177, 181, 218, 226, 234. Fourth, TRM respond to antigen with 
robust cytokine responses and direct cytolysis action97, 155, 231. These are often, but not 
limited to, type 1 and/or type 17 responses, and TRM can frequently produce multiple 
cytokines simultaneously100, 113, 128, 224, 235-237. 
 
Schenkel et al. and others illustrated that TRM act as immune sentinels as well as direct 
effectors. Through rapid production of pro-inflammatory cytokines following antigen 
recognition, TRM induce an antiviral state in surrounding cells including CXCL9, CXCL10 
and vascular cell adhesion protein-1 (VCAM-1) upregulation on nearby endothelium. This 
leads to the recruitment of a whole host of other immune cells, including circulating 
memory CD8+ T cells, B cells and inflammatory monocytes; activation of natural killer 
(NK) cells; and maturation of DCs71, 129, 224, 231, 238, 239. The whole process depended on a 
combination of TRM-derived IFN-g, TNF-a, and IL-2224. Thus, TRM act as both adaptive and 
innate-type immune ‘alarm’ cells in their own right. TRM-mediated immunity and the tissue-
wide state of alert induced has shown to be so powerful that it can provide bystander 
protection against antigenically distinct pathogens to those immunised with in mouse 
models71, 220, 221, 238. Furthermore, local TRM induction can lead to more far reaching 
protection. Vaccinia immunisation at just one site led to TRM seeding throughout the entire 
skin100, while skin infection with the same virus led to the generation of lung-tropic TRM 
that protected against pulmonary challenge227. Importantly, TRM in the central nervous 
system (CNS) can mediate clearance of lymphocytic choriomeningitis virus (LCMV) 
without causing overt immunopathology and tissue destruction, a feat not matched by 
circulating T cells129. 
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1.2.3.2 Human TRM function 
 
TRM also play important protective roles in humans. In the skin, HSV-specific CD8+ TRM 
persist long-term, and the density of these cells correlated directly with suppression of 
viral reactivation at sites of previous lesions143. Lung TRM are enriched for influenza-
specific clones131-133, while cervical TRM are enriched for herpes simplex virus (HSV)-2-
specific cells240. The same is found for hepatitis B virus (HBV)-specific clones within liver 
TRM that provide the best protection against the disease148.  
 
Robust cytokine responses are a key facet of human TRM biology. Like mouse TRM, type-
1 and type-17 responses have been most often documented. Two studies showed CD8+ 
TRM from the lungs produce more IFN-g, TNF-a, and IL-2 than TEM, as well as comprising 
more multifunctional cells that produce all three131, 132. Such multifunctional cells have 
been best associated with protective immunity241-243. Interestingly, lung CD8+ TRM had a 
high abundance of mRNA for IFN-g and TNF-a at rest, allowing rapid cytokine responses 
following stimulation134. In another study, resident cells in the lung have been linked to 
better IL-2, IL-10, and IL-17 production than non-residents. This same study showed that 
the former two cytokines were part of a body-wide CD4+ and CD8+ TRM signature91. IL-10 
expression at rest complements the constitutive self-regulatory programme seen in TRM91. 
In the liver, elevated IL-2 has been reported in resident CD8+ TRM cells148; while in the 
stomach, TRM make more IFN-g and IL-17 than TEM counterparts (although no 
multifunctional cytokine advantage was noted in this study)136. In the skin, TRM mostly 
secrete IFN-g and IL-289, have a lower threshold for cognate activation than blood T 
cells244, and were able to single-handedly protect against cutaneous infections in the 
absence of circulating T cell subsets150. Cheuk et al. has demonstrated how CD49a can 
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be used as a functional discriminator of skin TRM cells – showing that CD49a+ and CD49a- 
cells preferentially express IFN-g and IL-17 respectively188. On this theme, Watanabe et 
al. showed CD103+ TRM in skin produced more IFN-g, TNF-a, and IL-22; but diminished 
proliferative capacity compared to the CD103- subset152. Lastly, lung CD8+ TRM have 
shown more cytotoxic potential than circulating T cells132, 134, although this was not 
paralleled in their liver equivalents148, 149. 
 
1.2.3.3 Implications for vaccines 
 
With these prolific immune properties in mind, TRM sound like the ideal guardians of the 
body. Able to respond rapidly, and robustly not only directly to antigen, but to alarm and 
recruit the rest of the immune system; able to provide heterosubtypic protection; and able 
to confer protection at anatomically distinct sites without causing excessive tissue 
destruction. TRM sound like the perfect cell type to manipulate for disease intervention. 
Indeed, in mouse models inducing local tissue resident skin cells through skin 
scarification with vaccinia virus has led to up to 100,000 times better prevention against 
viral reinfection, than when immunised through the subcutaneous, subdermal, and 
intramuscular routes228. Similarly, live-attenuated influenza virus (a common licenced 
influenza vaccine) administered intranasally, generated TRM that were able to provide 
cross-strain protection, properties that were not seen with standard subcutaneous 
injection221. Indeed, in a respiratory syncytial virus (RSV) infection model, immunisation 
through the intramuscular route actually increased pathogenesis, whereas intranasal 
immunisation induced TRM-mediated protection222. Moreover, the efficacy of a recently 
developed malaria vaccine, PfSPZ, has been pinned on resident lymphocytes in the liver 
of rhesus monkeys245. Additional data has suggested TRM generation improves responses 
 36 
in vaccinations against mycobacterium tuberculosis186, and even drastically improves HIV 
responses in mouse models 246, 247. 
 
Such promising studies have led to many leading immunologists in the field proposing 
that new vaccines should be optimised to prioritise TRM generation23, 86, 108, 186, 248. This 
would hypothetically principally involve immunisation at sites relevant to protection, such 
as therapies directed to the gut, or synovium administered through endoscope or 
arthroscope respectively23. The ‘prime and pull’ strategy also has promise. Coupling 
standard subcutaneous immunisation with local chemokine application has been 
successful in optimising anti-HSV-2 responses in the murine FRT124. However, in certain 
situations the efficacy of TRM is also their undoing as these cells are starting to emerge 
as key players in various autoimmune and inflammatory diseases. 
 
 
1.2.4 CD4+ Tissue Resident Memory T cells 
 
Tissue-resident CD4+ T cells have been investigated far less than CD8+ TRM. This is likely 
in part due to the infection context in which TRM are generally studied - viral infections of 
mice generate a far more robust CD8+ T cell response compared to CD4+ T cells23. This 
is unfortunate, as CD4+ T cells are the dominant T cell population in the skin, mucosal 
tissues and lungs of mice and humans88-91, 133, 152, 186, 213, 218, 249. Similar to CD8+ T cells, 
the majority of memory CD4+ T cells in these human tissues are phenotypically tissue 
resident88. Thus, resident CD4+ T cells represent an immunological goldmine of 
unanswered questions waiting to be addressed. 
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In mice, CD4+ TRM have been described in the skin199, 218, lungs99, 102, 112, 133, 229, 250, FRT99, 
intestines237, salivary glands126, LNs251, and bone marrow118. In humans, analogous 
findings have been made in the skin82, 89, 103, 151, 152, FRT 144, 240, stomach136, 
conjunctiva146, salivary glands91, lungs82, 88, 90, 91, 131, 135, 252, gut82, 88, 90, 91, 253, and liver82. 
CD4+ T cells are often located in the parenchymal regions of these NLTs rather than at 
epithelial sites where CD8+ T cells tend to predominate108. For example, CD4+ T cells 
favour the dermis of the skin, and the underlying lamina propria of the FRT99, 151, 218. 
 
For both mouse and man, the majority of the same markers used for CD8+ TRM can be 
applied to their CD4+ counterparts (Fig. 1.2.3)91. CD4+ TRM display the effector memory 
phenotype (CD45RA-CCR7-), express CD69 and downregulate KLF-2 and S1PR188, 91, 
102, 133, 186. Just as for CD8+ TRM, CD69 is widely accepted as the best surface marker of 
resident CD4+ T cells91, 186. Again, similar to CD8+ TRM, the expression of CD49a, and an 
increased density of CD11a expression, was also favoured by different tissue-resident 
CD4+ T cells in the lungs102, 131, 254, although the association with CD49a was stronger in 
CD8+ T cells91. However, CD103 has repeatedly proved a very poor marker for CD4+ 
TRM23, 88, 91, 102, 126, 186, 213, 218, 255. Perhaps this is due to less reliance on epithelial tethering 
compared to CD8+ TRM, as in human skin CD103+ CD4+ TRM were only found in the 
epidermis, not the dermis152. Additionally, as part of the core gene expression signature 
that both human CD4+ and CD8+ TRM share, Kumar et al. identified upregulation of PD-1, 
CXCR6, and the downregulation of CX3CR191. Last, Wong et al. recently stratified human 
CD4+ TRM into four main clusters based on dimensionality reduction algorithms. They 
describe two subsets elevated in skin (CLA+HLA-DR-CD25-, CLA+HLA-DR+CD25+), and 
two lung-enriched subsets (CCR5+CD27-, CCR5+CD27-) (CLA – cutaneous lymphocyte 
antigen)82. 
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Figure51.2.2 - Common characteristics of human CD4+ TRM cells. Current knowledge on Shared 
phenotypic and functional features of human CD4+ TRM from different tissues. Markers associated with 
tissue retention, homing, functional inhibition; and commonly enhanced cytokines are shown in the top, 
right, left, and bottom quadrants respectively. All markers/cytokines shown have been reported on CD4+ 
TRM from at least two different NLTs, and in two independent studies. Tissue residence in CD4
+ TRM (like 
CD8+ TRM) is associated with the loss of tissue egress receptor S1PR1 (shown in grey with strikethrough 
font). CD103 and CD49a have been repeatedly associated with CD4+ TRM, but are often not a discriminator 
but markers of further subsets, hence their inclusion in parentheses. Figure concept drawn from Kumar et 
al. (ref 91). For additional information, see text.! !
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Recent work by Oja et al. investigated the transcriptional profile of CD4+ TRM in the lungs, 
partnering work performed by Hombrink et al. for lung-resident CD8+ T cells134, 135. This 
study revealed that lung CD4+CD103+ TRM express low levels of the tissue egress 
receptor S1PR1 and associated TF KLF2; transcriptional regulators T-bet and Eomes; 
and high CXCR3, CXCR6 and CCR5. Interestingly, although Hobit was upregulated at 
message level, no protein expression was seen, once again arguing against its use as a 
TRM differentiator in humans. The authors speculate it could be involved in lung CD4+ TRM 
development, and later dispensable in their maintenance. CD4+ TRM expressed high 
levels of effector cytokine mRNA, including IFN-g, but also high levels of inhibitory 
receptors such as CTLA-4, PD-1 and 2B4 to limit excessive TRM responses135. 
Interestingly, the lung CD8+ TRM described in the partner study by Hombrink et al. were 
extremely similar to the lung CD4+ TRM described by Oja et al., suggesting the residency 
signature supersedes differences in T cell lineage. These similarities included a reliance 
on the Notch1 signalling pathway for TRM presence in the lungs, as confirmed by knockout 
mouse models134, 135. 
 
Other than data on the reliance on Notch-1 for human lung CD4+ TRM135, limited research 
has been conducted on the development and maintenance requirements for CD4+ TRM, 
and the few existing studies are somewhat conflicted. Some have suggested that CD4+ 
TRM are more dependent on antigen for their development than CD8+ TRM, as this is the 
case in the salivary glands and FRT of mice99, 126. Perhaps antigen is not needed for 
maintenance in all tissues however, as Teijaro et al found that TRM can persist in the 
murine lung without cognate stimuli102. In the FRT of mice, CD4+ TRM organise into 
memory lymphocyte clusters (MLCs) along with CD8+ T cells, DCs, and macrophages99. 
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These MLCs were distinct from tertiary lymphoid organs (TLOs) as they had no lymphatic 
architecture, or GCs; and persisted in the absence of infection and inflammation256. These 
structures have been proposed to maintain CD4+ TRM through CCL5 secreted by 
macrophages within the cluster. This constitutive chemokine secretion was in turn due to 
low level CD4+ TRM-derived IFN-g caused by cognate signals, suggestive of a requirement 
for antigen for CD4+ TRM maintenance 256. Similar CCL5-dependent CD4+ TRM association 
in MLCs have since been observed in the dermis around hair follicles213.  
 
TGF-b is often vital for CD8+ TRM development and maintenance, acting partly through 
upregulation of CD103. Perhaps then as CD103 upregulation is a less important aspect 
of CD4+ TRM biology, TGF-b is consequently less important in their development. Some 
studies in the mouse salivary glands and intestines agree with this hypothesis126, 208, 
however in the kidney TGF-b is required for the development of CD103- CD4+ TRM cells257. 
It is plausible that other pro-inflammatory cytokines such as IL-12 and IFN-b could aid in 
the differentiation and persistence of CD103- CD4+ TRM, as has been shown recently for 
mouse intestinal CD103- CD8+ TRM210. It may be the case that like circulating memory 
CD4+ T cells, CD4+ TRM depend on IL-2 also69, 73, 74, 258. This has been shown for both 
allergic asthma- and LCMV-reactive TRM development in the lungs of mouse models259, 
260. Interestingly, both TH1 and TH2 type TRM cells required IL-2 for their generation, in a 
process where B cells inhibit the early formation of TH1 TRM, but are critical for their long-
term maintenance260. In sum, it can clearly be seen that despite the confusion created by 
these early studies that have so far investigated different species, tissues and TRM 
induction regimens; a combination of different tissue-specific cognate and non-cognate 
signals is likely needed to generate and maintain CD4+ TRM, and these signals are likely 
subtly distinct from those regulating CD8+ T cell residence. 
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Due to different tissue niche preferences, CD4+ TRM show distinct migration and 
morphology patterns to CD8+ resident T cells. Whilst resident CD8+ T cells in the 
epidermis display a resting dendritic morphology and slow velocities, CD4+ TRM retain 
more rounded shapes and are much more motile in the dermis, travelling greater 
distances within the skin218. Likewise, CD4+ TRM have been found spread out within the 
vaginal lamina propria, as well as aggregated in MLCs256. In the lung, while CD8+ TRM 
predominantly localise to areas of tissue injury, CD4+ TRM are thought to cluster in 
bronchus-associated lymphoid tissue structures135, 261. 
 
Some have postulated the increased motility of CD4+ T cells in tissue sites may also point 
to more transient tissue residency compared to CD8+ T cells. Collins et al. showed in 
parabiotic mice that the majority of CD4+ T cells are in equilibrium with the circulation of 
infection-naïve mice, and that CD69 and CD103 were modulated on entry and exit, 
suggesting transient residency. However, consistent with other studies in mouse models, 
and human skin, a long-term resident CD4+ T cell population formed after infection89, 152, 
213, 262. Thus, CD4+ T cells in tissue could comprise a more heterogeneous population 
than CD8+ T cells, including recirculating cells, transient residents, and long-term resident 
memory cells that together mediate optimum immunosurveillance. 
 
CD4+ TRM are superior to circulating CD4+ T cells in responses to many infections. In 
mouse models, this has been seen following infections of the lungs102, 112, 229, 263-265, 
skin199, FRT99, 124, and gut237, 266. Just like other CD4+ T cell lineages, the resident 
population controls infection efficiently through rapid recruitment and activation of other 
aspects of the immune system. In the skin, CD4+ TRM recruit and activate inflammatory 
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monocytes239, while in bone marrow resident CD4+ T cells provide B cell help through 
CD40-CD40L interactions118. In the FRT following HSV-2 infection, circulating CD4+ T 
cells take 2 days to enter the tissue, and a further 3 days to start secreting IFN-g, whereas 
CD4+ TRM are constantly secreting IFN-g at low levels and this can be enhanced extremely 
rapidly upon antigen encounter99. Furthermore, CD4+ TRM are sufficient to protect against 
HSV-2, even in the absence of CD8+ TRM267. As for CD8+ TRM, CD49a may act as a 
functional distinguisher of CD4+ TRM, In the murine lungs, CD49a+ cells had a far more 
robust IFN-g response and increased survival when compared to those lacking this 
molecule254. 
 
Human CD4+ TRM tend to be better cytokine producers than circulating CD4+ TEM. This is 
best illustrated through the study by Oja et al. where lung CD4+CD103+ TRM IFN-g, IL-2, 
and TNF-a responses not only more rapid than circulating memory equivalents, but of a 
better quality too. A great many more multifunctional responders were also present in the 
TRM pool135. In addition, an upregulation of both IL-2 and IL-10 have both been considered 
as hallmarks of TRM biology91. Watanabe et al. revealed TRM in human skin produce type-
1, type-2 and type-17 cytokines more efficiently than recirculating cells152, while Booth 
showed gastric CD4+ TRM displayed significantly higher IFN-g, TNF-a, and CCL4, as well 
as a higher CD107a expression marking enhanced degranulation and cytotoxicity136. 
Lung and spleen CD69+ TRM also express more IL-17 and IFN-g mRNA than their CD69- 
counterparts91. Comparing CD103+, and CD103- TRM in the skin, the former were the best 
cytokine-producers, but had a more limited proliferative potential152. CD4+ TRM in the lung 
are thought to be highly type-1-multifunctional, and enriched for influenza- and 
mycobacterium tuberculosis (Mtb)-specific clones131, 252. Finally, CD4+ TRM are also 
extremely likely to be involved in human autoimmune pathology. These cells influence 
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disease recurrence in psoriasis103, in a mechanism that likely involves long-term resident 
TH22 cells151. Furthermore, adoptive transfer of gut-resident CD4+ TRM into an 
immunodeficient host caused disease in inflammatory bowel disease (IBD) mouse 
models268, and fittingly may also be involved in the human disease253. 
 
Together, CD4+ TRM appear to be just as potent as CD8+ TRM in protection from infection, 
due to rapid activation and robust cytokine responses. Despite the limited data, their 
abundance in tissues, and proximity to barrier surfaces makes it almost undeniable that 
they are highly involved in protective responses, and by extension, organ-specific 
inflammatory disease. There may be a division of labour between CD4+ and CD8+ 
resident T cells, due to their distinct tissue niches, migration preferences, maintenance 
requirements, and inherent functions152, 186, 218. The specific contributions and 
collaborations between CD4+ and CD8+ TRM, CD4+ TRM longevity properties, and their 
exact roles in local immune responses in different tissues are all key questions still to be 
answered. 
 
 
1.3 The Liver as an Immune Organ 
 
1.3.1 Biology of the Human Liver 
 
The liver is a remarkable organ. It performs over 500 functions, including vital roles in 
digestion and nutrient storage, plasma protein synthesis, blood detoxification, and 
immune homeostasis. The importance of the liver in survival is emphasized by its size, 
being the largest internal organ; its receival of 25% of the cardiac output – more than any 
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other organ; and its unique ability to regenerate that likely evolved out of the necessity to 
protect these functions [reviewed in ref 269]. 
 
The liver produces and excretes bile, allowing the emulsification and subsequent 
breakdown of fats and fat-soluble vitamins270. It is involved in the metabolism and storage 
of proteins, carbohydrates, lipids, vitamins and trace elements. This allows for control of 
blood glucose levels; the storage of iron for erythrocyte production and the production of 
plasma proteins and hormones such as albumin, clotting factors, complement proteins 
and thrombopoetin; as well as many other roles. A wide range of endogenous proteins 
(urea, bilirubin etc.) as well as the majority of drugs are also metabolised in the liver, 
preventing build-up of toxic metabolites271-274. It is likely due to the large frequency of 
such potentially damaging insults the liver receives, as well as toxins from the gut, that it 
developed the ability to regenerate269. On top of these functions, the liver is considered 
an immune organ – containing a large immune component, acting as a second line of 
defence to pathogen entry through the digestive tract, and playing non-redundant roles 
in systemic immune tolerance275-277. 
 
One helpful way to visualise the liver architecture (Fig. 1.3.1) is through imagining its 
stepwise construction, beginning with the liver vasculature. The liver receives blood from 
two sources. Approximately 80% comes from both the portal vein which drains from the 
splanchnic circulation, carrying nutrients and microbial products from the gut. The 
remaining 20% arrives from the hepatic artery, which drains from the coeliac trunk278-280. 
Blood from both percolates as vessels branch further into liver sinusoids. Sinusoids are 
lined by hepatic sinusoidal endothelial cells (HSEC), unusual due to their large (50-
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180nm) fenestrations that allow solute access to hepatocytes271. Blood exits the liver via 
central veins that then drain into the hepatic veins280. 
 
Hepatocytes, the parenchymal cell of the liver, comprise between 60-80% of liver cells 
(and around 78% of tissue volume), and carry out all the main metabolic, protein 
synthesis, detoxification and storage functions discussed above279, 281-284. Hepatocytes 
are arranged in chords that radiate towards the centre of hexagonal hepatic lobules, 
running alongside the sinusoids. At lobule intersections are the portal areas which consist 
of portal venules and hepatic arterioles that carry blood to the liver, bile ducts, lymphatic 
vessels, and vagus nerve branches. Central veins are positioned at the centre of each 
lobule279, 285. Hepatocytes can be classified as zone 1, 2, or 3, ascending depending on 
the proximity to blood input from the portal areas. Hepatocytes in these different zones 
differ in their metabolic capacities, a phenomenon known as metabolic zonation271. A 
large proportion of resident macrophages called Kupffer cells, and liver-associated NK 
cells called Pit cells are located within the sinusoids; whereas in the space of Disse (the 
space between the abluminal side of the sinusoids and the basolateral surface of 
hepatocytes) hepatic stellate cells (HSCs) that are involved in storage and synthesis of 
vitamin A, and synthesis of extracellular matrix proteins can be found279, 284, 286. Of note, 
as well as the hepatic lobules, liver functional units can be described in terms of liver acini 
(that centre on input portal venules and hepatic arterioles), or portal lobules (that centre 
on portal areas)285. 
 
Finally, the biliary tree must be integrated into our representation. Hepatocytes produce 
bile that is secreted into bile canaliculi, formed by tiny passages formed between apical  
 
! (%!
!
Figure61.3.1 - Liver microarchitecture. A - Liver functional units can be described in terms of liver lobules 
(within black dashed area), acini (red dashed area), or portal lobules (blue dashed area). The liver lobule 
are hexagonal areas comprised of hepatocyte chords that radiate from portal areas (or portal triads) where 
blood enters at the hexagon vertices, towards central veins (CV) in the middle. A liver acinus shows a 
diamond-shaped area centred on portal vessels (that run between liver lobules - not shown) and shows the 
tissue area supplied by these branches. Contrastingly, a portal lobule centres on a portal triad and thus 
shows the area supplied (and drained by) by this triad. B - A portion of a liver lobule. Blood flows from portal 
veins (PV) and hepatic arteries (HA), mixes in the sinusoids, and exits the liver via the central veins. 
Hepatocytes (Heps) produce bile that travels along canaliculi towards bile ducts (BD) comprised of biliary 
epithelial cells (BEC) in the portal triad. C - Close up representation of a hepatic sinusoid. Hepatocytes lay 
underneath hepatic sinusoidal endothelial cells (HSEC) that themselves form the fenestrated sinusoidal 
endothelium. The space of Disse (SOD) is the gap between these two cell types, where hepatic stellate 
cells (HSCs) are located. Servier medical art utilised as the basis of part B. References: 271, 279, 285. 
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surfaces of neighbouring hepatocytes. From here bile drains towards the portal areas 
where it enters bile ducts, both lined by biliary epithelial cells (BEC)279, 285. 
 
1.3.2 Immunological properties of the Liver 
 
As well as being a key driver of innate immunity through complement and acute-phase 
proteins, cytokines and chemokines, the liver possesses an exceptionally large immune 
component279, 281. Kupffer cells are the largest resident macrophage population in the 
human body, representing 80-90% of all tissue macrophages281, 287. These cells play vital 
roles in the phagocytosis of microbes and debris, toxin clearance, and erythrocyte 
recycling288. Both antigen-presenting myeloid DCs (mDCs), as well as proinflammatory 
plasmacytoid DCs (pDCs) are also found in the liver under resting conditions289, primarily 
in portal areas in order to monitor the portal circulation290. Approximately 1010 
lymphocytes are contained within an average healthy human liver, containing both 
resident and recirculating cells281, 291. Particularly interesting is the large and unusual 
complement of innate lymphocytes. NK cells make up 30-50% of liver lymphocytes287. 
Whereas the two main NK cell subsets, CD56LO and CD56HI, are present at approximately 
a 9 to 1 ratio in the periphery, these subsets are similarly abundant in the liver289. Natural 
killer T (NKT) cells and gd-T cells are also markedly enriched in the liver compared to 
blood275. However, conventional, ab-T cells are still the dominant lymphocyte population 
in the liver, just like in blood275, 281, 289; but the CD4:CD8 ratio is reversed (2:1 and 1:3.5 
in blood and liver respectively)292. Of note, mucosal-associated invariant T (MAIT) cells 
(an innate invariant population that recognises the MHC class I analog MHC-related 1 
[MR1] that presents bacterial antigens) represents around 30% of T cells in the liver – 
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making them the largest innate T cell population in humans289. Lastly, B cells comprise a 
minor lymphocyte population, around 6% of liver lymphocytes281. 
 
Other features make the liver unique from an immunological standpoint. First, fenestrated 
endothelium and the lack of a substantial basement membrane allow T cells direct access 
to the underlying hepatocytes286, 293, 294. Such parenchymal access is not possible in other 
organs295. Second, contact time between T cells and liver APCs is increased by low blood 
flow rates caused by small sinusoid diameters, and perturbations due to physical 
occlusions by Kupffer cells281, 296. Third, HSEC possess phagocytic and antigen 
presentation capabilities, and express scavenger receptors and other markers more 
traditionally associated with lymphatic endothelium cells than vascular endothelium297. 
Fourth, the liver is the primary site of lymphocyte development in the foetus, which may 
have some evolutionary hangover effects to the adult liver environment298-300. Fifth, the 
liver is the only organ that can facilitate direct antigen presentation and activation of CD8+ 
294, 301, 302, as well as CD4+ T cells303. However, the outcome of these interactions is 
normally immune tolerance, the promotion of which is a defining aspect of liver 
immunobiology294, 296. 
 
1.3.3 Immune Tolerance in the Liver 
 
Regulation of T cell immunity must occur at every stage in order to prevent autoreactivity. 
Central tolerance in the thymus prevents the escape of potentially autoreactive clones. 
Peripheral tolerance has many aspects; including anergy or apoptosis in response to 
insufficient co-stimulation, and direct inhibition by TREGS. Intrinsic regulatory mechanisms 
exist, limiting T cell response times or magnitude; and inherent plasticity allows skewing 
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to different, less pathogenic, subsets (immune deviation), or egress from site of tissue 
damage. Although generally considered detrimental, immunosenescence and exhaustion 
(decline in cellular function that is age-associated, or due to chronic antigen stimulation 
respectively) both also suppress the immune response. Last, immune privilege applies to 
organs like the eye or the brain, where immune cell tissue access is limited304, 305. 
 
The liver is a highly tolerogenic organ, employing many of these mechanisms to limit 
immunity. It is likely that the necessity to promote tolerance over immunity evolved to 
prevent unnecessary responses to the multitude of food and microbial antigens arriving 
from the gut, as well as the numerous neo-antigens created by liver metabolism306. 
Hepatic immune tolerance was first observed when pig liver transplants were tolerated 
even across full MHC mismatch, and the paradigm subsequently strengthened when co-
transplant of other organs that were normally rejected alone, were accepted along with 
donor liver307, 308. Similarly, human allogenic liver transplants are tolerated better than 
other organs, even following removal of immunosuppressive regimens287. The liver is also 
responsible for the maintenance of oral tolerance277, 309. Last, tumours often metastasize 
to the liver, and the tolerance effect is misappropriated by certain pathogens such as HBV 
and hepatitis C virus (HCV)306.  
 
Multiple cell types can present antigen to CD8+ and CD4+ T cells in the liver; including 
hepatocytes, HSEC, Kupffer cells (KCs), resident DCs, and HSCs. All of these are 
involved in the liver tolerance effect. CD8+ T cells are often deleted, or left functionally 
impaired by these interactions; while CD4+ T cells preferentially undergo switching into 
more tolerogenic (TH2 and TREG) types, as well as suffering their own dampening of 
function (Fig. 1.3.2)284, 291, 306, 310, 311. 
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Immature mDC types (with low MHC and costimulatory molecule expressions) 
predominate in the liver, and interactions with these mDCs inhibits proliferation, and 
promotes anergy of CD8+ T cells; and can skew towards TH2 and TREG induction in CD4+ 
T cells281, 306, 310, 312, 313. Similarly, HSEC presentation to CD4+ T cells results in the 
dampening of TH1 functionality, but the enhancement of TH2 cytokine production310, 314. 
CD8+ T cells that recognise antigen displayed on HSEC are unable to proliferate or mount 
substantial cytokine responses, and undergo early apoptosis281, 306, 315, 316. KCs secrete 
inhibitory prostanoids and nitric oxide, and were vital in the development of systemic 
tolerance to portal antigen injection in mouse models. Furthermore, KCs and HSEC also 
constitutively express immunoregulatory cytokines IL-10 and TGF-b, that promote 
immature DC phenotypes and TREG induction277, 279, 306, 310, 311. Interestingly, it may be the 
constant exposure to the low levels of lipolysaccharide (LPS) (up to 1ng/ml in the portal 
circulation) that results in a state of ‘LPS-resistance’ among KCs and HSEC that in turn 
causes high IL-10 release in the liver and an overall dominant tolerance effect277, 279, 291, 
317. 
 
 
HSCs are an additional major source of TGF-b, and they too have been directly implicated 
in the generation of pTREGS through a retinoic acid-dependent mechanism in mice306, 318, 
319. Finally, many liver-resident cells (hepatocytes, HSEC, mDCs, pDCs and KCs) 
express inhibitory ligands such as programmed death-ligand (PD-L)1 and/or 2, or express 
first apoptosis receptor (Fas) ligand that directly promotes effector cell apoptosis; but do 
not express co-stimulatory ligands such as CD80 or CD86294, 310, 311, 320. To date, no 
evidence supports a role for BEC in modulating T cell responses through presentation284, 
291, 321. 
! ,'!
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Figure71.3.2 - Immune tolerance mechanisms acting on hepatic CD4+ T cells. Illustrated are the 
various ways that different hepatic cell types can promote tolerance in CD4+ T cells. Many cells directly 
inhibit T cell activation or cause apoptosis through inhibitory ligands PD-L1 and/or first apoptosis receptor 
(FasL). Additionally, direct inhibition through inhibitory cytokine production has been shown for HSECs, 
KCs, intrahepatic TREGS, and HSCs. KCs can additionally produce nitric oxide (NO) and inhibitory 
prostanoids such as prostaglandin E2 (PGE2). Many different liver cells can present antigen to CD4s, either 
through constitutive or induced MHC class II expression; but such interactions often skew to the TH2 (HSEC, 
mDC, hepatocyte), or TREG lineages (mDC, HSC). Hepatocytes may also be able to induce TR1 type cells 
in mice322; while HSECs can dampen TH1 function314. MDSCs can suppress CD4
+ T cells through L-Arginine 
(L-Arg) depletion323. Finally timely live cell engulfment (entosis) and release may act as a suppression 
mechanism by preferentially releasing TREGS when required, although this has not been experimentally 
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verified (hence the ? [Z.Stamataki, unpublished data]). For further details and additional cellular 
interactions, see text body.                  (Legend cont. on next page) 
Lineage skewing is shown by normal arrows (where lineage listed along the arrow is being skewed 
towards), and by inhibition arrows (where lineage skewed away from is listed). Figure inspired by design 
from Crispe, 2014 (ref 311). Additional references used - 277, 294, 306, 310, 312, 319. 
 
 
Therefore, non-parenchymal cells from the liver are extremely good at preventing full T 
cell activation. Interestingly, other liver subsets control T cell responsiveness. These 
include myeloid-derived suppressor cells (MDSCs) that constrain T cell activation323, 324; 
and intrahepatic myeloid cell aggregates for T cell clonal expansion (iMATES) that 
promote CD8+ T cell activation311, 325. Finally, innate lymphocytes such as NK and NKT 
cells also alter the balance of T cell immunity vs. tolerance in the liver326-330; 331. 
 
Hepatocytes also contribute to immune tolerance. Hepatocytes only express MHC class 
I constitutively, though MHC class II and costimulatory molecules can be upregulated by 
inflammatory signals – a unique feature amongst all parenchymal cells277, 332, 333. 
Therefore, most work on hepatocyte - T cell interactions has focussed on CD8+ T cells. 
In contrast to when antigen is presented conventionally in lymph nodes, exclusive antigen 
expression on hepatocytes leads to dysfunctional CD8+ responses in transgenic mouse 
models296, 334-337. Benseler et al. more recently demonstrated three waves of hepatocyte-
mediated CD8+ T cell tolerance as a result of these interactions. First around 80% of the 
cells are deleted by suicidal emperipolesis (an antigen-specific active T cell invasion into 
hepatocytes, followed by their lysosomal degradation), while most of the remaining cells 
are inhibited through PD-1-PD-L1 interactions. Any leftover cells display low TCR 
expression levels and are functionally unresponsive294, 338. Because of the massive 
deletion of activated CD8+ T cells in the liver, the liver has been described as a T cell 
‘graveyard’ in the past, referring to the idea that the liver is where many activated systemic 
T cells go to die339-341. It has long been known that liver CD4+ and CD8+ T cells are more 
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activated than cells in the blood314, 342, and influenza-specific T cells can be found in the 
liver where they cause bystander damage, despite no intrahepatic virus presence343. 
However, it is important to point out that by no means all cells that travel to the liver are 
deleted; effective immune responses can still be achieved in the liver; and the liver is a 
hospitable environment for memory cells277, 296. 
 
Meanwhile, forced MHCII expression on hepatocytes results in cognate CD4+ T cell 
activation, but insufficient to cause hepatitis in mice332. Furthermore, murine CD4+ T cells 
that encountered antigen on hepatocytes were skewed towards TH2 functionality, and 
were less able to provide help to virus-specific CD8+ T cells344. Indeed, hepatocytes are 
such powerful agents of immune tolerance that when Lüth et al. expressed myelin basic 
protein in hepatocytes, mice were protected from otherwise lethal autoimmune 
neuroinflammation in an MS model in a TREG-dependent manner345. Others suggest 
mouse hepatocytes are able to induce inhibitory TR1 cells 322. In vitro studies have shown 
human hepatocytes modulate mDCs to inhibit CD4+ T cell activation through IL-10346, and 
are thought to be able to directly cause apoptosis in T cells through PD-L1 expression347. 
Furthermore, our lab have demonstrated human hepatocytes can engulf, store, and 
excrete CD4+ T cells, particularly conventional TREGS [unpublished observations]. 
However, whether this promotes tolerance through the timely release of stored TREGS, or 
prevents excessive inhibition through regulatory T cell sequestration, is still under 
investigation. 
 
Despite these multiple regulatory measures, the liver can promote immunity to certain 
pathogens such as hepatitis A virus; or in individuals that spontaneously clear HBV or 
HCV infection. Overriding liver tolerance can be caused by proinflammatory signals such 
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as type I IFNs, or toll-like receptor (TLR) ligands; or due to cross-presentation by certain 
conventional APCs in the liver, or in SLOs281, 294, 295, 325, 348-350. Third, antigen density plays 
a key role, with lower densities of antigen favouring full activation (as lower antigen 
density presumably promotes only the activation of strongest affinity T cells and limits T 
cell exhaustion)294, 302. Therapeutically, checkpoint blockade agents that target inhibitory 
molecules such as PD-1 or its ligands have shown some efficacy in the reversal of T cell 
exhaustion and the restoration of protective immunity294, 351, 352. Unfortunately though, T 
cell responses are compromised in many chronic liver diseases, as discussed below 
(section 1.3.5). 
 
 
1.3.4 T cell migration into the Liver 
 
Homing molecules are the ligands and receptors involved in the chemotaxis, localisation 
and retention of leukocyte subsets. Broadly they can be parsed into chemokines and 
adhesion receptors. Chemokines (chemotactic cytokines) are small proteins that 
specifically attract leukocytes that express their apposite receptors. Chemokines are 
named based on the amino acid composition at the first two cysteine residues (CC, CXC, 
and CX3C chemokines possess 0, 1, and 3 amino acid residues between these cysteines 
respectively; while the non-conformist XC chemokines lack two adjacent cysteine 
residues)353. Chemokines are promiscuous, often biding multiple receptors with differing 
affinities, and causing subtly different responses in different cell types; allowing for 
extremely detailed control of leukocyte migration354. Adhesion receptors include integrins 
and selectins that allow physical tethering and retention of immune cells; as well as 
extravasation into tissues. Together these homing receptors allow for precise control of 
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locomotion, directing immunity and homeostasis through tissue-specific programmes 
(see 3.1). 
 
The process of leukocyte migration across endothelium and into tissue can dogmatically 
be broken down into four steps. First is the capture phase where weak leukocyte 
interactions, often mediated by endothelial selectins, continually form and break, slowing  
immune cell migration and producing characteristic rolling. Next, chemokines presented 
on the endothelial glycocalyx are detected by the leukocyte, resulting in conformational 
activation of integrin molecules that in turn mediate firm adhesion, the third stage. Finally, 
leukocytes extravasate into the tissue, following chemokine signals to the focus of 
inflammation286, 355. 
 
While this process is followed in most vascular beds, migration into the liver displays a 
number of stark differences. First, most immune cells enter the liver parenchyma through 
the sinusoids, whereas in most other organs, tissue access is largely restricted to post-
capillary venules356, 357. Second, HSEC express very low levels of selectin molecules 
constitutively, and the leukocyte rolling phase does not occur in the liver356, 358-361. The 
slow/intermittent flow in sinusoids may negate the need for this step, with cells skipping 
straight to firm adhesion instead; or other molecules such as Intracellular adhesion 
molecule (ICAM)-1 or vascular adhesion protein-1 (VAP-1) take up this role in the hepatic 
sinusoids286, 360, 362. HSEC constitutively express ICAM-1 and ICAM-2 at a higher level 
than other endothelial cells, as well as low levels of VCAM-1; and upregulate all three 
further following inflammation286, 363. Both ICAM-1 and VCAM-1 have proved important in 
optimum adhesion to HSEC in vitro362, 364, as well as Stabilin-2 – an integrin aMb2 ligand 
also constitutively expressed by HSEC365. Third, the extravasation process is distinct as 
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HSEC lack tight junctions and consequently express low levels of cell junctional molecule 
and extravasation-linked CD31, which is strongly expressed in other vascular 
endothelium355, 360, 366. Fourth, HSEC can express many molecules more typical of 
lymphatic than vascular endothelium. These include scavenger receptors such as CD36, 
liver/lymph node-specific intercellular adhesion molecule-3-grabbing integrin (L-SIGN), 
lymphatic vessel endothelial hyaluronan receptor-1 (LYVE-1), common lymphatic 
endothelial and vascular endothelial receptor-1 (CLEVER-1); and transmembrane 
glycoprotein VAP-1297, 356, 367. CLEVER-1 and VAP-1 are of particular importance in 
recruitment to the human liver. CLEVER-1, constitutively expressed on HSEC but 
upregulated further in inflammation, promotes the transmigration of TREGS 
preferentially368, 369. VAP-1 is constitutively expressed on resting HSEC and lymphatic 
endothelium, but not any other vascular beds360. VAP-1 mediates firm adhesion and 
transmigration364, 370-372, and through its unusual monoamine oxidase activity promotes 
the upregulation of ICAM-1, VCAM-1, MAdCAM-1, and selectins; and binding of gut-tropic 
a4b7 lymphocytes373-376. Membrane-bound VAP-1 levels are increased in steatohepatitis; 
and the levels of soluble VAP-1 and its enzymatic activity correlate with disease activity 
in chronic liver, but not other inflammatory diseases376-381. For summary, and a 
comparison with portal vascular endothelium homing molecule requirements, see Fig. 
1.3.3. 
 
Certain homing molecule combinations endow T cells with specific tissue-tropism. For 
example, integrin a4b7 and CCR9 expression; and combinations of CCR4 and CCR10 
promote homing to the gut and skin respectively116. However, to date no tissue specific 
phenotype has been attributed to the liver360, 367. T cells expressing CCR1, CCR5, 
CXCR3, or CXCR6 are all preferentially recruited into inflamed liver tissue; but all of these 
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receptors are associated with general inflammatory infiltrates rather than specific for 
liver353, 367, 382, 383. CCR5 ligands CCL3-5 are expressed at portal endothelium, and 
consequently intrahepatic CCR5+ T cell frequencies are particularly high353, 360, 362, 367, 382, 
384. CXCR3 ligands CXCL9, CXCL10, and CXCL11 are all produced by inflamed HSEC, 
as well as hepatocytes, stellate cells, KCs, other infiltrating leukocytes, and damaged 
BEC in primary biliary cirrhosis (PBC)353, 356, 385-387. TH1, TH17, and effector CD8+ T cells 
all express CXCR3 at increased levels in inflamed human livers, allowing their recruitment 
through sinusoidal endothelium and into the hepatic parenchyma353, 367. Other chemokine 
receptors are then likely responsible for subsequent positioning, such as CCR6 in TH17 
migration to bile ducts388. Interestingly, CXCR3 is also used by TREGS in liver migration, in 
order to co-localise with their TEFF counterparts353, 367. Upon reaching the liver, TREGS then 
use CCR10 or CCR4 to locate near cholangiocytes or intrahepatic DCs respectively389, 
390. CXCL16 is mostly expressed on inflamed BEC, but also hepatocytes and HSEC391; 
and so attracts T cells expressing its apposite receptor CXCR6353. CXCR6 expression 
has been shown to be essential for the retention of T cells in the liver148, 180, 392, 393; and 
the same can be applied for CXCR6 expression on  
NK, and NKT cells394, 395; arguing of its importance as a liver retention marker. The 
immune cell possession of other chemokine receptors have also been linked to homing 
to particular areas of the liver. For example, CXCR1+ T cells have been shown to be 
associated with inflamed hepatocytes396, and CCR6, CXCR4, and CX3CR1 have all also 
been associated with infiltration of bile duct areas353, 388, 389, 397-399. Intrahepatic 
CCR7+CD62L- T cells have also been described, leading to suggestions these cells are 
trafficking to draining lymph nodes via afferent lymphatics, or associated with tertiary 
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Figure81.3.3 - Homing molecules in lymphocyte recruitment to the inflamed and non-inflamed 
human liver. A - Non-inflamed portal vasculature constitutively expresses ICAM-1, ICAM-2, and VCAM-1. 
VAP-1 is also present alongside junctional adhesional molecules  (JAMs) and CD31. Low levels of portal 
associated cytokines CCL3, CCL4 and CCL5 are also presented at rest. B - Following inflammatory signals, 
upregulation of E-, and P-selectins is observed; as well as CCL25 and MAdCAM-1 (ligands for gut-
associated T cell homing receptors CCR9 and integrin #4$7 respectively). CCL28 and CCL21 upregulation 
can also be observed (CCL21 upregulation has been associated with the formation of portal-associated 
lymphoid tissue400). C - HSEC also constitutively express VAP-1, and both ICAM molecules, as well as 
CLEVER-1 and Stabilin-2. Levels of JAMs and CD31 are low, perhaps owing to the lack of tight junctions 
between HSEC. HSEC express low levels of CXCR3 ligands (CXCL9-11), and CXCR6 ligand CXCL16; 
and production of all of these is increased in inflammation, as well as gut-tropic ligands CCL25 and 
MAdCAM-1(D). Image adapted from reference 363, which was itself an adaptation from reference 401.!
  
Fig. 1.3.4 - Molecular determinants of lymphocyte migration to the non-inflamed, and 
inflamed human liver 
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lymphoid structures that are present in many chronic liver diseases353, 362, 392. Last, 
evidence from an overlap between the gut and liver immune system comes from data 
showing that the chronically inflamed hepatic endothelium in IBD-associated livers 
expresses CCL25 and mucosal vascular adressin cell adhesion molecule-1 (MAdCAM-
1) that attract T cells expressing the gut-tropic homing molecules CCR9 and integrin 
a4b7401-404. Moreover, in mouse livers, HSEC can directly imprint this gut-tropic phenotype 
independent of intestinal DCs405. 
 
A recent study uncovered a novel intrahepatic T cell migration mechanism. Guidotti et al. 
utilised multiple advanced imaging approaches to suggest that surprisingly, early CD8+ 
effector T cell trafficking in transgenic mouse livers was independent of a4 and b2 
integrins, VAP-1, chemokine receptors and antigen recognition. Instead, for many TEFF, 
arrest depended on docking to endothelium-bound platelet aggregates. This allowed 
subsequent crawling along the endothelium, probing underlying hepatocytes through 
fenestrae, and even exerting of cytotoxic effector functions on target hepatocytes, all from 
within the sinusoids406, 407. Although compelling, this study only accounts for the early 
migration of 50% of CD8+ TEFF cells in mice – finding the others to be independent of all 
these adhesion mechanisms! Of note, another study found murine naive CD8+ T cells to 
rely on ICAM-1 - aLb2 integrin interactions for antigen-dependent trapping in the liver408, 
indicative of disparate context and cell-type dependent mechanisms. As discussed 
above, in humans VAP-1, integrin binding, and chemokine receptor expression are all 
undoubtedly important for the adhesion and migration of many T cell types356, 360, 385, 388, 
390; but nevertheless, it will be interesting for future studies to determine whether platelet 
docking can account for a proportion of human liver T cell trafficking phenomena, and 
whether this can also be applied to CD4+ T cells. 
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The fate of effector T cells following migration into the parenchyma has been far less 
studied than requirements for entry. Conceivably, these cells would either apoptose, 
egress back to the circulation, or remain resident once they have carried out their effector 
functions. Excitingly, immunologists are beginning to investigate liver resident T cell 
populations, a topic covered fully in section 5.1. 
 
1.3.5 T cells in Liver health and pathology 
 
Despite the remarkable ability of the liver to cope with most insults, chronic liver injury is 
a major worldwide healthcare problem. Most commonly, causes include repeated abuse 
with alcohol or poor diet, hepatotropic viruses, or autoimmune attack. Regardless of 
underlying cause, progression to chronic liver disease displays the same hallmarks – 
persistent inflammation that leads to fibrosis, cirrhosis and increased risk of liver 
cancer409. This section will briefly cover roles and phenotypes of CD4+ T cells in each 
liver disease aetiology used in this study.  
 
1.3.5.1 The Healthy Liver 
 
Data from recent tissue mapping studies investigated T cell phenotypes and function in 
healthy livers. Of relevance to our work, Wong et al. has demonstrated intrahepatic CD4+ 
T cells tend towards CXCR3, CXCR4, and CCR7 expression, and like most other tissues, 
TH1 cells comprised the biggest population82. Although analyses of bulk populations may 
not reveal distinct expression patterns, donor numbers were low, and portal flush 
methodology was used instead of tissue digestion; this study still provides a good 
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introduction to intrahepatic CD4+ T cell phenotypes82. Otherwise, data on CD4+ T cells in 
the human liver is surprisingly scarce. Some studies have gathered limited data on 
healthy intrahepatic CD4+ T cells as controls for their investigations into disease 
populations; showing for instance that both TREGS390, 410, 411, and TH17 cells412, 413, are 
scarce in the healthy human liver. Other studies have investigated CD8+ T cells in the 
healthy liver in much more depth148, but it remains to be seen whether liver CD4+ T cells 
display similar alterations to their better studied CD8+ counterparts. 
 
1.3.5.2 Autoimmune Liver Disease 
 
Autoimmune hepatitis (AIH), PBC, and primary sclerosing cholangitis (PSC) comprise the 
three main autoimmune liver conditions. AIH is characterised by interface hepatitis and 
autoimmune-mediated destruction of hepatocytes; while the targeted cells in PBC and 
PSC are the BEC of small interlobular and medium hepatic bile ducts respectively414. The 
exact aetiology behind these diseases is unknown, suffice to say that all three develop 
due to complex genetic and environmental interactions. Hepatocyte-derived autoantigens 
stimulate T cell activation and damage in AIH, possibly through molecular mimicry or 
failed central tolerance mechanisms; and resultant self-perpetuating multi-cellular 
immunity ensues414, 415. Mitochondrial constituent pyruvate dehydrogenase complex, E2 
subunit (PDC-E2) is a major autoantigen in PBC, and forms the basis of one pathway to 
injury. Modified PDC-E2 can be found on the surface of apoptotic cells. However, 
apoptotic cholangiocyte PDC-E2 remains unmodified, acting as an immunogenic apotope 
(apoptotic epitope)284, 416-418. This stimulates immune responses in susceptible 
individuals; leading to further biliary cell destruction, neoantigen generation and increased 
antigen presentation in the inflamed area414. Interestingly, molecular mimicry may also 
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be at play as anti-PDC-E2 antibodies cross react with several bacterial species including 
E. coli, and a member of the Sphingomonas genus; and several commonly used 
xenobiotics can modify PDC-E2 to increase immunogenicity414,419-421. Finally, PSC is 
thought to develop from excessive responses to microbes, or innocuous antigens that 
propagates further injury, biliary inflammation and again, neoantigen formation414. 
Importantly, if left untreated, all three diseases progress to liver failure. 
 
T cells form major components of liver autoimmunity. T cells are highly represented in 
inflammatory infiltrates, and in AIH these are predominantly CD4+ T cells414. Typical of 
autoimmune pathologies, TH1 responses are believed to predominate, as demonstrated 
by studies on human blood in AIH and PBC422;423, 424; as well as the liver in PBC and 
PSC425-427;428. However pathogenic TH17 cells may also play key roles. In AIH, preliminary 
studies have demonstrated expansions of circulating and intrahepatic TH17 cells and 
associated cytokines IL-17, IL-23, IL-1b and IL-6. Furthermore, IL-17 stimulated the 
further release of IL-6 from hepatocytes, positing the idea of positive feedback to generate 
more TH17 cells413. In PBC, circulating TH17 cells can be found in greater number429, and 
liver-infiltrating IL-17+ lymphocytes are also increased in abundance412. The importance 
of TH17 cells in PSC pathogenesis is highlighted by the association of genes involved in 
TH17 differentiation and signal transduction with disease in genetic linkage studies414, 430. 
Accordingly, bacteria in portal ducts in PSC has shown to stimulate TH17 responses from 
PBMCs in vitro431. 
 
TREG alterations have also been documented in liver autoimmunity, although results have 
often been contradictory (seemingly largely due to variations in TREG markers used). 
Depletions in the number and suppressive capacities of TREGS in AIH patient blood have 
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been documented432, 433; but more recent data using a more complete marker set 
(FoxP3+CD25HICD127LO versus CD25+) argues against defects in either parameter, and 
actually argues for increased TREG frequencies in active disease434. Furthermore, no 
numerical TREG deficit is observed in AIH livers390, 435. Similarly, arguments over the 
existence of TREG depletion in PBC patient blood continue410, 411, 429, though it is generally 
agreed that the frequency of liver-infiltrating TREGS in PBC is significantly lowered411. 
Thankfully, no data yet contradicts the finding that TREG frequency and function is 
decreased in both liver and blood of PSC patients436, 437. 
 
Comprehensive characterisation of liver-infiltrating human T cells is required to further 
identify disease-linked culprit populations and/or pathways relevant to the pathogenesis 
of these cells. Sadly though, such studies are largely lacking. One in-depth study by 
Liaskou et al. illustrated a 10-fold enrichment of CD28- CD4+ T cells in PSC livers. These 
cells were predominantly TEM; expressed CXCR6, CX3CR1, and CCR10 that are 
associated with biliary tract infiltration; and possessed high cytotoxic potential. 
Interestingly, proinflammatory TNF-a induced CD4+CD28- T cell differentiation in vitro, 
while active vitamin D inhibited it437. This may relate to an older study that noted impaired 
proliferation and cytotoxicity of liver infiltrating lymphocytes in PSC, an effect that too was 
partially dependent on TNF-a428. Similarly, CD28- T cells may be important in PBC too. 
Isse et al. showed elevated CD4+CD28- T cell numbers in damaged bile ducts in PBC438; 
while Tsuda et al. found an enriched population of CD28- CD57+ CD8+ TEM that 
preferentially expressed integrin-a4b7 and secreted increased levels of IFN-g and IL-5 in 
PBC patient blood, alongside evidence that CD8+CD57+ cells infiltrate into portal areas in 
the disease439. 
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1.3.5.3 Dietary Liver Injury 
 
Alcoholic liver disease (ALD) and non-alcoholic steatohepatitis (NASH) are very common 
liver diseases in the western world. As their names suggest, these conditions are 
principally due to chronic excess alcohol consumption, and sustained excess caloric 
intake respectively (though clearly stratification into one or the other group is not always 
straightforward). Non-alcoholic fatty liver disease (NAFLD) is commonly used to refer to 
a less advanced dietary liver injury that is not associated with inflammatory and fibrotic 
damage. 
 
ALD is an inflammatory disease. Toxic by-products of ethanol metabolism not only cause 
hepatocyte apoptosis directly, but lead to excess radical formation and related adducts 
that stimulate inflammation through acting as damage-associated molecular patterns 
(DAMPs) and/or B and T cell immunogens440, 441. Chronic ethanol exposure itself also 
activates Kupffer and NKT cells, upregulates TLR expressions, promotes hepatocyte 
proinflammatory cytokine production442. Continuing damage often appears to lead to the 
development of associated autoimmunity, against cytochrome P450 enzymes, or 
oxidised phospholipids for example442. Inflammatory processes also drive the 
pathogenesis of NASH. In this condition, hepatocyte cell death is caused by lipotoxicity 
and oxidative injury. Hepatocyte death leads to DAMP formation, stimulation of TLRs, 
activation of innate immune cells and subsequent adaptive cell recruitment which 
continues the inflammatory cycle. Pro-inflammatory adipokines from adipose tissue, and 
bacterial endotoxin leakage into the circulation can both also contribute to this 
progression443, 444. Like ALD, adaptive immune responses against lipid peroxidation by-
products are frequently detected in NASH patients445. 
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ALD liver infiltrates contain both CD4+ and CD8+ T cells441. However, in alcoholic patient 
blood, one study reported a decrease in all T cell numbers, especially within the CD8+ T 
cell compartment446. TNF-a concentrations are raised in the plasma of alcoholic patients, 
prompting vague speculation that TH1 responses are important to pathology447. More 
peripheral blood data shows elevations of activated CD57+ CD4+ T cells in ALD, but these 
activated cells are seen in many inflammatory conditions448. The only study found that 
investigated intrahepatic T cells in ALD demonstrated a clear increase in TH17 cells 
(assumed from CD3+IL-17+ staining), the frequency of which correlated with patient 
fibrosis scores449. 
 
T cells are thought to be involved in the progression to NASH in patients and different 
mouse models of disease444, 445, 450-452. In one mouse model, injury was driven by 
increased representation of activated TH1 cells that promoted proinflammatory 
macrophage activation. Interestingly, both T and B cell responses against a lipid 
peroxidation adduct were detected450. This same adduct is also detected in many NASH 
patients450. A recent study reported significantly fewer intrahepatic CD4+ T cells in mice 
models of NASH that was driven by cell-type-specific free fatty acid-mediated oxidative 
processes. They also showed very low numbers of intrahepatic CD4+ T cells in human 
livers, reduced compared to viral disease, though comparable to healthy controls453. In 
human studies, Inzaugarat et al. documented increases in circulating human CD4+ T 
cells, specifically in memory CD4+ T cells that were producing IFN-g454. Rau et al. provides 
data that show human peripheral CD4+ T cells make more IFN-g too455. Data from 
Boujedidi et al. indicate a disease specific alteration in chemotaxis – showing peripheral 
CD4+ T cells from NASH patients migrate better to CXCL12 than control subjects456. 
 66 
Mouse models heavily implicate TH17 cells in the pathogenesis of NASH457-460, whereas 
TH22 cells may be protective458. Furthermore, IL-17 promotes steatosis and pro-
inflammatory IL-6 production from the human hepatocyte cell line HepG2, suggestive of 
a mechanism457. In human livers, elevated levels of IFN-g461; as well increases in IL-17, 
IL-17-expressing T cells, and other TH17-related genes have been detected412, 455, 457, 462. 
The study by Rau et al. is the best of its kind to date to phenotype intrahepatic CD4+ T 
cells in NASH. It concludes they are more activated and more capable of IFN-g, IL-4, IL-
17, and IL-21 production than healthy liver controls, perhaps not a surprising finding given 
the inflammatory nature of the condition. However, they did demonstrate that progression 
to NASH correlated with intrahepatic TH17 frequencies455, demonstrating early signs of 
their importance in human NASH pathogenesis451. The authors also put forward a 
decrease in naïve TREG frequency in the blood, although minimal changes were seen in 
activated/memory TREGS455. Other than this study, it is unclear whether TREG phenotype 
or function is affected in NASH; with studies using mouse models currently conflicted 
about whether there is a relative reduction of these cells within livers463, or not453. 
 
1.3.5.4 Viral Liver Disease 
 
Hepatitis B virus (HBV) and hepatitis C virus (HCV) are the two most significant 
hepatotropic viruses; with chronic infection respectively affecting approximately 350, and 
170 million people worldwide464. HBV infections are usually self-limiting, with 95% of 
those infected spontaneously clearing the virus. However, HCV infection progresses to 
chronicity in the majority (~70%)465. An efficient prophylactic vaccine only currently exists 
for HBV infection,  although a promising HCV vaccine is currently in phase II clinical 
trial464, 466. Effective treatment options consist of type 1 IFNs for both chronic infections, 
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nucleoside/nucleotide inhibitors for chronic HBV, and ribivarin and new direct acting 
antivirals for chronic HCV infection464, 467. 
 
Many similarities exist in the immunopathology of both diseases. CD4+ and CD8+ T cell 
responses are vital in the clearance of HBV and HCV465 468-470, although neutralising 
antibodies are only currently thought to be critical in controlling HBV infection464, 471. T cell 
responses against both viruses must be robust, sustained, and of broad specificity in 
order to mediate complete spontaneous clearance465,464. Accordingly, progression to 
chronicity is associated with T cell exhaustion, and substantial clonal deletion in HCV and 
HBV alike. HCV- and HBV-specific CD4+ T cells from the liver as well as peripheral blood 
of patients often express high levels of exhaustion markers such as PD-1472;473, and T-
cell immunoglobulin and mucin-domain containing-3 (Tim-3)474;475; and substantial 
impairments in proliferation and cytokine production476-484;485. Likewise, similar exhausted 
phenotypic and functional alterations have been observed on peripheral and intrahepatic 
CD8+ T cells in patients with chronic HCV351, 474, 486-490, as well as chronic HBV infection473, 
475, 491-498. The better studied exhausted antiviral CD8+ populations can also present with 
high levels of KLRG-1, 2B4, and CTLA-4; and low expression of CD127192, 488, 489, 494;493, 
499-501. Notably, the most exhausted cells in both patient groups present at an intermediate 
(CD27+ TEM) and not late (TEMRA) differentiation stage488;499. Partial reversal of the 
exhaustion phenotype has been observed following blockade of one or more of these 
inhibitory receptors in vitro351, 489, 494, 502-504;473, 475, 485. However, even blocking multiple 
inhibitory receptors did not have any effect on some patient T cells505, and PD-1 blockade 
has so far had limited therapeutic efficacy in patients with chronic HCV352.  
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The reasons behind the weak T cell responses in chronic HBV and HCV can be blamed 
on the interlinked events of viral persistence, lack of sufficient CD4+ T cell help, and 
excess immunoregulation465. In addition, viral escape is thought to play a big role in 
subverting T cell responses in HCV464, 465. Interestingly, progression to chronicity in HBV 
is thought to be worsened when antigen-specific CD8+ T cell responses are inadequate 
to control infection, and so ongoing inflammatory processes recruit non-specific 
‘bystander’ T cells that cause inflammatory damage without the benefit of specifically 
targeting infected cells496, 506. TH1 responses are correlate with clearance in both 
diseases482, 507;491, 508, 509, while conflicting data on TH17 responses means their exact role 
in clearance is still unclear504, 510-513;514, 515. A recent study has also implicated inducible 
T-cell costimulator (ICOS)+ TFH cells in the clearance of HCV516. By contrast, increases 
in numbers and regulatory capacity of TREGS has been documented in the blood and liver 
of HCV patients504, 517-522. Analogously, the field is in agreement that TREG numbers are 
increased in chronic HBV blood, but some dispute whether their ability to inhibit effector 
T cells is affected523-525; although intrahepatic TREGS are thought to be both increased in 
numbers and function526. Additionally, granulocytic MDSCs have associated with 
preventing robust anti-HBV T-cell responses through an L-arginine depletion 
mechanism323, whereas NK cells have been shown to directly kill antiviral intrahepatic 
CD8+ T cells in chronic HBV328. Finally, a role for MDSCs in promoting HCV persistence 
has also been hinted at, with MDSCs suppressing CD8+ T cells through the production of 
reactive oxygen species527. 
 
As mentioned above, dissecting immune responses within the human liver is key to 
understanding and altering the disease course. Alongside the studies discussed, recent 
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work involving resident T cell subsets in HBV infection has deepened our knowledge on 
the contribution of this crucial subset to pathogenesis148, 149 (see 5.1). 
 
1.3.5.5 Other Liver Diseases 
 
The sections above cover the vast majority of the liver aetiologies used in this study. The 
remaining samples were acquired from patients with polycystic liver disease (PLD), non-
cirrhotic portal hypertension (NCPH) Budd-Chiari syndrome (BCS), and cryptogenic liver 
disease. One sample came from a sufferer of secondary biliary cirrhosis (SBC), while the 
majority of control peripheral blood used was obtained from patients with 
haemochromatosis (HFE). 
 
PLD is a genetic disorder culminating in the growth of cysts throughout the liver, which 
can infrequently obstruct portal or hepatic vein blood flow leading to liver failure528. NCPH 
is a broad spectrum of diseases encompassing any cirrhosis-independent process that 
substantially increases portal venous blood pressure. Such factors include prothrombotic 
conditions, infections and immune disorders, or exposure to certain medications529. BCS 
is a form of NCPH where hepatic venous outflow is specifically obstructed530. SBC on the 
other hand, describes bile duct obstruction that is not caused by autoimmune attack of 
BEC. HFE is another genetic disorder, this time affecting the regulation of iron levels in 
the bloodstream. Sufferers absorb, and deposit excess iron within hepatocytes, which 
can lead to liver damage and eventual cirrhosis531. Lastly, as the name suggests, 
cryptogenic liver disease is defined by unknown aetiology. 
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The broad (or unknown) nature of most of these diseases makes immunology research 
largely inane. There does not appear to be any studies on altered T cell responses in 
PLD, but some differences within HFE patients do occur. Relatively low numbers of CD8+ 
T cells in blood and liver have been reported, but most studies show that CD4+ T cell 
numbers are unaffected532-536. 
 
1.3.6 Tissue Resident Memory cells in the Liver 
 
Like many other organs, TRM have also been identified in the human liver82, 148, 149, and 
have already been shown to be important in HBV pathogenesis148. A full and detailed 
discussion on the current knowledge on liver TRM is covered in section 5.1, and so will not 
be repeated here. 
 
 
1.4 Investigation aims and hypotheses 
 
Given the immunological properties of the liver in health, and the need to further identify 
relevant populations in liver pathology; the liver is an attractive organ for further study. 
From the above discussion, it is evident that there are a number of gaps in our 
understanding. First and foremost, CD4+ T cells, a population of such importance to 
global immunity, are drastically understudied in the human liver. Second, while the 
migration of T cells into the liver has been well characterised; the consequences once 
they reach the parenchyma are still debated. How long do cells stay, and what 
characteristics and new abilities might the hepatocytes imprint them with? This links us 
nicely to the immensely important TRM population. The paucity of CD4+ T cell knowledge 
extends to the TRM field, and especially the hepatic compartment where no study has yet 
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characterised substantial CD4+ TRM populations82. Relatively simple questions 
concerning CD4+ TRM remain, such as what role are these cells playing in different human 
pathologies? How long can these cells remain in tissues? How are these cells generated? 
Is there a spectrum of cells with different dwell times? Sufficient access to human tissue 
samples has thwarted the answering of many of these questions, and limited progress in 
understanding the role of intrahepatic TRM in human disease besides. 
 
In these studies, I attempted to answer many of these questions by investigating the 
phenotypes and functions of CD4+ T cells at three key interaction points within the liver. 
First the migration of peripheral-blood derived CD4+ T cells into the hepatic parenchyma 
was modelled (chapter 3). This allowed the consequences of parenchymal, as opposed 
to endothelial, migration to be documented; and crucially offers a way to study disease-
relevant CD4+ T cells that would migrate into the liver in autoimmune and viral liver 
diseases without using liver tissue. Second, the fate of CD4+ T cells following short term 
in vitro contact with hepatocyte cell lines was investigated (chapter 4). These experiments 
illustrated the impact hepatocytes could have on these cells, and hinted at what roles the 
T cells could be taking up. These studies both link to the investigation into a human 
hepatic CD4+ TRM type (chapter 5). Using both healthy liver samples, and liver samples 
from multiple different aetiologies allows for comparison of any findings across disease 
groups, with the potential to highlight alterations in disease. Furthermore, collating data 
with the in vitro hepatocyte co-culture work may provide answers on the generation, and 
longevity properties of hepatic CD4+ TRM. Finally, the identification and in-depth 
characterisation of these cells will allow for their placement in the ever-expanding matrix 
of human TRM from different tissues.  
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Chapter 2 – Materials and Methods 
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2.1 Isolation of PBMCs and PBMC-derived CD4+ T cells 
 
2.1.1 Isolation of Peripheral blood mononuclear cells 
 
Venous blood samples were obtained with written informed consent from patients with 
haemochromatosis (HFE), HCV, or PBC; while matched liver patient peripheral blood 
was taken shortly before liver transplant surgery. All samples obtained from the Liver unit 
at the Queen Elizabeth Hospital, Birmingham, UK (South Birmingham ethical approval 
reference 06/Q2708/11). HFE blood was considered healthy for the purposes of this 
study. PBMCs were isolated from whole blood by standard density centrifugation: 35mls 
whole blood was carefully layered on 15mls Lympholyte-H media (Cederlane, Canada), 
and centrifuged for 20 minutes (270 × g, brake 1). PBMCs were then harvested from the 
central layers (between plasma and Lympholyte), washed (centrifuged for 5 minutes, 270 
× g , full brake; supernatant removed, resuspended in new solution) twice in phosphate-
buffered saline (PBS - Gibco, UK; or in-house) and counted using a haemocytometer. 
For large volumes (<140mls) of starting whole blood, a prior 20-minute centrifugation step 
was carried out (270 × g , brake 1), the buffy coats harvested, diluted in PBS, and this 
was then layered on Lympholyte. 
 
2.1.2 CD4+ T cell isolation 
 
CD4+ T cells were isolated from blood derived PBMCs using the CD4+ EasySepTM human 
CD4+ T cell enrichment kit (Stemcell Technologies, UK). This involved resuspending 
PBMCs in T cell isolation media (Table 2.1) at 5 x 107 cells/ml in a 15ml Falcon tube, then 
adding 50µl/ml of antibody cocktail for 10 minutes, followed by 100µl/ml vortexed 
magnetic particles for a further 5 minutes. The magnetic particles bind to the antibodies 
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that themselves bind to unwanted immune cells and erythrocytes. After topping up the 
tube to 10ml with T cell isolation media (or 5ml for <1 x 108 starting PBMCs) the tube was 
placed into an EasySepTM magnet (‘The Big Easy’, Stemcell Technologies, UK) to allow 
the withholding of unwanted cells. Desired cells were then poured off into a new tube, 
washed and counted. CD4+ purity was consistently over 98% as tested with anti- CD4 
staining and flow cytometry (Fig. 2.1). 
 
Naïve and Memory CD4+ T cells were isolated using EasySepTM human naïve CD4+ T 
cell enrichment, and EasySepTM human memory CD4+ T cell enrichment kits respectively 
(both Stemcell Technologies, UK), according to manufacturer’s instructions. Naïve T cell 
isolation required a prior 15 minute incubation step with anti-CD45RO antibodies, while 
the antibody cocktail in the memory CD4+ T cell isolation kit contains anti-CD45RA 
antibodies that remove unwanted naïve T cells. The rest of the protocol is principally the 
same as for total CD4+ T cell isolation described above. 
 
2.2 Cell culture assays 
 
2.2.1 Simple culture 
 
Hepatic epithelial cell lines (Huh-7, HepG2, Hep3B) and non-hepatic epithelial cell lines 
(A549, AdAh, Caco-2, HeLa) were cultured in complete DMEM; LX2 cells were cultured 
in DMEM – 2% FBS; primary BEC in BEC media; and primary HSEC in HSEC media 
(see Table 2.1 for all media details). Huh-7, HepG2, Hep3B, HeLa; AdAh; A549; and 
Caco-2 were kind gifts from Prof. Jane McKeating; Dr Claire Shannon-Lowe; Dr Dalan  
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Figure92.1 - CD4+ T cell purity following isolation from PBMC. Demonstration of highly pure CD4+ 
population by surface staining and flow cytometry following isolation of PBMC-derived CD4+ T cells. 
Histogram is representative of 3 independent experiments.!
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Bailey; and Dr Emma Shepherd (all University of Birmingham) respectively. All cell lines 
were routinely mycoplasma tested every 3 months. Pre-experimentation, all cell types 
were cultured in flasks, and these were coated with 40µg/ml type-1 rat-tail collagen 
solution (Sigma Aldrich, UK) for HSEC and BEC cell culture. Primary BEC and HSEC 
were kindly isolated and provided by Gill Muirhead, University of Birmingham. Briefly, this 
involved collagenase digestion and harvest of non-parenchymal cells through density 
centrifugation, followed by immunomagnetic isolation using epithelial glycoprotein HEA-
125 and CD31 for BEC and HSEC respectively371, 388, 537. Previous work has shown BEC 
and HSEC purity to be >95% and >85% respectively538, 539, and both were used within 5 
passages. All cell culture incubation was at 37°C, 5% CO2. 
 
Adherent cells were harvested by trypsinisation (with 0.05% Trypsin-EDTA solution – 
ThermoFisher Scientific, UK). Cells were then resuspended in the specified media, and 
plated out in 24-well plates (1ml cell suspension/well) in order to achieve 100% 
confluence. Seeding density was found using surface area calculations and the following 
formula: 
 𝑉𝑜𝑙𝑢𝑚𝑒	𝑜𝑓	𝑠𝑢𝑠𝑝𝑒𝑛𝑠𝑖𝑜𝑛	𝑓𝑜𝑟	1	𝑤𝑒𝑙𝑙	𝑐𝑜𝑐𝑢𝑙𝑡𝑢𝑟𝑒 = 3445567844556 	× 	5000µl × < =>/=44@ 
 
Where 𝑥= % starting confluence of cell line. This formula assumes that cells begin in T75 
flasks (surface area of 7500mm2), are resuspended in 5mls media and are being plated 
into 24-well plates (200mm2 surface area/well). Other flask/well sizes were adjusted for 
accordingly. 
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Media Details 
T cell isolation 
media 
PBS + 2% FBS (Sigma Aldrich, UK), 1mM EDTA (ThermoFisher 
Scientific, UK) 
Complete DMEM 
DMEM (ThermoFisher Scientific, UK) + 10% FBS, 100U/ml Penicillin, 
100µg/ml streptomycin, 1% L-Glutamine, 1% NEAA (all four 
ThermoFisher Scientific, UK). 
DMEM – 2% FBS DMEM + 2% FBS, 100U/ml Penicillin, 100µg/ml streptomycin, 1% L-Glutamine, 1% non-essential amino acids. 
BEC media 
1:1 Ham’s F12 media (ThermoFisher Scientific, UK) & DMEM + 10% 
heat-inactivated human serum (HD supplies, UK), 2mM 
Penicillin/Streptomycin, 10µg/L EGF, 10µg/L HGF (both Peprotech, 
UK), 124IU/L Insulin, 20µg/L Hydrocortisone (both Queen Elizabeth 
Hospital Pharmacy, Birmingham, UK), 10µg/L Cholera Toxin, 0.2nM 
Tri-iodothyronine (both Sigma Aldrich, UK). 
HSEC media 
Human Endothelial Serum-free media (ThermoFisher Scientific, UK) 
+ 10% heat-inactivated human serum, 2mM Penicillin/Streptomycin 
10µg/L HGF, 10µg/L VEGF (Peprotech, UK). 
Complete RPMI RPMI (ThermoFisher Scientific, UK) + 10% FBS, 100U/ml Penicillin, 100µg/ml streptomycin, 1% L-Glutamine, 1% NEAA 
FACS Buffer PBS + 1% FBS, 2mM EDTA, 0.01 NaN3 (Sigma Aldrich, UK) 
 
Table 2.1 - List of media used. Media types listed in order of appearance in text. Companies listed only 
first time reagent is used. DMEM - Dulbecco’s Modified Eagle Medium; EDTA - Ethylenediaminetetraacetic 
acid; EGF - Epidermal growth factor; FBS – Foetal bovine serum; HGF – hepatocyte growth factor; NaN3 
– sodium azide; NEAA – Non-essential amino acids; PBS – phosphate buffered saline; RPMI – Roswell 
Park Memorial Institute (media); VEGF – Vascular endothelial cell growth factor. 
 
 
In the case of mixed liver cell cultures (Fig. 4.1.6), each cells’ media made an equal 
contribution to the overall solution. Once confluence was reached, the required number 
of isolated CD4+ T cells were carefully added to the wells in 100µl complete RPMI (Table 
2.1). Following culture period of choice, CD4+ T cells were harvested gently to minimise  
non-immune cell disturbances, and used in downstream applications. Included T cell only 
controls started with 1ml complete DMEM, before T cells (in complete RPMI) were added. 
 
 
2.2.2 Simple culture variants 
 
2.2.2.1 T cell stimulation and proliferation assays 
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Three different T cell stimulants were used. Anti CD3/CD28 stimulation beads 
(DynabeadsTM Human T-activator CD3/CD28 – ThermoFisher Scientific, UK) were 
washed and prepared per manufacturer’s instructions, and added to T cells at a 
concentration of 25µl beads/106 cells to give a 1:1 cell-to-bead ratio. Protein Kinase C 
(PKC) activator Phorbol 12-myristate 13-acetate (PMA) and calcium ionophore Ionomycin 
were used together at concentrations of 50ng/ml and 1µM respectively (both Sigma 
Aldrich, UK). T cell mitogen Phytohaemagglutinin-M (PHA-M) was added to cells at 
50µg/ml (Sigma Aldrich, UK). 
 
Monitoring cytokine production involved the culturing of T cells with the above stimulants 
in the presence of protein transport inhibitor Brefeldin A (10µg/ml; Sigma Aldrich, UK). T 
cells were resuspended in complete RPMI containing the stimulants and Brefeldin A for 
the specified time period (37°C, 5% CO2), before the stimulants washed off and 
intracellular staining and flow cytometry performed (see section 2.5). 
 
Assessment of proliferation in response to these stimuli was done using CellTraceVioletTM 
proliferation dye (ThermoFisher Scientific, UK). Prior to the culture/co-culture period, T 
cells were first washed three times in PBS, then suspended at 1 x 107 cells/ml in 5µM 
CellTraceViolet solution (diluted in PBS) for 20 minutes in the dark. Dye was quenched 
in serum-containing complete RPMI for 5 minutes, cells were washed twice more, and 
then used in downstream applications. 
 
Additionally, cytokine stimulations were performed (Fig. 3.1.5). T cells were cultured in 
complete RPMI containing either the pro-inflammatory cocktail (IL-1b, IL-6, IL-22, TNF-a, 
IFN-g - all Peprotech, UK), or each of its constituents at a cell concentration of 1 x 107 
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cells/ml for 24 hours before adding into downstream assays. All cytokines used at a 
concentration of 10ng/ml. 
 
2.2.2.2 Assessment of T-cell contact dependence 
 
Where the influence of direct T cell-hepatocyte contact on CD69 upregulation was under 
investigation (Fig. 4.3.3), 0.4µm pore transwell inserts (Scientific Lab Supplies, UK) were 
used. At this pore size, it is not possible for T cells to transmigrate. Huh-7 cells were 
simply plated out in the bottom of wells as described, allowed to settle and then such 
transwell inserts were added to the wells along with 150µl complete DMEM on top. CD4+ 
T cells were then added to the top of the inserts, in 100µl complete RPMI. After overnight 
co-culture, T cells were harvested, analysed, and compared with standard co-culture 
conditions. 
 
2.2.2.3 Huh-7 fixation 
 
For Huh-7 fixation (Fig. 4.3.4) three different fixatives were used as follows. For both 
100% methanol and 1% formaldehyde (both Sigma Aldrich, UK), media was first removed 
from the confluent Huh-7 cells, the cells were carefully washed twice with PBS. The 
fixative was added to the confluent Huh-7 monolayers (200µl/well) for 20 minutes, 
washed off 4 times with PBS and complete DMEM restored, before T cells were added. 
For 0.025% glutaraldehyde (Sigma Aldrich, UK) fixation, the Huh-7 cells were first 
trypsinised, washed in PBS and resuspended in 1ml fixative for 3 minutes. Cells were 
thoroughly washed (2x centrifugation wash) and plated into new 24 well plates in 
complete DMEM before T cells were added. 
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2.2.2.4 Modulating ICAM-1 – LFA-1 interactions 
 
When assessing the influence of ICAM-1 or LFA-1 on CD69 upregulation (Fig. 4.3.5), the 
following protocols were used. To block ICAM-1 on the Huh-7 cells, anti-ICAM-1 (clone 
BBIG-I1, R&D Systems, UK) was added to each well of the confluent Huh-7 cells at 
10µg/ml in 200µl complete DMEM for 20 minutes, washed off three times with PBS, and 
the media restored. Blocking or stimulating LFA-1 components on the T cells involved a 
20-minute pre-treatment step in 200µl complete RPMI (per million T cells) before washing 
twice with PBS and adding to the Huh-7 cells. Blocking CD18 – clone 7E4, 10µg/ml 
(Beckmann Coulter, UK); stimulating CD18 – clone MEM-48, 5µg/ml (Abcam, UK); 
stimulating CD11a – clone MEM-83, 5µg/ml (Abcam, UK). Recombinant human ICAM-1 
(ThermoFisher, UK) was added at 12.5µg/ml (in 200µl distilled water) to wells of a 48-
well plate for an hour to coat, before washing 3 times and adding T cells once the plate 
was dry. Isotype controls for these experiments were mouse IgG1 (Biolegend, UK & 
ThermoFisher Scientific, UK). 
 
2.2.3 Migration assays 
 
2.2.3.1 Transwell migration assays 
 
In addition to co-culture conditions described above, cell lines were seeded onto the 3µm 
pore, high density transwell inserts (Scientific Lab Supplies, UK) placed in complete 
DMEM-containing 24-well plates (1ml/well), at the same density as static co-culture wells 
(150µl/insert). Once 100% confluence was reached, 1 x 106 CD4+ T cells were added to 
 81 
each insert (100µl/insert) and plates cultured for specified time period. Cells were gently 
harvested from the top of the transwell insert (non-migrated), the insert discarded, and 
then harvested from the bottom of the well (migrated). T cells were then used in 
downstream applications. If manual cell counts were required (Fig. 3.3.1), small aliquots 
of the migrated cells were taken, diluted 1:1 with dead cell marker Trypan Blue (Sigma 
Aldrich, UK), and counted with a haemocytometer. Migrated cell counts were compared 
to counts from aliquots of the corresponding T cell only controls. This allowed for 
calculation of % migration when compared to the input population size. When inserts 
and/or wells were coated with type-1 rat tail collagen (Fig. 3.1.4), this was done using a 
40µg/ml solution that was added for a few seconds then removed, before plates were 
allowed to dry prior to the assay(s). If dual hepatocyte monolayers were required (Fig. 
4.3.2), transwell inserts were inverted, 150µl cell line solution added to the top, inserts 
cultured for 3-4 hours (or until cell adherence), and then the insert turned over and placed 
in complete DMEM in 24-well plates. The second (now top) layer could then be seeded 
as normal in the well of the transwell insert. 
 
2.2.3.2 Gel culture and ‘Trans-gel’ migration assays 
 
Each ml of collagen gel was formed by mixing 830µl rat-tail type 1 collagen dissolved in 
acetic acid (2.15mg/ml; First Link Ltd, UK), with 160µl FBS and 170µl 10x media 199 
(ThermoFisher Scientific, UK). The pH of the solution was neutralised with careful 
addition of 1N NaOH (Sigma Aldrich, UK). All reagents were kept ice-cold to allow an 
even solidifying of the gel. 300µl gel was carefully seeded per well and incubated (37°C, 
5% CO2) for 15-30 mins, or until set. Huh-7 cells above gels were simply seeded on top 
of set gel. Huh-7 cells below gel were seeded first (in only 200µl completed DMEM) then 
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gel was set on top and 800µl complete DMEM added (drip wise). For the Huh-7 within 
gel condition, gel was made and equilibrated without FBS component, then the T cells 
were incorporated within the FBS fraction. Gel could then be set in the incubator and 
complete DMEM added on top. 
 
For ‘trans-gel’ assays, T cells were added to Huh-7 cells above gels overnight. Non-
migrated cells were harvested carefully from the gel top after the addition of 500µl warm 
EDTA for 2 minutes. Migrated cells were harvested after a gel digest with 300µl/well 2x 
collagenase (Sigma Aldrich, UK). 
 
2.3.4 Suppression assays 
 
Suppression assays were based around established methodology540. Briefly, candidate 
suppressor cells were cultured with CellTraceVioletTM-labelled responder T cells (Tresp) 
in flat-bottom 96-well plates, at different ratios with anti-CD3/CD28 stimulation beads 
(25µl/million cells), 1µg/ml anti-CD3 and anti-CD28 antibodies (both ThermoFisher 
Scientific, UK), or anti-CD3 and anti-CD28 antibody tetramers (ImmunocultTM Human 
CD3/CD28 T cell Activator, Stemcell Technologies, UK; 25µl/million T cells). Candidate 
suppressor T cells were generated either from overnight Huh-7 co-culture (hTCs), or from 
overnight culture alone (tTCs). TGF-b was used as a positive control (1µg/ml; Peprotech, 
UK). For  percentage suppression and cell surface phenotype outputs, cells were cultured 
together for 5 days; for cytokine analyses, cells were cultured together overnight. 
Percentage suppression, as determined by flow cytometric analysis, was calculated as 
follows: %	𝑑𝑖𝑣𝑖𝑠𝑜𝑛	(𝑇𝑟𝑒𝑠𝑝	𝑎𝑙𝑜𝑛𝑒) − %	𝑑𝑖𝑣𝑖𝑠𝑖𝑜𝑛	(𝑇𝑟𝑒𝑠𝑝	𝑤𝑖𝑡ℎ	ℎ𝑇𝐶)%	𝑑𝑖𝑣𝑖𝑠𝑖𝑜𝑛	(𝑇𝑟𝑒𝑠𝑝	𝑎𝑙𝑜𝑛𝑒) 	× 	100 
 83 
 
A diagram of this set up, along with explanations of both standard and constant 
suppression assays can be found in Fig. 4.2.1 and section 4.3. 
 
2.3 Isolation of immune cells from liver and lymph nodes 
 
Donor liver tissue was obtained from the Queen Elizabeth Hospital, Birmingham, UK with 
written informed consent (South Birmingham ethical approval reference 06/Q2702/61). 
Liver tissue was taken from various end-stage liver disease patients, or ‘healthy’ donors 
that were unsuitable/not used in time for transplantation (see Table 2.2 for breakdown). 
Lymph nodes were identified and excised from healthy donor tissue. 
 
 N= % FEMALE MEDIAN AGE (IQR) 
DONOR 8 29* 51** (19.5) 
ALD 20 15 59 (14.25) 
NASH 8 50 60.5 (9.3) 
PBC 7 71 44 (11.5) 
PSC 12 25 35.5 (12.3) 
AIH 1 0 21 (N/A) 
HCV 2 0 59 (6) 
HBV 1 0 42 (N/A) 
CRYPTOGENIC 2 50 53.5 (10.5) 
BCS 1 0 31 (N/A) 
PLD 3 100 61 (7) 
NCPH 1 0 63 (N/A) 
SBC 1 100 58 (N/A) 
 
Table 2.2 – Liver donor patient information. Numbers of livers of each disease group used, along with 
gender and age summaries. Grey text indicates donor numbers <6. Matched lymph nodes (n=3) all taken 
from healthy donors. Matched blood (n=6): 2 ALD, 2 NASH, 1 PLD, 1 Cryptogenic. AIH, Autoimmune 
Hepatitis; ALD, Alcoholic Liver Disease; BCS, Budd-Chiari syndrome; CRYPTOGENIC, Cryptogenic Liver 
Disease; DONOR – Healthy Donor Liver; HBV, Hepatitis B; HCV, Hepatitis C; NASH, Non-Alcoholic 
Steatohepatitis; NCPH, Non-Cirrhotic Portal Hypertension; PBC, Primary Biliary Cholangitis; PLD, 
Polycystic Liver Disease; PSC, Primary Sclerosing Cholangitis; SBC, Secondary Biliary Cholangitis. * One 
patient sex information missing so data compiled from the remaining 7 donors. ** One patient age missing 
so data compiled from the remaining 7 donors. 
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Liver-infiltrating mononuclear cells (LIMCs) were isolated by mechanical digestion and 
density centrifugation. Liver tissue was finely chopped then rinsed with ice-cold PBS until 
the supernatant ran clear to minimise blood cell contamination. Tissue was macerated 
further using a stomacher machine (Seward, UK) for 6 minutes at 260rpm. Tissue 
homogenate was ground through a fine mesh and transferred to 50ml falcon tubes. Liver 
samples were washed multiple times until the supernatant became clear (an optional 
extra 10-minute, 55 × g centrifugation step (brake 0) followed by harvest of the 
supernatant was used for particularly debris-rich livers). The samples were then layered 
on Lympholyte-H media, and then centrifuged (20 mins, 270 × g, brake 1), harvested and 
counted as described for PBMCs above. 
 
To isolate lymph node mononuclear cells, lymph nodes were first roughly chopped and 
then transferred to gentleMACSTM C tubes (Miltenyi Biotec, UK) with 10mls non-
supplemented RPMI. Homogenisation was carried out using a gentleMACSTM dissociator 
(Miltenyi Biotec, UK). Homogenate was then pushed through a fine mesh, washed and 
cells isolated by density centrifugation as for LIMCs. 
 
2.4 LIMC cultures and liver slice methodology 
 
For analysis of cytokine production by different CD69-expressing subsets (section 5.6), 
LIMCs were first stained for CD69, CD4, CD56, and gd-TCR (see Table 2.3 for list of 
antibodies and section 2.5 for antibody staining protocols), before 3 washes and 
stimulation with PMA & Ionomycin, anti-CD3/CD28 beads, or PHA-M for 2 or 5 hours 
(concentrations as in section 2.2.2.1), all in the presence of protein transport inhibitor 
Brefeldin A. Cytokine production was measured by intracellular staining and flow 
cytometry. 
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Liver slices used in section 2.6 were cut to a thickness of 2mm with a TruSlice tissue 
slicer (CellPath, UK). These uniform pieces were then placed into 48-well plates in 500µl 
DMEM – 2% FBS per well. Autologous PBMCs were added on top in complete RPMI 
(100µl/well), cultures incubated for 5 hours, and then the PBMCs harvested for 
downstream analysis. 
 
2.5 Flow cytometric analyses 
 
2.5.1 Surface staining 
 
Following 2 PBS washes to remove media, cells to be stained were incubated (room 
temperature - RT, 20 mins, dark) with antibodies of interest or isotype-matched controls 
(IMCs) in FACS buffer (Table 2.1). 50µl of antibody solution was added per 1-2 million 
cells of interest. Cells were then washed twice in FACS buffer (centrifuged 270 × g, 5 
mins), and resuspended in 300µl/tube 1% formaldehyde solution (Sigma Aldrich, UK). 
Samples were either then run directly or stored for up to 7 days at 4°C before running on 
the flow cytometer. Antibody dilutions were all determined individually through titration 
experiments. All antibodies used, their fluorochromes, dilutions and IMCs are listed in 
Table 2.3. 
 
Compensation beads (OneComp eBeadsTM; ThermoFisher Scientific, UK) were used to 
allow correction for spectral overlap in multicolour experiments. 1 drop of beads was 
added to each tube containing 100µl FACS buffer. One matched antibody of each colour 
(fluorochrome) was added to each tube at the same test concentration as added to the 
cells. Incubation was for 20 mins (RT, dark), then beads were washed twice and 
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resuspended in 600µl PBS ready for running on the cytometer. Beads could be pre-made 
and used for experiments for up to 2 weeks. 
 
If live/dead staining was required, this was incorporated into the staining protocol 
immediately before surface antibody addition. Following PBS washes, live/dead dyes 
Zombie Aqua, or Zombie NIR (1/400 and 1/1000 dilutions in PBS respectively; both 
Biolegend, UK) were added at 50µl per million cells for 10 minutes at RT in the dark. 
Antibody solutions were then added directly to the cells without the need for washing. 
 
Last, counting beads (AccuCheck counting beads; ThermoFisher Scientific, UK) were 
used in section 3.4 according to manufacturer’s instructions. 5µl thoroughly resuspended 
beads were added to a 300µl sample before acquisition. The bead population was gated 
on and used to calculate the absolute cell number in the beginning sample as follows: 
 
𝑁𝑜. 𝑜𝑓	𝑐𝑒𝑙𝑙𝑠	𝑖𝑛	𝑠𝑎𝑚𝑝𝑙𝑒 = 	 𝑁𝑜. 𝑜𝑓	𝑏𝑒𝑎𝑑𝑠	𝑎𝑑𝑑𝑒𝑑𝑁𝑜. 𝑜𝑓	𝑏𝑒𝑎𝑑𝑠	𝑐𝑜𝑢𝑛𝑡𝑒𝑑 	× 	𝑁𝑜. 𝑜𝑓	𝑐𝑒𝑙𝑙𝑠	𝑖𝑛	𝑔𝑎𝑡𝑒	𝑜𝑓	𝑖𝑛𝑡𝑒𝑟𝑒𝑠𝑡 
 
The number of beads added was calculated by multiplying the number of beads/µl (from 
each lot’s certificate of analysis [CoA]) by 5 (as 5µl added/sample). Accuracy was verified 
by internal control – two bead populations were separated by fluorescence and the 
proportion of each matched to the CoA before using generated counts. 
 
2.5.2 Cytokine & Intracellular staining 
 
Following surface staining and fixation with 1% formaldehyde or 3% paraformaldehyde 
(15 mins, RT; Sigma Aldrich, UK), or cell stimulation for cytokine detection and fixation; 
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cells were resuspended in 0.1% saponin (Sigma Aldrich, UK) for 10 minutes. After one 
wash in 0.1% saponin (270g, 5 mins), cells were resuspended in intracellular antibody 
cocktails (or IMCs) in 0.1% saponin solution for 30 minutes, before 2 final washes and 
resuspension in 300µl/tube FACS buffer. All antibodies used listed in Table 2.3. 
 
For Hobit and FoxP3 staining, we instead used the FoxP3 Transcription factor staining 
set (ThermoFisher Scientific, UK). Hobit staining involved fixation with the 
fixation/permeabilisation solution (50µl/tube) for 30 minutes on ice, centrifugation and 
removal of the supernatant (270g, 5 mins) and addition of the anti-Hobit antibody (see 
Table 2.3) diluted in the permeabilisation component (50µl/tube) for 30 mins (on ice, kept 
dark). Next, cells were washed twice with permeabilisation buffer (500µl each) and the 
fluorescently-labelled secondary anti-human IgM antibody was added in permeabilisation 
buffer (30 mins, ice, dark). After 1 final wash, cells were resuspended in FACS buffer 
ready for analysis. For FoxP3 staining the same protocol was followed, but without need 
for a secondary antibody step. 
 
2.5.3 Flow cytometry 
 
Samples were acquired with a 9-colour ADP CyAnTM flow cytometer running Summit 
v4.3 software (both Beckmann Coulter, UK). Offline analyses (compensation, gating, 
generation of plots and population statistics) were carried out with FlowJo v.10 (Flowo 
LLC, USA). 
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Antigen Fluorochrome Dilution Company (Ref.) IMC 
CCR10 PE 1/50 Biolegend (341504) A-Hm IgG (Biolegend 400908) 
CCR5 PE 1/50 Biolegend (359106) Rt IgG2b (Biolegend 4006363) 
CCR6 AF488 1/50 Biolegend (353414) Ms IgG2b (Biolegend 400329) 
CCR7 PE-Cy7 1/50 Biolegend (353226) Ms IgG2a (Biolegend 400232) 
CCR9 PerCP-Cy5.5 1/20 Biolegend (358906) Ms IgG2a (Biolegend 400252) 
CD103 APC 1/40 BD Biosciences (563883) Ms IgG1 (BD Biosciences 550854) 
CD127 BV510 1/40 Biolegend (351332) Ms IgG1 (Biolegend 400172) 
CD25 PE 1/40 BD Biosciences (555432) Ms IgG1 (Biolegend 400112) 
CD25 PE-Cy5 1/50 Biolegend (302608) Ms IgG1 (Biolegend 400118) 
CD27 FITC 1/50 Biolegend (356404) Ms IgG1 (Biolegend 400108) 
CD27 APC-Vio770 1/25 Miltenyi Biotec (130-098-605) Ms IgG1 (Miltenyi Biotec 130-096-653) 
CD28 PE 1/50 Biolegend (302908) Ms IgG1 (Biolegend 400112) 
CD3 APC Fire750 1/200 Biolegend (300470) Not required 
CD3 BV510 1/100 Biolegend (317332) Ms IgG2a (Biolegend 400267) 
CD38 APC-Vio770 1/100 Miltenyi Biotec (130-099-151) Ms IgG2a (Miltenyi Biotec  130-096-638) 
CD4 APC 1/100 BD Biosciences (555349) Ms IgG1 (Biolegend 400120) 
CD4 BV510 1/100 Biolegend (344634) Ms IgG1 (Biolegend 400172) 
CD4 FITC 1/200 Biolegend (317408) Ms IgG2b Biolegnd 400310) 
CD45RA BV421 1/50 BD Biosciences (562885) Ms IgG2b (BD Biosciences 562748) 
CD45RA V450 1/50 BD Biosciences (560363) Ms IgG2b (BD Biosciences 560374) 
CD49a PE 1/50 Biolegend (328304) Ms IgG1 (Biolegend 400112) 
CD49d BV421 1/50 Biolegend (304322) Ms IgG1 (Biolegend 400158) 
CD56 APC-Vio770 1/50 Miltenyi Biotec (130-100-690) Ms IgG1 (Miltenyi Biotec 130-104-618) 
CD69 APC 1/50 Biolegend (310910) Ms IgG1 (Biolegend 400120) 
CD69 FITC 1/25 Biolegend (310904) Ms IgG1 (Biolegend 400108) 
CD69 PE-Dazzle594 1/50 Biolegend (310942) Ms IgG1 (Biolegend 400176) 
CD8 PE-Cy5 1/200 Biolegend (301010) Ms IgG1 (Biolegend 400118) 
CD80 APC 1/400 Biolegend (305220) Ms IgG1 (Biolegend 400120) 
CD86 BV421 1/50 Biolegend (305426) Ms IgG2b (Biolegend 400342) 
CTLA-4* PE-Dazzle594 1/25 Biolegend (349922) Ms IgG1 (Biolegend 400176) 
CX3CR1 PE-Cy7 1/100 Biolegend (341612) Rt IgG2b (Biolegend 400618) 
CXCR1 PE-Cy7 1/40 Biolegend (320620) Ms IgG2b (Biolegend 400326) 
CXCR3 AF488 1/100 Biolegend (353710) Ms IgG1 (Biolegend 400129) 
CXCR6 APC 1/50 Biolegend (356005) Ms IgG2a (Biolegend 400219) 
CXCR6 PerCP-Cy5.5 1/50 Biolegend (356010) Ms IgG2a (Biolegend 400252) 
FoxP3* PE 1/20 eBioscience (12-4776-42) Rt IgG2a (eBioscience 12-4321-42) 
Fas APC 1/100 Biolegend (305612) Ms IgG1 (Biolegend 400120) 
HLA-DR FITC 1/50 BD Biosciences (555811) Ms IgG2a (Biolegend 400208) 
HLA-DR BV421 1/50 Biolegend (307636) Ms IgG2a (Biolegend 400260) 
Hobit* - 1/10 Gift from Prof. Van Lier, Sanquin Institure, Amsterdam, NL Ms IgM (Biolegend 401604) 
IFN-γ* APC 1/167 BD Biosciences (554702) Ms IgG1 (BD Biosciences 550854) 
IL-10* BV421 1/33 Biolegend (501421) Rt IgG1 (Biolegend 400429) 
IL-10* PE 1/25 Biolegend (501404) Rt IgG1 (Biolegend 400408) 
IL-17A* APC-Cy7 1/50 Biolegend (512320) Ms IgG1 (Biolegend 400128) 
IL-17A* PerCP-Cy5.5 1/50 Biolegend (512313) Ms IgG1 (Biolegend 400150) 
IL-2* PE 1/167 eBioscience (12-7029-82) Rt IgG2a (eBioscience 12-4321-42) 
IL-4* PE-Cy7 1/50 Biolegend (500824) Rt IgG1 (Biolegend 400416) 
IL-6* PE 1/33 Biolegend (501107) Rt IgG1 (Biolegend 400408) 
Integrin β7 PE 1/100 Biolegend (321204) Rt IgG2a (eBioscience 12-4321-42) 
Ki67* PB 1/25 Biolegend (350512) Ms IgG1 (Biolegend 400151) 
KLRG-1 PE 1/100 Biolegend (367712) Ms IgG2a (Biolegend 400214) 
PD-1 PE 1/50 Biolegend (329906) Ms IgG1 (Biolegend 400112) 
S1PR1 eFluor660 1/50 eBioscience (50-3639-41) Ms IgG1 (eBioscience 50-4714-80) 
TGF-β* APC 1/25 Novus Biologicals (IC420A) Ms IgG1  (Biolegend 400120) 
TNF-α* eFluor450 1/50 eBioscience (48-7349-41) Ms IgG1 (eBioscience 48-4714-82) 
γδ-TCR APC-Vio770 1/50 Miltenyi Biotec (130-109-360) Ms IgG1 (Miltenyi Biotec 130-104-618) 
Mouse IgM*† PE 1/50 Biolegend (408608) Not required (secondary antibody) 
 
Table 2.3 – List of antibodies used for flow cytometric-based detection. All antibodies used in these 
studies along with fluorochrome information, final dilutions used, and company and isotype-matched control 
details. Fluorochrome abbreviations: AF – AlexaFluor; APC - Allophycocyanin; BV – Brilliant Violet; Cy – 
Cyanine Cy7; FITC - Fluorescein isothiocyanate; PE – Phycoerythrin; PerCP - Peridinin Chlorophyll Protein 
Complex; V450 - Violet 450. Antibody host species abbreviations: A-Hm – Armenian Hamster; Ms – Mouse; 
Rt – Rat. eBioscience is now part of ThermoFisher Scientific. All products ordered from UK subsidiaries. * 
- indicates antibody used for intracellular staining. † - indicates used as a secondary antibody. 
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2.6 Immunofluorescence 
 
Immunofluorescence staining was carried out on 3µm-thick formalin-fixed paraffin 
embedded sections. Sections were first dewaxed and rehydrated by being put through 3 
xylene, 2 ethanol, and 2 water washes for 3 minutes each. Slides were microwaved for 
30 mins in pre-warmed high pH antigen unmasking solution (Vector Labs, UK) and 
subsequently cooled. Next, slides were placed in Harris’ haematoxylin (Leica, UK) for 60 
seconds, to quench background autofluorescence, and washed off twice in water for 3 
minutes each. Wash buffer (TBS [Tris-buffered saline]-Tween; Agilent, UK) was added 
for 5 minutes, followed by 2% Casein solution (in distilled water; Vector Labs, UK) for 10 
minutes. Primary antibodies or IMCs were then diluted in wash buffer and added 
overnight. The following day, secondary antibodies (in wash buffer) were added for 1 hour 
following 3 washes with wash buffer. After a final wash buffer addition and placement into 
water, slides were mounted with prolong gold mountant (ThermoFisher Scientific, UK). 
All wash buffer steps and antibody incubations involved the addition of 200µl volume; and 
were carried out in the dark, on a low speed rocker. All antibodies used are detailed in 
Table 2.4. Both primary and secondary antibodies were individually titrated to determine 
the optimum test concentration before use together. 
 
Imaging was carried out using a Zeiss LSM 880 Laser scanning microscope, running 
Zeiss Zen software (both Zeiss, UK). Offline analysis, image correction and presentation 
also used Zeiss Zen software. 
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Target Antigen Species/Isotype Fluorochrome Dilution Company (Ref.) 
CXCR6 Rabbit IgG - 1/50 Abcam, UK (ab8023) 
CX3CR1 Rabbit IgG - 1/50 ThermoFisher Scientific, UK (711353) 
CD69 Mouse IgG2a - 1/25 R&D Systems, UK (MAB23591) 
CD4 Mouse IgG1 - 1/50 Leica, UK (CD4-368-L-CE-H) 
NKp46 Mouse IgG2b - 1/50 R&D Systems, UK (MAB1850-100) 
(IMC) Rabbit IgG - 1/100 Biolegend, UK (910801) 
(IMC) Mouse IgG2a - 1/25 Biolegend, UK (401504) 
(IMC) Mouse IgG1 - 1/62.5 Biolegend, UK (401404) 
(IMC) Mouse IgG2b - 1/50 Biolegend, UK (401212) 
Rabbit IgG† Goat IgG AlexaFluor594 1/1000 ThermoFisher Scientific, UK (A-11012) 
Mouse IgG2a† Goat IgG AlexaFluor647 1/200 ThermoFisher Scientific, UK (A-21241) 
Mouse IgG1† Goat IgG AlexaFluor350 1/500 ThermoFisher Scientific, UK (A-21120) 
Mouse IgG2b† Goat IgG AlexaFluor488 1/500 ThermoFisher Scientific, UK (A-21141) 
 
Table 2.4 - Antibodies used for immunofluorescence detection. In descending order, antibodies shown 
are primary test antibodies, primary isotope-matched controls, and secondary antibodies. Secondary 
antibodies are marked with  †. 
 
 
2.7 Data analysis, Data presentation & Statistics 
 
Data was presented graphically and tested for statistical significance using GraphPad 
Prism v6 software (Graphpad, US). Additional calculations were performed using 
Microsoft Excel (Microsoft, US). Diagrams and other artworks were created using a 
combination of Microsoft Powerpoint (Microsoft, US), Gravit designer (Gravit GmbH, DE), 
and Servier medical art (Les Laboratoires servier, SAS, FR). All combined data displayed 
as median with non-parametric descriptions unless otherwise specified. Statistical tests 
used were as follows: Wilcoxon matched-pairs signed rank tests were used to compare 
two paired groups; Freidman tests with Dunn’s multiple comparison tests compared three 
or more paired groups; and Kruskal-Wallis tests with Dunn’s multiple comparisons tests 
were used to compare three or more unpaired groups. Statistical difference 
representations follow the standard convention (* p<0.05, ** p<0.01, *** p<0.001, **** 
p<0.0001). Individual figure legends contain donor number information for each 
experiment. All work carried out is my own unless specifically stated in the figure legend. 
Dominik Niesen (D.N) contributed substantially to data collection in sections 3.5, while 
Fras Ahmad (F.A) made small contributions to data collection in section 4.2. Emily 
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(Xiaoyan) Li (X.L) provided major help with LIMC preparation and staining throughout 
chapter 5. 
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Chapter 3 – Migration through hepatic epithelia reveals 
intrinsic, liver disease-specific cytokine profiles in 
peripheral blood CD4+ T cells 
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3.1 Introduction – Migration as a key component of T cell function & chronic liver 
disease-specific alterations in peripheral blood 
 
T cell function and migration are intrinsically connected31. Both parameters can be used 
to subset cells: function determined by cytokine production is used to place cells into 
helper subsets (TH1, TH2, TREG), whereas differential homing capabilities allow for the 
branching of memory cells into three main groups (TCM, TEM, TRM). The homing abilities 
of a T cell are tightly regulated throughout its life cycle, with differential modulation of 
adhesion and chemokine receptors observed with changes in T cell activation, 
differentiation, and tissue tropism360. Naïve T cells must efficiently traffic to the T cell 
zones of SLOs in order to encounter cognate antigen presented on APCs. Following 
activation, T cells upregulate specific homing receptors, the exact combinations of which 
depend on the nature of infecting pathogen, and site of priming541. For example, priming 
in skin draining LN promotes upregulation of E- and P-selectin ligands, CCR4 and/or 
CCR10 promoting entry to the skin, while in GALT, CCR9 and integrin a4b7 expression 
is preferentially induced, allowing T cell homing to the gut31, 70, 542. Furthermore, T helper 
subsets often show preferential chemokine receptor associations: TH1 cells express 
CXCR3, CCR5 and CXCR6, TH2 cells express CCR4 and CCR8. TH17 cells express a 
combination of both the above – CXCR3, CXCR6, and CCR4; as well as CCR6353. TREGS 
are generally thought to express CCR4 and CXCR3353, but can also specifically 
upregulate the same chemokine receptors as their effector counterparts to follow them to 
effector sites and monitor their activities there543. Once in NLTs, CD8+ T cells must directly 
contact infected target cells in order to mediate targeted cytotoxicity, whereas CD4+ T cell 
pro-inflammatory cytokine production must also be localised to the infected site to tightly 
direct communication to the target cells and/or minimise bystander tissue damage. The 
resolution stage of inflammation also relies on efficient migration, through the prevention 
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of further pro-inflammatory cell influx, egress of surviving cells to the blood and lymph, 
and entry of immune regulatory cells544, 545. Lastly, the efficient division of labour between 
memory cells that allows TCM to repopulate the memory pool from SLOs, while TEM and 
TRM perform immunosurveillance and effector responses in NLTs, is also possible through 
specific homing patterns70. Thus, control of migration is a key aspect of T cell biology at 
every stage, and should be considered a vital component of their function. 
 
CD4+ T cells play key roles in driving the pathology of viral and autoimmune liver 
pathologies414, 465, 546. Most studies on human T cell populations implicated in disease 
pathogenesis have been conducted using peripheral blood410, 465, 547. For HCV, studies 
comparing peripheral T cell populations from resolved acute, and chronically-infected 
patients have concluded that robust, sustained, and broadly focussed CD4+ T cell 
responses are crucial for viral clearance477, 480-483, 546, 548. In progression to chronicity, 
HCV-specific CD4+ numbers dwindle dramatically476, 479, 482, 484, 549, 550. Similar to CD8+ T 
cells486-488, 551, remaining CD4+ T cell populations show hallmarks of exhaustion – high 
expressions of inhibitory markers such as PD-1; and impaired proliferation, IFN-g and IL-
2 responses to HCV antigen stimulation472, 474, 476-479, 482, 504. Additionally, while strong TH1 
responses are correlated with clearance, skewing towards TH2, or TREG, has been 
implicated as part of the chronic disease course504, 507, 552. Accordingly, conventional TREG 
numbers are higher in the blood of chronically infected compared to acute resolved or 
healthy patients517, and are superior at inhibiting CD8+ proliferation and cytokine 
responses compared to these control groups504, 519, 520. In sum, CD4+ T cells in chronic 
HCV can largely be defined by functional inactivation, and shifts towards more regulatory 
subsets.  
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In contrast to HCV, the number of studies on CD4+ T cells in PBC pathogenesis is 
surprisingly poor. Normal total CD4+ numbers in blood have been reported, though 
elevation in HLA-DR expression was seen compared to healthy controls553. Alterations in 
TREGS have been observed, with some suggesting that PBC patient blood contains a 
reduced frequency of TREGS410, 429; while others claim this is only evident in the liver, 
accompanied by increased TH17 responses411. Basic cytokine profiling of patient sera 
seems to point towards TH1 and/or TH17 immunity primarily424, 429, whereas experiments 
in liver additionally implicate IL-5412, 425, 426, 439. Finally, recent data suggests the frequency 
of circulating TFH is increased in PBC patient blood, alongside enhancements in their 
function (measured by IL-21 production and promotion of B cell maturation)554. Therefore, 
it can be seen that data on disease-specific alterations CD4+ T cell phenotype and 
function in PBC are still severely lacking. 
 
Ideally, diseased liver tissue would be used to advance our understanding of viral and 
autoimmune liver disease immunopathology. However, access to liver tissue is relatively 
scarce, and unfortunately the use of blood is not an ideal alternative as we are currently 
limited in our ability to detect relevant effector T cells in the circulation547, 555. Furthermore, 
although MHC-tetramer based approaches have been effective at studying hepatic virus-
specific cells in peripheral blood192, 488, 556; and autoreactive cells in PBC557; this does not 
give information on the total CD4+ T cell pool entering the inflamed liver, and cannot be 
applied to autoimmune diseases like PSC where driving autoantigen(s) are still 
unknown558. We sought a way to circumvent the tissue access problem, and 
simultaneously pinpoint peripheral blood T cells that may be involved in pathogenesis. 
Hypothesising that the most responsive T cells would be those with the greatest capacity 
to migrate into liver tissue; we modelled T cell migration into the parenchyma using 
 96 
transwell migration assays. Armed with preliminary data from our lab that first suggested 
CD4+ T cells that migrated through hepatoma monolayers increased IFN-g production 
following stimulation, and second raised the possibility of the cytokine profiles revealed 
by transmigration assays being distinct in chronic HCV patients, we composed the 
following aims: 
 
1. Investigate the cytokine expression profiles of circulating T cells before and after 
migration through hepatic epithelia 
2. Characterise migrated and non-migrated T cells for cell surface antigen expression 
3. Determine whether the act of migration through hepatic epithelia induces these 
phenotypic and functional changes 
4. Establish if T cell cytokine expression following migration can reveal disease-
specific restrictions in patients with liver disease of autoimmune or viral aetiology 
 
3.2 Migration of CD4+ T cells through hepatic epithelia reveals differences in the 
production of TNF-a, IFN-g, and IL-4  
 
In order to determine if CD4+ T cell cytokine production potential is different pre-, and 
post-migration; we carried out transwell migration assays and monitored the production 
of TH1 cytokines IL-2, TNF-a, and IFN-g; TH2 cytokine IL-4; and TH17 cytokine IL-17 
following stimulation. Briefly, these assays involved culturing Huh-7 hepatoma cells to 
100% confluence on a transwell insert and allowing the overnight migration of PBMC-
derived CD4+ T cells (Fig. 3.1.1A). Huh-7 cells were chosen principally for their ability to 
reliably form complete continuous monolayers (Zania Stamataki - personal  
! &-!
!
!
Figure103.1.1  - Migration of CD4+ T cells through hepatic epithelia reveals increased IFN-!, TNF-#, 
and IL-4 responses following stimulation. A – Transwell migration assay set up. Huh-7 cells were 
cultured to 100% confluence in 24 well plates – either at the bottom of the well, or on high density, 3'm 
pore transwell inserts. Isolated PBMC-derived CD4+ T cells were then added to both conditions as well as 
to media alone (a T cells only control) and cultured overnight. T cells were harvested from above (non-
migrated) and below (migrated) the transwell insert, as well as from static co-culture and T cells only; 
stimulated with PMA/Ionomycin with Brefeldin A, and intracellular cytokine production detected through 
intracellular staining and flow cytometry. B – Representative flow cytometry plots showing IL-2, IFN-", TNF-
#, IL-4, and IL-17 production in the CD4+ T cell subsets.         (Legend cont. on next page) 
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C – Combined % CD4+ T cell expression data from all healthy donors collected for all cytokines studied. 
Graphs show all data points + median values. N=9-21, 1 donor assayed for for IL-2, IFN-γ and TNF-α 
staining by D.N. 
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communication). Non-migrated and migrated fractions were then harvested, stimulated 
with PMA/Ionomycin (and Brefeldin A) for 5 hours, and cytokine detected by intracellular 
staining and flow cytometry. T cells alone, and T cells cultured on confluent Huh-7 layers 
on the bottom of 24 well plates (referred to as co-culture) were included as assay controls. 
Migrated cells clearly contained greater percentages of cells that were able to produce 
IFN-g and TNF-a, as well as IL-4 (Fig. 3.1.1B,C). Migrated IL-2 and IL-17 showed no clear 
differences from T cells only controls. Interestingly, although there was a significant 
decrease in the fraction of TNF-a+ cells in co-culture, the vast majority of comparisons 
revealed static co-culture did not affect cytokine production. Previous work by others in 
the lab has demonstrated that these differences, in TNF-a and IFN-g at least, were not 
dependent on the prior activation state of a T cell, or blood versus liver origin, as both 
blood CD4+ T cells previously activated with CD3/CD28 stimulation, and liver-derived 
CD4+ T cells demonstrated the same cytokine production patterns [D. Niesen – 
unpublished observations & Fig. 3.4.1]. Similarly, migration through first HSEC and then 
Huh-7 together (mimicking the architecture of the liver) did not affect the upregulation of 
cytokine+ cells in the migrated pool [D. Niesen – unpublished observations]. Together 
these data reveal differences in both type-1 and type-2 cytokine potential following 
migration through hepatic epithelia that is not evident through simple co-culture systems. 
For ease, we designate this enrichment of cytokine-producing cells in the migrated 
fraction compared to the other conditions, the transwell migration effect. 
 
Eager to understand if the transwell migration effect was restricted to the Huh-7 hepatoma 
cell line, we stained for IL-2, TNF-a and IFN-g following migration through two additional 
hepatocyte cell lines – HepG2 and Hep3B. Preliminary data showed broadly similar 
enhancements in cytokine production were seen regardless of hepatoma cell line used,  
!'..!
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!
Figure113.1.2 – Migration through multiple epithelial cell types reveals increases in TH1 cytokine 
production among CD4+ T cells. Transwell migration experiments were carried out as in Fig. 3.1.1, but 
using additional hepatic (HepG2, Hep3B), and non-hepatic epithelial cell lines (AdAh, A549, Caco-2, HeLa). 
Percentages of CD4+ T cells expressing IL-2, TNF-#, or IFN-" in co-culture, non-migrated, and migrated 
conditions were analysed and presented as fold changes from T cells only controls in the bar charts above. 
N=3, median + IQR displayed. 
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although IFN-g production following migration through Hep3B cells was less clear-cut 
(Fig. 3.1.2). To determine whether we were seeing a hepatocyte specific, or general 
epithelial effect, we used a variety of cell lines generated from epithelia of other tissues 
(AdAh – nasopharyngeal, A549 – alveolar, Caco-2 – colorectal, HeLa – cervical). It 
appeared migration through all epithelial cell lines resulted in the transwell migration 
effect to a similar degree, at least for IL-2 and IFN-g, though more data is needed to 
confirm this statistically. 
 
Aiming to extend our system beyond transwell migration assays, we adapted gel-
migration assay methodology currently used by collaborators559. Huh-7 cells were 
cultured in three conformations – below, within and above type-1 rat tail collagen gels; as 
well as in a standard 24-well plate (2D) as a control (Fig. 3.1.3A). Hepatocyte growth and 
morphology was monitored over time to determine the best conformation to take forward 
and compare with transwell assays. Huh-7 cells cultured below the gels appeared to grow 
slowly and adopted more dendritic morphology (Fig. 3.1.3B). Cells within the gel 
displayed a more classic ‘box-like’ morphology but failed to reach confluence even at 
greatly enhanced seeding densities and extended culture periods. However, this 
conformation was the most promising for generating 3-dimensional cultures with more 
polarised hepatocytes (despite unsuccessful attempts to assess hepatocyte polarity – 
data not shown), another initial aim of these experiments. Cells cultured above the gel 
were the clear choice to take forward into migration assays due to favourable morphology 
and growth characteristics in this condition. We therefore directly compared the cytokine 
production from CD4+ T cells migrated through Huh-7 on transwells, with cytokine 
production from the same cells migrated through Huh-7 on collagen gels. This latter assay 
will be termed the ‘trans-gel’ assay through lack of discernible wit.  
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Comparing first the differences in % cytokine production compared to T cells only, trans-
gel assays allowed a similar IFN-g enhancement following migration; but, although no 
statistical differences were seen, no increases in TNF-a were apparent in the trans-gel 
assay; and IL-2 production actually seemed decreased in the gel-migrated pool (Fig. 
3.1.3C). To remove contact with the gel as a variable, migrated cells were also compared 
directly with their non-migrated cells from the same conditions (Fig. 3.1.3D). Similar 
patterns were observed – IFN-g % increases were apparent no matter the migration 
system, whereas no clear increases in IL-2 or TNF-a were seen in trans-gel assays. 
Wondering whether these differences between the two migration systems were due to 
some immunomodulatory effect of the collagen, we performed transwell assays where 
Huh-7 cells were cultured on type-1 rat tail collagen-coated plates. No differences were 
seen in any cytokine with or without collagen, even when migrated T cells came in contact 
with collagen directly post-migration (Fig. 3.1.4). Thus, the migration system used may 
affect divergences in IL-2 and TNF-a production, but not IFN-g. 
 
Last, we asked whether a proinflammatory environment that would be seen following 
recruitment into inflamed livers in vivo affected this transmigration effect. Preliminary data 
indicated that a pro-inflammatory cytokine cocktail skewed the non-migrated cells 
towards IFN-g-producing, at the expense of the migrated fraction [D. Niesen – 
unpublished data]. Aiming to replicate this ‘reversal effect’, and discern which specific 
cytokine(s) were responsible, we pre-treated PBMC-derived CD4+ T cells with pro-
inflammatory cytokines (IL-1β, IL-6, IL-22, TNF-α, IFN-γ) for 24 hours either alone in 
combination and performed transwell migration assays with Huh-7 cells as before. 
However, using 6 donors, we saw no differences in cytokine production profiles in the 
pro-inflammatory cocktail treated cells, regardless of condition (Fig. 3.1.5A). Similarly,  
!'.(!
!
!
Figure133.1.4 – The Presence of collagen has no impact on cytokine skewing following transwell 
migration assays. Blood-derived CD4+ T cells were subjected to standard transwell assay (Fig. 3.1.1, - 
collagen, white bars), or transwell assay conditions with Huh-7 cells cultured on collagen (+ collagen, light 
grey bars). For the + collagen T cell only and co-culture conditions this meant collagen coated 24 well 
plates, whereas for non-migrated and migrated + collagen conditions this meant collagen coated transwell 
inserts. Finally a + double condition (dark grey bars) was set up for the non-migrated and migrated cells 
where collagen coating was performed on the transwell insert as well as the plate bottom. Bars show % 
cytokine expression as median values (+95% CI) from 2 donors. 
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when assessing individual cytokines, no cytokine alone made any difference to TNF-a or 
IFN-g expression patterns (Fig. 3.1.5B). The only cytokine that appeared to have an effect 
was IL-22, which increased the percentage of CD4+ T cells producing IL-2 in every culture 
condition. 
 
In sum, these experiments show that following migration through hepatic and non-hepatic 
epithelia in transwell systems, the proportion of cells expressing TNF-a and IFN-g was 
enhanced; a finding that can be also applied to IL-4 production following Huh-7 migration. 
This transwell migration effect was only partially applicable to gel-culture, with alterations 
in IL-2 and TNF-a; and pro-inflammatory cytokine pre-treatments did not affect the 
phenomenon. 
 
3.3 CD4+ T cells display an altered memory phenotype and distinct activation 
profile following migration through hepatic epithelia 
 
To see whether an alteration in the cytokine-production capacity of migrated T cells was 
accompanied by a change in cell surface phenotype, we first looked at naïve and memory 
representation. Migrated cells displayed preferences for TEM and TEMRA cell types, in 
keeping with the enhanced migratory capacity of these cells in peripheral tissues (Fig. 
3.2.1). By contrast, T cells only, co-culture, and non-migrated conditions all presented 
with very similar naïve/memory make-up. 
 
Assessment of activation and inhibitory marker expression revealed some interesting 
patterns. The percentage of CD25, HLA-DR, PD-1 and Fas-expressing T cells were all 
enhanced in the migrated pool (Fig.3.2.2A). Notwithstanding, proportions of CD4+ T cells  
!'.-!
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Figure153.2.1 – Increased TEM and TEMRA representation in migrated CD4
+ T cells. Percentages of 
different naïve and memory CD4+ T cell populations assessed following transwell migration assay. A - 
Representative flow cytometry staining in the four transwell assay conditions. B - Combined percentage 
data from 12 healthy donors, one pie chart per transwell condition. Statistical comparisons were made 
within each naïve/memory designation, across transwell conditions (T - T cells only, C - Co-culture, NM - 
Non-migrated, M - Migrated). Table shows this data as well as IQR values for all conditions. Huh-7 cells 
used in these experiments. 1 of 12 donors assayed by D.N. 
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Figure163.2.2 – Altered activation state following migration through hepatic epithelia. Expression of 
the activation markers CD69, CD25, CD38, HLA-DR, PD-1 and Fas (A), as well as conventional regulatory 
T cells (CD25HICD127LO - B) were assessed following transwell migration assays through Huh-7 cells. Lines 
show median values. 
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expressing CD38 were decreased, while early activation marker CD69 was not 
significantly increased following migration when compared to T cells only. The CD69 
expression patterns in these experiments were of particular interest, showing robust and 
consistent upregulation in co-culture, followed to a slightly lesser degree in the non-
migrated condition. This finding forms the basis for chapter 4, where it will be discussed 
in length. Additionally, we assessed expression of CD127 alongside CD25 to determine 
TREG contributions in each condition. We found a marginally increased conventional TREG 
percentage following migration, but this was only statistically significant compared to co-
culture (Fig. 3.2.2B). Therefore, together these results determined that the migrated pool 
was enriched for effector memory and TEMRA cells, with distinct activation phenotypes. 
 
3.4 Migration involves selective recruitment of cytokine-responder CD4+ T cells 
through the monolayer, not de novo generation through the act of migration 
 
Based on the above data, we proposed two hypotheses in order to explain the changes 
in the migrated population. First, the act of migration through hepatic epithelia is 
imprinting the CD4+ T cells with an effector phenotype and enhanced cytokine production 
capacity. This could be due to physical and/or mechanical pressures exerted on a T cell 
during the migration process, or adhesion molecule interactions which have an activatory 
effect on the cell. Alternatively, migration is preferentially separating out CD4+ T cells that 
possess these effector phenotypes and are better able to respond to stimuli.  
 
To test these hypotheses, first it was important to determine the proportion of cells that 
migrated through the monolayer, as failing to account for this could lead to 
misinterpretation of data that shows apparently large changes in the migrated fraction, 
yet very minor/no changes in the non-migrated pool. We observed the proportion of CD4+ 
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T cells that migrated through the Huh-7 monolayers was small (Fig. 3.3.1A). An average 
of just 4.6% of unactivated cells migrated through the monolayers, rising to 19.4% 
amongst activated CD4+ T cells. However, the presence of Huh-7 monolayers augmented 
the proportion of T cell able to migrate, as seen when comparing with migration through 
transwell inserts alone. This effect was observed both with and without prior CD4+ T cell 
activation. 
 
Having seen only a small proportion of input T cells migrate through monolayers, we next 
asked whether we could see a clear induction of cytokine producing ability in greater 
numbers of T cells, as well as the previously observed greater percentages. To do this 
we incorporated counting beads as part of the flow cytometry protocol to determine how 
many cytokine+ and cytokine- CD4+ T cells there were in each transwell condition (co-
culture excluded as irrelevant in this case). Combining both non-migrated and migrated 
cells into one data display, it was obvious across all three donors that there were no 
increases in the numbers of T cells able to make IL-2, or IFN-g compared to the input 
population (T cells only, Fig. 3.3.1B). Additionally, combining our cytokine stains with 
stains for proliferation marker Ki-67 confirmed that migrated cells did not proliferate any 
more than their non-migrated counterparts, ruling out any enhancements in T cell 
numbers by cell division (Fig. 3.3.2). 
 
Similarly, we isolated naïve CD4+ T cells to prove that no de novo induction of memory 
cells was occurring with migration. After confirming the high purity of isolated naive T cells 
(Fig. 3.3.3A), we show that when naïve T cells are put through Huh-7 transwell migration 
assays no real switch to memory was seen (Fig. 3.3.3B). Following migration, there was  
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Figure173.3.1 - Migration through hepatomas provides an enhanced selection of CD4+ T cells with 
high functional potential. A - Both unactivated, and activated (with anti-CD3/CD28) CD4+ T cells were 
migrated through Huh-7 cells on a transwell insert, or a transwell insert alone, and the number of migrated 
cells was counted manually. Percentages of migrated cells were calculated by comparing with T cells only 
control numbers. Migration percentages in transwell assays with and without Huh-7 cells were compared. 
B - Counting beads were used to determine the absolute numbers of cytokine+ CD4+ T cells (red - IL-2, 
blue - IFN-γ) and cytokine- cells (white) in transwell assays with Huh-7 cells. 3  donors displayed separately. 
Data presented as stacked bars, and non-migrated + migrated combined data included to illustrate the lack 
of appreciable new cytokine-producing cell generation. Each donor data is comprised of two technical 
replicates, bar heights and error bars show median and range of these replicates. 
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Figure183.3.2 - Migrated cells do not proliferate any more than their non-migrated counterparts. 
Shown are IL-2 and IFN-" % expression (coloured bars) following transwell migration assay and 
PMA/Ionomycin stimulation in each condition. Overlaid are % divided cells, as measured by Ki-67 staining 
(open circles). N=1, 2 technical replicates for each staining procedure. 
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Figure193.3.3 - No memory conversion accompanies transwell migration through hepatic epithelia. 
Total, naïve, and memory CD4+ T cells from 2 healthy blood donors were isolated before being subjected 
to transwell migration assays through Huh-7 cells. A - Representative flow plots showing highly efficient 
naïve and memory isolation protocols. B - Proportion of isolated naïve T cells in each transwell condition 
that were given each naïve/memory designation as defined by CD45RA and CCR7 staining. C - Total CD4+ 
T cells from 3 donors were put through transwell assays with Huh-7 and absolute numbers determined with 
counting beads, similar to Fig. 3.3.1 (2 technical replicates per donor, median and range shown). 
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a small population of cells in the TEMRA gate that was not present in the other conditions. 
We did not think this represented a real conversion from naive into TEMRA as numbers of 
naïve cells that migrated were very small and so more prone to signal artefacts, and of 
course TEMRA need long-term persistent antigen stimulation to form which is not possible 
in our transwell assays as Huh-7 do not express MHC class II molecules (data not 
shown). Nonetheless to resolve this issue, we put total CD4+ T cells through migration 
assays and used counting beads to prove no appreciable memory T cell formation 
occurred (Fig. 3.3.3C). 
 
These data disprove the phenotypic induction hypothesis, due to no appreciable increase 
in IL-2+ or IFN-g+ numbers following migration, and no conversion from naïve to memory 
subsets. Instead they support an ‘enhanced selection’ phenomenon whereby the 
hepatoma monolayer specifically selects more active, effector type CD4+ T cells; at an 
enhanced rate from that seen due to the act of migration alone. 
 
3.5 Transwell migration assays reveal cytokine profiles that discriminate healthy 
donors, and patients with chronic PBC or HCV infection   
 
Thus far we have determined that migration through hepatic epithelia is able to enrich  
CD4+ T cells with the potential to produce cytokines from the total blood population. 
Previous work has shown that autoimmune and viral liver diseases have different CD4+ 
T cell components and linked functional abilities from healthy controls410, 412, 414, 437, 465, 476, 
518, 560. Furthermore, many studies on the immune responses to viral or autoimmune liver 
diseases have been carried out on peripheral blood cell populations. This is as liver tissue 
is more difficult to access. However, researchers run the risk of missing immune 
phenotypes and characteristics that are only present in the liver tissue, at the site of 
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inflammation. We wondered whether by assaying blood T cells that can migrate into the 
liver parenchyma, we would be able to sidestep this limitation. Therefore, using blood 
from HCV and PBC patients, we utilised transwell migration assays with hepatic epithelia 
as a tool, in the hope of revealing intrinsic differences not possible to discern from bulk 
peripheral T cells, and to investigate any distinctions between disease groups. 
 
As discussed in section 3.2, unactivated CD4+ T cells from healthy donors presented with 
increased TNF-a and IFN-g fractions following migration, and diminished TNF-a in co-
culture. (Fig. 3.4.1A, also Fig. 3.1.1). Activated healthy donor CD4+ T cells that migrated 
showed an additional increase in the percentage of IL-2+ cells, but the decrease in TNF-
a in co-culture was lost; and the increase in migrated IFN-g was not as pronounced. This 
last aspect of the data was likely due to higher starting (T cells only) IFN-g responsiveness 
masking any increases to some extent. Nonetheless, in HCV patient blood alone, the 
fraction of migrated cells producing all three cytokines was significantly higher following 
migration, despite the relatively high starting values of these cytokines. The cytokine 
profile showed by PBC patients was the most distinct however. Despite increased IFN-g 
in the migrated cells, TNF-a showed no change from T cells only and migrated IL-2 
proportions were actually less than T cell only controls. In addition, diminished IL-2 and 
TNF-a capacity was seen in co-culture.  
 
These results are summarized in Fig. 3.4.1B, where significant differences are colour-
coded to form a heat-map. Using this visualisation method, it was evident that once again 
very few distinctions could be made using static co-culture (3/13 statistical differences).  
!''%!
!
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Figure203.4.1 - Transwell migration assays allow the discrimination of different chronic liver 
diseases according to CD4+ T cell function. A - Transwell migration assays were carried out using CD4+ 
T cells from healthy (HD) blood donors (n=21; 1 performed by D.N), previously activated (anti-CD3/CD28) 
healthy blood donors (n=20; 11 performed by D.N), HCV blood donors (n=10; 8 performed by D.N), and 
PBC blood donors (n=11; 1 performed by D.N). Following harvest and 5h PMA/Ionomycin stimulation; 
percentage expression of IL-2, TNF-#, and IFN-" in each transwell condition were determined by as shown 
in the plots (medians + all data points). B - Data from A represented as a heat-map where statistically 
significant differences compared to T cells alone corresponded to intensity of colour. Standard statistical 
difference p value representations *, **, ***, and **** denoted 1, 2, 3, and 4 on the scale. Red and green 
indicated negative and positive displacements respectively. 
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Instead, transwell migration assays were much more efficient at separating T cells on the 
basis of their functionality (9/13 differences). In conjunction with these data, we compared 
cytokine-expressing T cells across the different healthy donor and disease groups (Fig. 
3.4.2). Interestingly, HCV patient CD4+ T cells were often the best producers of all three 
cytokines, with T cells only, co-culture, and migrated conditions all demonstrating this 
trend.  
 
Combined, these data illustrate that transwell migration assays can reveal intrinsic, 
disease-specific differences in cytokine responses that are not perceptible through static 
co-culture assays alone. Reciprocally, it is possible that the magnitude and direction of 
these cytokine shifts may be of use to determine disease aetiology in this patient cohort. 
 
3.6 Discussion 
 
Addressing the three aims of this chapter, we first demonstrated that migration through 
hepatic epithelia in transwell assays led to increased IFN-g, TNF-a, and IL-4 responses 
in the migrated CD4+ T cell compartment, and an enrichment for distinct activated, TEM 
and TEMRA phenotypes. We then showed the act of trans-hepatocyte migration was not 
inducing this phenotype. Instead the transwell migration effect was due to an enhanced 
selection mechanism, where hepatomas preferentially allowed more activated, stimuli-
responsive T cells to migrate through. Last, we identified cytokine patterns that distinguish 
peripheral blood CD4+ T cells from viral, and autoimmune liver diseases that were only 
revealed through transwell migration assays (Box 3.1). 
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Effector memory and TEMRA migration in preference to naïve and TCM was expected as 
these cell types possess a greater array of homing receptors required for entry in the 
tissue, as befits the central versus effector memory homing paradigm70. We also 
documented an increased cell surface expression of some (CD25, HLA-DR, PD-1, Fas), 
but not all (CD69, CD38) activation-associated markers in migrated cells. This broadly 
fits with our model of more activated T cells being  better able to migrate. HLA-DR is a 
late marker of activation24, 26, 561, indicative of previous cognate interactions (as opposed 
to induced by cytokines and other non-cognate mediators)26, 562, 563. PD-1 and Fas, are 
also associated with exhaustion, and activation-induced cell death respectively; both also 
requiring substantial antigen contact564, 565. Therefore, it is possible to go even further and 
suggest that the specific migration-associated activation phenotype is likely due to 
previous antigen-induced contact, as opposed to due to exposure to non-cognate stimuli 
that could explain CD69 and CD38 expression [refs 29, 562, 566, and our own unpublished 
data]. CD25 can also be induced by both cognate and bystander interactions567, and is 
also proportionally increased in the migrated pool, complicating interpretations; although 
perhaps antigen-triggered CD25 upregulation dominates here. The cognate-interaction 
hypothesis could be tested through directly comparing CD3/CD28 stimulated with 
Chapter 3 – Core Findings: 
 
• Following migration through hepatic epithelia, CD4+ T cells displayed 
proportional increases in IFN-g, TNF-a, and IL-4 in response to stimuli 
• Migrated cells also contained greater TEM frequencies and a predominantly 
activated phenotype 
• These differences between migrated and non-migrated cells were due to 
preferential migration of activated, stimuli responsive TEM, at an enhanced rate 
when compared to migration through transwell insert alone (enhanced selection) 
• Migration assays revealed distinct cytokine production patterns that are specific 
to autoimmune and viral liver diseases, and healthy controls 
Box 3 3.1 – Core findings from chapter 3 
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cytokine-stimulated cells for their capacity to migrate through transwells, and 
accompanying phenotypic marker analysis. 
 
The fact that not all activation markers were elevated in the migrated pool is intriguing. 
Any increases in early activation marker CD69 in the migrated cell pool may have been 
dwarfed by those induced by static co-culture and the non-migrated condition (see 
chapter 4), but CD38+ migrated cells were proportionally decreased. CD38 has interesting 
biology beyond a marker of activation; acting as a key regulator of endothelial 
transmigration, a multifunctional ectoenzyme, and a correlate of immunosuppressive 
function in TREGS38. Whether any of these aspects of CD38 expression link to the 
decreased levels following hepatoma transmigration may constitute worthwhile avenues 
for further investigation. Future work adding new markers, and combining them with those 
already assessed will allow further discrimination of this migration-competent cell type. 
Therefore, migration assays revealed distinct, activated profiles that could be specifically 
suggestive of previous antigen encounter. 
 
Interestingly, we found the proportion of both TH1 (TNF-a, IFN-g), and TH2 (IL-4) cytokine-
producing cells to be increased in the migrated T cell pool. This indicates that the 
hepatomas we used were not specifically selecting a particular T-helper phenotype, but 
rather a generally activated, effector cytokine-competent cell type. Additionally, if the 
general paradigms are to be believed, it would argue that neither preferential chemokine 
expression on TH1 (CXCR3, CXCR6, CCR5), nor on TH2 (CCR4, CCR8) cells are vital 
for migration through the monolayer353. Therefore, other homing molecules could be 
encouraging cells to migrate, such as ICAM-1 binding through LFA-1, and CXCR4-
CXCL12 interactions, as myself and others in our lab have started to show [Z. Stamataki 
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- unpublished observations, and data not shown]. Future chemokine receptor blocking 
experiments and chemokine-directed chemotaxis experiments using the same transwell 
assay system could be performed to test these hypotheses. 
 
The transmigration effect was not just Huh-7 specific: different hepatic and non-hepatic 
epithelial cell lines replicated this effect. This could mean that T cells that have migrated 
through epithelial cells of many organs share these cytokine profiles, although only TH1 
cytokines were tested in these experiments, and primary, non-cancerous cells would be 
needed to determine if this migration profile would be a feature of transmigration through 
non-neoplastic epithelia. This phenomenon is likely epithelial-specific, as lymphocytes do 
not migrate through non-activated liver endothelial cells directly364, 568. Our data suggest 
that the act of migration alone separates functionally activatable subsets – migration 
through bare transwell inserts resulted in similar increases in IFN-g and TNF-a 
percentages (data not shown). 
 
Using gel migration assays, we uncovered deviations from the transwell migration effect, 
with both IL-2+ and TNF-a+ migrated cells unchanged in representation. This difference 
was not due to the presence of collagen in the gel. Perhaps the differences were due to 
an effect of slower T cell velocities in the gel, or different mechanical pressures569. 
Nonetheless, attempting to replicate these findings with collagen-free gels such as 
matrigel would be an interesting comparison570. Although the transwell migration assays 
allowed efficient separation of disease-linked cytokine profiles, and as such are 
recommended for continuing use for this purpose, a better understanding of physiological 
T cell responses to migration through the liver parenchyma may be achieved through 
other models. This was the initial aim of the collagen gel system, including attempting to 
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polarise the hepatocyte cell lines to a more in vivo representative cell type as has been 
seen in other gel systems570, 571. Taking these experiments forward we could migrate 
autologous donor CD4+ T cells through precision-cut liver slices (cut using a Krumdiek 
slicer). Although the liver architecture would remain intact and viable for up to 48h572, 
tissue damage factors may contribute, and autologous patient blood is difficult to acquire. 
Alternatively, ‘liver chips’, biomimetics which incorporate multiple liver cell types into 
physiologically representative complex 3-dimensional architecture with modifiable fluid 
flow dynamics, may provide an attractive alternative in the future573. Some such systems 
now support the monitoring of immune cell trafficking574. Finally, perfusing labelled 
autologous T cells into liver wedges is another option being explored in our department575. 
This system would allow us to utilise unreconstructed liver components in their most 
natural state. Although using wedges would not specifically allow us to see the effect of 
hepatocytes on a T cell, T cells could be harvested from the wedge tissue and vasculature 
by mechanical digestion and perfusion respectively, allowing general tissue specific 
influences on T cell biology to be studied. 
 
Initially, we wondered whether the transwell migration effect was due to the hepatic 
epithelia altering the biology of the T cells. This was a reasonable assumption based on 
the fact that T cells only, co-culture, and non-migrated conditions all displayed a similar 
phenotype, with migrated cells being the only changed population. Logically, we would 
expect reflective changes in the non-migrated population if a selection effect was 
responsible. Also, it is possible that hepatocytes could have had made non-cognate 
impressions on the function and phenotype of a T cell, as shown by others in the past347, 
576, 577. However, problems in this interpretation arose when trying to explain the shift 
towards memory phenotypes as antigen recognition was not occurring in our system, and 
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our assays were all under 24h in duration. Assessing the percentages of T cells that 
migrated, and looking at absolute T cell numbers was key in settling this dispute. 
Observing very few T cells migrate at resting conditions, we were able to explain the lack 
of discernible corresponding changes in non-migrated populations as this population was 
far greater in numbers. Data showing no new appearance of cytokine+, TEM, or TEMRA 
numbers in the migrated pool also served to confirm this. Therefore, we demonstrated 
that specific T cell migration through Huh-7 cells was a selection mechanism, not an 
induction phenomenon. We termed this an enhanced selection due to the fact that 
migration efficiency was increased in the presence of Huh-7 cells. It is noteworthy that 
enhanced selection was not observed for B cells, which required CXCL12 to migrate 
through Huh-7 monolayers [Z. Stamataki – unpublished observations]. T cell-specific 
enhanced selection is interesting as Huh-7 cells represent an additional physical barrier, 
so perhaps are encouraging migration through adhesion receptor expression and/or 
providing cytokine signals to the T cell migration candidates. Both possibilities could be 
tested using blocking experiments as mentioned above. Overall, recognising that hepatic 
epithelia select particular activated T cells, rather than induce phenotypic changes, will 
allow us to further understand the influences of a hepatocyte on a T cell’s biology. 
 
We next profiled the cytokine responses of migrated cells from HCV and PBC patient 
blood. Relatively little is known about functional alterations of intrahepatic T cells in these 
diseases, despite T cells being central to the pathology of both414, 465. Issues with the use 
of liver tissue include poor availability, often insufficient quantity, and low accessibility of 
tissue at different disease stages506, 547, 555. Mouse models are often poor substitutes for 
human chronic liver disease, and the use of chimpanzees has significant ethical and 
financial considerations547, 578. Although the use of human peripheral blood sidesteps 
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many of these issues, the main challenge is reliably identifying disease-linked 
populations. MHC-tetramers have been incredibly important tools in aiding the profiling 
antigen-specific T cells in both diseases481, 486, 550, 556, 557, but such studies rely on prior 
knowledge of the antigens and MHC haplotypes involved555. Furthermore, the often 
extremely small frequencies of viral- or autoantigen specific cells in peripheral blood 
makes detection difficult or even impossible555, 556, 579, requiring enrichment steps that 
may alter native cell biology555, 580. The most advanced advance on these techniques are 
the use of activation markers such as CD25 and CD40L as indicators of response to viral 
antigen stimulation of T cells from chronic HCV-infected blood479, 484, 549. These activation 
markers are thought to emerge even if no proliferative or cytokine responses are seen, 
and therefore are well suited to studying the exhausted cell populations seen in HCV555. 
In our study, we offer an alternative on this theme. We exploit the inherent activated status 
of migration-capable CD4+ T cells to investigate not only antigen-specific T cells, but the 
whole pool of activated T cells that may enter the site of inflammation, the liver 
parenchyma, in HCV and PBC. 
 
We observed that CD4+ T cells from different chronic liver diseases revealed different 
cytokine response patterns when put through transwell migration assays. These 
differences were not evident with static co-culture, reinforcing the usefulness of transwell 
migration as a tool to study activated T cells in peripheral blood. Moreover, the cytokine 
profiles revealed by transwell assays appeared distinct in each disease, which offers 
potential for their use in disease determination, and the further study of migrated 
populations that could be important in disease progression and outcome. 
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While these data alone do not prove migrated cells are involved in pathogenesis, it 
provides links to their role in the disease process that can be tested further. Similar to the 
activation marker studies discussed in the previous paragraph, we have interrogated an 
activated population with the ability to enter the liver parenchyma, so we are likely to be 
enriching for disease-specific cells. Interestingly, the profiles as revealed by transwell 
assays appeared to be disease-specific, raising the possibility of the specific involvement 
of migrated cells in disease pathogenesis. Such a role for non-viral specific intrahepatic 
CD8+ T cells has been proposed previously in chronic HBV infection. Failure to establish 
an efficient initial T cell response in some patients appeared to lead to inflammation-
driven recruitment of non-specific cells that contribute to liver damage but not viral 
clearance496, 506. Alternatively, transwell migration assays could be used for disease 
determination, potentially increasing the readouts for the efficacy of therapeutic 
interventions in liver disease patients. In contrast to other studies that showed weak 
antigen-specific type 1 CD4+ T cell responses in chronic HCV infection476, 479, 482, we 
observed more robust responses in HCV infection than in healthy blood. Differences 
could be down to the presence of many non-HCV specific clones that are not functionally 
inhibited in the migrated pool (that could still be involved in HCV damage through 
bystander activation or other mechanisms), or our use of mitogens to coax responses 
from cells, overriding the exhausted or anergic phenotype. Future address of type 2, type 
17, circulating TFH, and regulatory responses would allow determination of any skewing 
of helper subsets in these diseases, as has been suggested in HCV and PBC411, 504, 510, 
552, 554. Therefore, we hypothesise that by modelling migration into the parenchyma, we 
are picking out disease relevant T cells from the blood, without need to sample liver 
tissue. 
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It would be interesting to examine whether other chronic liver diseases also showed 
distinct patterns. We could start by using other viral and autoimmune patient donors, HBV 
and PSC, before moving onto dietary injury liver diseases such as ALD and NASH. 
Further assay of the migrated populations in each disease would also help determine if 
this pool was relevant to the disease pathology. For example, as a first step, harvested 
migrated T cells from HCV patients could be stimulated with HCV viral antigens in antigen 
presentation assays in order to measure antigen-specific responses. Similar experiments 
could be carried out with PBC patient T cells, using PDC-E2 autoantigens414, 557. If the 
migrated population is found to be disease-specific we could address outstanding 
questions such as what is the relevance of the depleted IL-2 production capacity in 
migrated PBC blood T cells? Could this reflect an exhausted T cell phenotype, no longer 
able to support survival and self-replication; or perhaps a reduced ability to promote TREG 
maintenance, resulting in a less controlled pro-inflammatory response? Similarly, does 
the increase in all cytokines in migrated HCV patient blood T cells suggest elevated 
bystander activation in this population, like that described in HBV infection496? Thus, 
future work investigating antigen specificity, in vitro impacts on accessory cells, and 
integrated phenotypic and functional characterisation would help address disease-
specific alterations in chronic liver diseases. 
 
To increase biological relevance, we aim to use primary human hepatocytes (PHH) in 
future studies in order to remove any potential tumour effects. Modelling parenchymal T 
cell migration need not stop there as any or all of precision cut slices, microchips, or liver 
wedge systems could be used as more realistic models of the liver microenvironment, as 
discussed above. The importance of multi-parametric staining and bioinformatics tools 
would also be advantageous. Lastly, as mentioned, combining cytokine stains to look at 
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multifunctionality may help distinguish migrated T cells from different diseases further; 
while combining multiple activation markers would allow for the discrimination of precise 
phenotypes that are able to migrate into the liver parenchyma. 
 
In conclusion, we have used transwell migration assays as a tool to separate out specific 
activated effector type CD4+ T cells from peripheral blood with high cytokine producing 
potential, and clear consistent variations on this theme were apparent across different 
liver diseases. These data led us to propose that the migrated populations are important 
to the specific disease processes. Further work with primary hepatocytes, additional 
disease groups, and antigen responsiveness of the migrated cells; will help us to 
determine physiological relevance, applicable breadth, and disease relevance 
respectively. Determining these factors will help us understand how migration into the 
parenchyma changes T cells on a population level, which in turn may help to understand 
intricate mechanisms behind pathology in different chronic liver diseases. 
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Chapter 4 – Hepatocyte co-culture induces an activation-
independent CD69INT phenotype in CD4+ T cells 
 129 
4.1 Introduction – CD69 
 
CD69 (also historically called activation inducer molecule [AIM]) is a homodimeric 
transmembrane glycoprotein and member of the type II C-type lectin family29, 581. Located 
in the NK gene cluster on chromosome 12 (chromosome 6 in mice), CD69 shares 
structural, but not functional homology with NK activatory and inhibitory receptors CD94, 
and NKG2 molecules29; Its expression is controlled by multiple transcription factors 
including nuclear factor kappa B (NF-κB), erythroblast transformation-specific related 
gene-1 (ERG-1), activator protein-1 (AP-1), and hypoxia inducible factor 1a (HIF-1a)30, 
582. CD69 is best known as an early activation marker, upregulated on all leukocytes and 
platelets following stimulation28. However, this molecule has a number of other reported 
roles; most notably in the control of leukocyte migration and tissue residence, propagating 
regulatory cell development, and in the overall regulation of immune responses29. The 
importance of CD69 as a key marker of TRM has already been discussed in detail (section 
1.2), but its other roles are covered here. 
 
CD69 is particularly important in controlling the migration of T cells. By antagonising 
tissue egress receptor S1PR1, CD69 prevents entry to the efferent blood and lymph, 
thereby increasing dwell time in both SLOs and NLTs71. This is not only important for 
precisely controlling the length of stay in SLOs, which in turn allows naive T cells time to 
receive optimum stimulation and differentiation cues31; but is also vital for the 
development and maintenance of TRM cells as discussed in section 1.2 110. CD69 also 
affects migration through control of chemokine expression patterns and associated 
chemokine responsivity as demonstrated in CD69-deficient mice583. Additionally, CD69 
is important in both thymic and peripheral TREG development. tTregs derive specifically 
from CD69HI progenitors584, and CD69 also appears important in mediating efficient pTREG 
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induction, and enhancement of TREG function585, 586. This process is likely through both 
CD69-triggered TGF-b production, that is needed for TREG polarisation581, 587; and the 
triggering of the the JAK3/STAT5 (JAK – Janus kinase; STAT – signal transducer and 
activator of transcription proteins) signalling pathway downstream of CD69 that promotes 
TREG development while simultaneously inhibiting effector TH1 and TH17 differentiation30, 
588. 
 
In its best-known role, CD69 is the earliest T cell activation marker. Not expressed on 
resting T cells, CD69 expression occurs as early as 2 hours following cellular activation, 
peaks between 18 and 24 hours, then declines27, 28. This is in contrast to other activation 
markers CD25, CD38 and HLA-DR that arise progressively later after the initial activation 
event24-26, 561, a difference that has been attributed to the presence of pre-formed 
intracellular CD69 protein stores in resting lymphocytes589. CD69 is not only upregulated 
through cognate antigen recognition; but also via cytokines such as type I interferons, 
TGF-b, and TNF-a; presence of local glucocorticoids; hypoxia; and interactions with the 
microbiota29, 30, 171, 582, 585, 590. Functionally, the role of CD69 is less clear – is this molecule 
simply a consequence of cellular activation, or is it contributing to it? In the absence of a 
known ligand for CD69, early studies used antibody-mediated CD69 ligation to study the 
CD69 signalling pathway. In vitro application of these stimulatory antibodies induced 
proliferation, generation of the pro-inflammatory cytokines IL-2 and TNF-a, increased 
glycolysis, and increased calcium flux27, 581, 591-594; but also, TGF-b synthesis595, 596. CD69 
was also required for T cells to stimulate macrophages597. Therefore, from these data it 
appeared CD69 was generally acting as a pro-inflammatory, activatory receptor.  
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However, in vivo data paint a different picture, indicating CD69 does not act as a 
costimulatory molecule581, 598. Constitutive T cell CD69 expression did not lead to 
enhanced pro-inflammatory responses581, 599, 600, and knocking out CD69 demonstrated 
no impairment of T cell activation or proliferation598, 601. However, CD69-deficient mice 
often show dysregulated and elevated pro-inflammatory immune responses, as evident 
in mouse models of asthma602, arthritis595, IBD583, 585, myocarditis603, bacterial 
clearance604, and cancer596, 605. However, examples to the contrary have also been less 
frequently reported606-608. These discrepancies could be down to differences in mouse 
models used, that in turn are differentially more dependent on different immune cellular 
and molecular components, but in any case, these studies combined highlight the great 
potential of CD69 as a complex, multipurpose regulator of adaptive immune responses. 
Furthermore, the arguments for CD69 acting as an immune regulator are not limited to 
mouse models. Anti-CD69 autoantibodies have been detected in a subset of human RA 
patients, and the presence of these directly correlates with disease severity609. Therefore 
in vivo prevailing theory dictates that CD69 is acting as a regulator of inflammation. 
 
Recent data has uncovered candidate endogenous ligands for the CD69 molecule that 
begin to help explain some of these properties at a molecular level. Two candidate CD69 
ligands have been proposed – Galectin-1, and Calprotectin (S100A8/S100A9 
complex)610, 611. Expressed on DCs and macrophages, Galectin-1 (through this 
interaction with CD69) promotes JAK3/STAT5 activation and TREG development, 
concomitant skewing away from TH17 lineages, and an increased T cell IL-10 production 
through the AHR pathway610, 612. Calprotectin is a calcium-binding protein expressed by 
various myeloid cells. Its ligation of CD69 in human PBMCs also resulted in a skewing 
towards TREG cells, accompanied by enhanced TGF-b production611. In addition, CD69 
 132 
can form lateral (cis) interactions with the system L1 amino acid transporter complex 
LAT1-CD98, as well as S1PR1613, 614. CD69 association with LAT1-CD98 increases 
uptake of tryptophan and other amino acids, promoting mTOR pathway activation and 
HIF-1a activation, as well as activity of AHR30, 613, 615. Intense mTOR signalling is required 
for TH1, TH2, and TH17 differentiation30, while low intensity signalling is necessary for TREG 
development616. Conversely, AHR signalling promotes TH17 differentiation and HIF-1a 
downregulation613, 617. Moreover, S1PR1 directly represses TREG lineage commitment, 
enhancing signalling through the mTOR pathway618. Perhaps CD69-mediated mTOR 
activation through LAT1-CD98 is sufficient for the low level mTOR signalling necessary 
for TREG promotion, whilst CD69-mediated S1PR1 downregulation prevents this signal 
becoming too intense and promoting effector cell differentiation. Combined, it is becoming 
clear that CD69 can precisely tune immune responses through complex signalling 
pathway interactions we are just beginning to grasp; promoting or repressing effector cell 
differentiation based on cellular context, putative ligand availability, oxygen content, 
prevailing cytokine signals and the metabolite milieu [reviewed in ref 30]. 
 
In addition to aiding the differentiation of conventional TREG cells, CD69 also marks a 
novel regulatory T cell subset in its own right29. In a mouse model of systemic lupus 
erythematosus (SLE), CD69+ CD4+ T cells suppressed their CD69- counterparts619. Han 
et al. built on this work, demonstrating these CD69+ suppressive CD4+ cells are induced 
by liver tumours in mice, but do not express FoxP3, and suppress through membrane-
bound TGF-b (mTGF-b)620. Similar CD69+mTGF-b+FoxP3- CD4+ T cells have since been 
detected in human blood, with suppression in vitro shown to be TGF-b and IL-10 
dependent621. Furthermore, CD69+ T cells were present in HCC patient blood and liver 
where they were associated with worsening disease progression, whereas the frequency 
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of these cells correlated with lower risk of developing graft-versus host disease post-
transplantation622-624. Crucially, Han et al. showed these cells were induced by liver 
tumours and suppress normal anti-tumour responses via mTGF-b623. Finally, recent data 
have indicated it may be possible to distinguish regulatory from recently activated T cells. 
Stable long-term expression of CD69 controlled by non-canonical NFκB signalling is 
thought to mark regulatory or tissue-resident phenotypes, whereas the classic transient 
CD69 expression pattern mediated by the canonical NFκB signalling pathway is a clear 
giveaway of recently activated cells29, 625, 626. 
 
Thus, CD69 is a multifaceted molecule, with the ability to act as a marker of activation, 
tissue residency, and of regulatory cell types. In this chapter, we will systematically 
address the activation, and regulatory angles to determine what CD69 upregulation 
following hepatic epithelia contact means for the T cell. The possibility of co-culture-
induced CD69 upregulation representing an aspect of tissue residence formation will be 
discussed further in Chapter 5. With this in mind, we concocted the following aims: 
 
i. Establish whether CD69 upregulation on CD4+ T cells by hepatic epithelia 
represents an activation event 
ii. Determine if these CD69+ CD4+ T cells acquire linked suppressive functions 
iii. Identify the possible mechanisms behind hepatocyte-induced CD69 
upregulation 
 
 
4.2 Co-culture with hepatic epithelia promotes an activation-independent CD69 
upregulation on CD4+ T cells 
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Building on previous work (section 3.3), we first showed that overnight co-culture with 
Huh-7 cells imbued blood-derived CD4+ T cells with CD69 expression (Fig. 4.1.1A,B). 
This was consistent across all 35 healthy blood donors. While CD4+ T cells cultured alone 
possessed an average of only 1.2% CD69 expression (range 0.3 – 5.5%), this was 
increased to a median of 60% (range 11.4 – 99.1%), corresponding to an average fold 
increase of 51.8 times (range 5.8x – 143x). Importantly though, this upregulation was 
always to an intermediate expression level (Fig. 4.1.1A). Comparable induction of CD69 
expression was observed not only with different hepatocyte cell lines (HepG2, Hep3B), 
but also in non-hepatic epithelia (A549, AdAh, Caco-2, HeLa) (Fig. 4.1.1C). Thus, we 
demonstrated a robust and consistent upregulation of intermediate-level CD69 
expression is triggered on CD4+ T cells following contact with both hepatic and non-
hepatic epithelia. 
 
We next asked what this CD69 upregulation represented. CD69 is best known as a 
marker of early activation581, so we decided to investigate this possibility first. Therefore, 
we compared CD69 upregulation by Huh-7 cells with conventional T cell activation stimuli 
anti-CD3/CD28, PMA/Ionomycin, and PHA. We also looked at sequentially later markers 
of activation CD25, CD38, and HLA-DR, for up to 7 days in culture. Although the 
percentage of cells expressing CD69 in Huh-7 co-culture was similar to the activation 
stimuli; the expression levels per cell were not increased from the few CD69+ T cells 
cultured alone (Fig. 4.1.2). This was in stark contrast to the high median fluorescence 
intensity (MFI) seen following T cell stimulant addition. Furthermore, expressions of  
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Figure224.1.1 - CD69 expression induced on blood-derived CD4+ T cells co-cultured overnight with 
both hepatic and non-hepatic epithelial cell lines. CD4+ T cells were purified from healthy donor 
peripheral blood, and cultured with hepatic/non-hepatic epithelia overnight, before CD69 determination by 
surface staining and flow cytometry. A - Representative flow cytometry plots showing CD69 expression 
following co-culture with Huh-7 cells, but not in T cells cultured alone (IMC control also shown). B - 
Combined CD69% expression data and median of CD4+ T cells from 35 donors cultured +/- Huh-7 cells. C 
- Median (+IQR) % CD69 expression data following overnight culture with hepatic (white bars), or non-
hepatic epithelia (grey bars). Epithelial cell lines same as used in Fig. 3.1.2. N=3 for all cell lines (except 
Hep3B - n=2) 2/3 experiments for part C carried out by F.A.. 
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Figure234.1.2 - Co-culture-induced CD69 upregulation is distinct from classical T cell activation. 
CD4+ T cells were cultured alone; with Huh-7 cells; or with classical activation stimuli (anti-CD3/CD28 
beads, PHA, or PMA & Ionomycin) for 7 days. Expression patterns of CD69, CD25, CD38, and HLA-DR 
(top to bottom panels) were assessed by staining and flow cytometric analysis at 4 different time points as 
shown. Both percentage marker expression (left panels) and median fluorescence intensity of the marker-
positive cells (right panels were shown). Only T cells only and Huh-7 conditions were statistically compared 
at each time point due to donor number considerations. T cells only, Huh-7 - n=8-10 for % data, n=3-4 for 
MFI data; anti-CD3/CD28 beads - n=4-5 for % data, n=3-4 MFI data; PHA - n=2 all data; PMA & Ionomycin 
- n=1 all data. 1 donor time-course (for CD69, CD25 and HLA-DR) carried out by F.A.
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CD25, CD38, and to a lesser extent HLA-DR were only increased with the three activation 
stimuli, by both percentage and MFI. Intriguingly, combining co-culture and activation 
stimuli together actually decreased the % CD69 upregulation from Huh-7 co-culture 
alone, but only with PHA and PMA/Ionomycin, not anti-CD3/CD28 stimulation (Fig. 4.1.3). 
Similarly, all activation stimuli combined with Huh-7 co-culture decreased CD38% 
expression, and no CD25 upregulation was seen when PMA/Ionomycin and Huh-7 cells 
were used together. Therefore, these data argue against Huh-7-induced CD69 
expression representing conventional T cell activation, due to the relatively low CD69 
expression levels, and failure to induce other activation markers compared to 
conventional T cell activation stimuli. 
 
We also observed that Huh-7 co-cultured CD4+ T cells did not proliferate appreciably over 
7 days, whereas as expected, activation stimuli triggered robust proliferation (Fig. 4.1.4A). 
The small amount of apparent cell division that was noted in the co-cultured cells was 
mostly due to the CD69-, not the CD69+ subset (Fig. 4.1.4B). In any case, it appears that 
this was an artefact of staining that was only seen in co-cultured conditions because cells 
did not halve their fluorescence with each division. Rather some appeared to not have 
taken up the dye efficiently as the cells were all at the negative end of the divided gate 
(Fig. 4.1.4C). We next illustrated that CD69+ T cells generated by Huh-7 co-culture did 
not preferentially apoptose compared to their CD69- counterparts (Fig. 4.1.4D). Although 
quite a lot of apoptosis was observed by day 7, this can be accounted for by the lack of 
IL-2 added to the cultures alongside the metabolically active Huh-7 cells depleting 
nutrients from the media. In order to compare CD69 upregulation in co-culture with that 
associated with conventional activation, we were also interested in further study of the 
dynamics of CD69 as an activation marker following conventional activation stimuli. We  
!'+*!
!
!
Figure244.1.3 - Combining hepatocyte co-culture and activation stimuli has unique effects on T cell 
activation status. Experiments designed and results presented as in Fig. 4.1.2, but with activation stimuli 
and co-culture combinations also included. All graphs show % marker expression, n=1 (2 technical 
replicates). 
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Figure254.1.4 - Co-cultured CD69+ T cells do not proliferate or apoptose more than their CD69- 
counterparts. A - % Proliferation over time as assessed by CellTrace Violet staining following CD4+ T 
cell culture alone, with Huh-7 hepatomas, or with the different activation stimuli (n=2, median and range 
shown). B - % division amongst CD69+ and CD69- cells in co-culture (n=2, median + IQR). C - Example 
flow cytometry plot showing staining artefact in some Huh-7 co-cultured T cells when assessing 
proliferation (day 4 Huh-7 co-culture example shown). D - % of dead CD4+ T cells over time as assessed 
by Zombie Aqua staining. T cells only, Huh-7 co-cultured CD69+, and Huh-7 CD69- cells shown (n=1 [2 
technical replicates], median + 95% CI). E - Activation marker expression per divided generation. Flow 
cytometry plots show examples of cell division at day 7 with or without PHA. Each division shown in a 
different gate. Adjacent line graphs show how expression of each activation marker changes with each 
generation in both % (top) and MFI (bottom). N=1 (2 technical replicates), median + range. 
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chose PHA as our model proliferation stimulus as it generated the clearest and the most 
divisions over 7-day culture. We noted that CD69 expression gradually weakened with 
each generation after the first division (Fig. 4.1.4E). CD25 took until division 3 to start 
declining, while CD38 took until division 4-5. HLA-DR declined at division 2, but at division 
7 started to rise again. Lastly, we investigated the stability of hepatocyte-induced CD69. 
Removing CD4+ T cells from co-culture, we noted that even after 72h there was no 
appreciable drop in CD69% expression, hinting at stable imprinting (Fig. 4.1.5). These 
data combined also suggest that Huh-7-induced CD69 upregulation was not part of an 
activation programme as no increases in proliferation or apoptosis were seen, and no 
drop in T cell CD69 expression was observed following removal of the ‘stimulatory’ agent 
(i.e. the hepatocyte). 
 
So far we have demonstrated that CD69 upregulation occurs with epithelial cell lines. 
However, this falls short of demonstrating physiological significance with a primary cell 
type. Further, we wondered whether other liver cell types were capable of inducing the 
same phenotypic change. Therefore, we used primary BEC and HSEC cells, as well as 
the hepatic stellate cell line LX2 as our potential inducers. No CD69 upregulation was 
seen following co-culture with HSEC (Fig. 4.1.6A). Following BEC co-culture, little 
upregulation was seen overnight, but by day 3 a clear substantial induction was evident. 
LX2 co-culture resulted in no upregulation at day 1, but a minor change at day 3 onwards. 
Notably, all cell types that produced an upregulation, did so to an intermediate expression 
level, as evidenced by comparison to anti-CD3/CD28 stimulation where the upregulation 
was high. Finally, in an effort to lay groundwork for future studies, we performed mixed 
cultures of combinations of these cell types. These data would give us an idea of how a 
T cell would regulate CD69 expression following contact with multiple cell types as it  
!'()!
!
!
Figure264.1.5 - CD69 expression does not diminish short term following removal. CD4+ T cells were 
co-cultured with Huh-7 and then carefully harvested and placed into culture alone. Expression of CD69 was 
then monitored for up to 3 days. N=1 (2 technical replicates), median + range. 
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Figure274.1.6 - CD69 upregulation can be induced by primary BEC as well as hepatoma cell lines. A 
- 7 day co-culture with different hepatoma cell lines (Huh-7, HepG2, Hep3B), hepatic stellate cell line LX2, 
primary HSEC, or primary BEC. Median (95% CI) expression shown (n=2-3). Below are representative flow 
cytometry histogram overlays showing the same data (plus included anti-CD3/CD28 stimulation, positive 
control; IMC, negative control). B - % CD69 expression following overnight co-culture with different liver 
cell lines in combinations shown. Darker shades of grey indicates more cell lines in culture together. N=1 
(2 technical replicates), median + IQR.  
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would in migrating through the liver.  We were only able to culture these cells overnight 
due to availability of donor material, but it appeared that BEC did not provide a synergistic 
effect on CD69 upregulation when combined with Huh-7; and neither did HSEC dampen 
the Huh-7 driven effect (Fig. 4.1.6B). However, LX2 cells did seem to attenuate CD69 
upregulation when combined with Huh-7, but this attenuation was not as strong when 
HSEC and BEC were also present. 
 
Together these data suggest the CD69 upregulation induced by Huh-7 cells does not 
reflect conventional T cell activation. This is due to intermediate expression levels, the 
failure to express other activation markers, and no discernible proliferation observed. This 
phenotype was stable following removal from the hepatocytes, and also detected in 
primary biliary epithelia, indicating that this is not a feature of neoplastic disease. 
 
4.3 CD69 upregulation did not represent unconventional TREG induction 
 
With Huh-7-mediated CD69 upregulation unlikely to represent conventional T cell 
activation, we turned our attention to another documented function of CD69 on T cells – 
as an unconventional regulatory T cell marker. CD69+ CD4+ T cells have been shown to 
form an unconventional regulatory T cell subset that are associated with hepatic 
carcinomas in mice and men620, 622, 623. Furthermore, long-term CD69 expression has 
been associated with this cell type in preference to a more conventional transient 
upregulation29, 625. Therefore, we investigated whether the CD69+ T cells generated by 
co-culture with Huh-7 cells possessed any regulatory capacity. 
 
In order to test this, we devised suppression assay methodology based on the 
standardised work of others540. We generated CD69+ T cells from overnight co-culture 
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with Huh-7 cells, before mixing the resulting T cells (hepatoma-cultured T cells - hTCs) 
with autologous untouched T cells (T responder cells - Tresp) that had been labelled with 
CellTraceVioletTM proliferation dye (Fig. 4.2.1). These two cell types were mixed at 
various ratios - 1 x 105 Tresp were present in all conditions, with numbers of hTCs varied 
to form simple doubling cell ratios. Anti-CD3/CD28 beads were added to the wells as the 
stimulant and TGF-b added to Tresp alone was used as a positive control for suppression. 
Cells were cultured together for 5 days, before harvesting, and the amount of proliferation 
determined by flow cytometry. From these proliferation rates, % suppression was 
calculated as follows:  
 %	𝑑𝑖𝑣𝑖𝑠𝑖𝑜𝑛	𝑇𝑟𝑒𝑠𝑝	𝑎𝑙𝑜𝑛𝑒	 − 	%	𝑑𝑖𝑣𝑖𝑠𝑖𝑜𝑛	𝑇𝑟𝑒𝑠𝑝	𝑤𝑖𝑡ℎ	ℎ𝑇𝐶%	𝑑𝑖𝑣𝑖𝑠𝑖𝑜𝑛	𝑇𝑟𝑒𝑠𝑝	𝑎𝑙𝑜𝑛𝑒 	× 	100 
 
This assay set up formed our standard suppression assay. 
 
To our surprise, from 1:1 Tresp:hTC, the addition of more hTCs resulted in apparent 
suppression (Fig. 4.2.2A). This was statistically significant at 1:2 and 1:4, and reached a 
modest suppression of 34%. Furthermore, the inclusion of exogenous IL-2 in these 
cultures made no difference to the result, indicating failure of Tresp survival was not a 
critical factor (data not shown). Unfortunately, the positive control, TGF-b, yielded 
disappointing suppression results – 4.5% average suppression (data not shown). This 
led us to improve the controls for these experiments by other means. First, it is noteworthy 
that for these standard suppression assays we were keeping Tresp numbers constant 
across the hTC ‘doses’, therefore changing hTC numbers and thus overall cell number  
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between conditions (i.e 1:1 had 1x105 Tresp + 1x105 hTC; 1:4 had 1x105 Tresp + 4x105 
hTC). Concerned that at higher hTC doses here we would just be seeing apparent 
suppression due to lack of space to proliferate, or lack of nutrient availability, instead of 
genuine regulatory cell-mediated proliferative inhibition, we devised a parallel 
experimental set up. For this second experimental iteration, we set the overall cell 
numbers/well at 1x105, and varied both Tresp and hTC accordingly. This second set-up 
we termed constant suppression assays. 
 
In the constant suppression assays, no suppression was observed at any dose (Fig. 
4.2.2B). This seemingly confirmed our suspicion that the competition for space or 
nutrients in the 1:2 and 1:4 Tresp:hTC doses was behind what we initially interpreted as 
suppression. However, this interpretation was again questioned when we included our 
final control. Instead of using hTC as ‘suppressors’ we used T cells cultured alone (tTC) 
to directly compare the effect of hepatocyte imprinting on a T cell, as suggested by 
others627. As all T cells were autologous, using tTCs was effectively culturing T cells 
separately for a day before putting them back together – a scenario that should obviously 
not invoke any kind of suppressive ability. Indeed, this is exactly what we found – no clear 
suppression when tTCs were used as the suppressors (Fig. 4.2.2C). Whether tTC + Tresp 
numbers were kept constant (constant suppression assay), or varied with the ratios used 
(standard suppression assay), no suppression was seen. If competition for 
space/nutrients was the major controlling factor, we would expect tTC cells to show 
apparent suppression in the standard assays just like hTCs did. Therefore combined, 
although this data is not yet clear, it appears hTCs are not able to reliably act as a 
suppressive cell type due to their lack of ability to suppress in different experimental set-
ups.  
!'(*!
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Figure294.2.2 - hTCs are unlikely to be suppressive in vitro. hTCs and Tresps were mixed in different 
ratios, activated, and cultured for 4 days as described in Fig. 4.2.1. The three graphs shown represent the 
evolution of results as more internal assay controls are added in. In A, the standard suppression assay 
(STD) was carried out revealing statistically significant increases in apparent suppression. In B, these data 
were compared with the constant suppression assay (CON - where summed hTCs and Tresp numbers 
were constant across the different cell ratios - see text for more info.). Last, in C, suppression was assessed 
in Tresps cultured with tTCs (T cells cultured without Huh-7 cells) in both the STD and CON configurations. 
hTC STD - n=6; hTC CON, tTC STD - n=3; tTC CON - n=2. Median values +/- IQR shown in all graphs.! !
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4.4 The CD69 upregulation mechanism involves direct cell-cell contact 
 
An outstanding question in Huh-7-mediated CD69 upregulation lies in determining the 
mechanism. To investigate this, we first looked at the CD69 upregulation dynamics. We 
demonstrated that CD69 upregulation was evident after as early as 2h in co-culture (Fig. 
4.3.1). This rapidity indicates that CD69 is likely pre-formed inside the T cell as others 
have suggested589. It is possible that the CD69-inducing pathway is likely already present 
on the hepatocyte, with no need for new transcription or translation following T cell 
contact. Isolation of memory and naïve T cell subsets allowed us to better determine the 
CD4+ T cell type(s) that are capable of CD69 upregulation in response to hepatocyte 
contact. Although we saw CD69 upregulation in both naïve and memory CD4+ T cells, 
this was more efficient in the latter subset (Fig. 4.3.2). Additionally, we reverted to 
transwell migration methodology in order to indirectly demonstrate CD69 upregulation 
was more efficient in the more activated cell types. By enabling migrated cells to land on 
a second hepatocyte monolayer, we showed an enhanced % of CD69 upregulation, when 
compared to CD4+ T cells in static co-culture (Fig. 4.3.2B). As we already determined that 
migrated cells are more activated than their non-migrated counterparts (see section 3.3), 
it follows that the cells best able to upregulate CD69 are likely also a relatively activated 
contingent. 
 
To see if CD69 upregulation required cell-cell contact with the hepatocyte, we included 
0.4µm pore transwells in our co-culture set ups. T cells restrained above these did not 
upregulate CD69 and so we concluded cell surface contact was required, with soluble 
mediators unimportant (Fig. 4.3.3). Honing in on the mechanism further, we fixed Huh-7 
cells before adding the CD4+ T cells. Resulting CD69 upregulation was dramatically  
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Figure324.3.1 - Huh-7-induced CD69 upregulation happens very rapidly. % CD69 expression in CD4+ 
T cells cultured alone (grey), or with Huh-7 cells (blue) at various early time points. N=1 (2 technical 
replicates - median + range shown). 
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Figure334.3.2 - CD69 upregulation efficiency is semi-dependent on memory and activation state. A - 
CD69 upregulation following overnight Huh-7 co-culture with purified isolated naïve (white), memory (black) 
or total (grey) CD4+ T cells. N=1 (4 technical replicates, median + IQR shown). B - Transwell migration 
assay using Huh-7 cells. % of CD69-epressing CD4+ T cells assessed in the following conditions: standard 
transwell conditions (T cells only, co-culture, non-migrated, migrated); dual Huh-7 layers (additional Huh-7 
monolayer plated on bottom of culture well - non-migrated and migrated); and transwell with no-Huh7 (non-
migrated and migrated). Diagram illustrates the three different transwell set ups described. N=1 (2 technical 
replicates, median + IQR shown). 
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reduced in cells fixed with three different fixatives (glutaraldehyde, formaldehyde, and 
methanol – Fig. 4.3.4). This result suggested that CD69 induction was an active process 
from the hepatocyte standpoint; the mere presence of surface ligand was not sufficient.  
 
So to this point we learned that CD69 upregulation requires active cell-surface ligand 
binding. One such candidate molecule that fits these criteria is ICAM-1. ICAM-1 can be 
expressed on both human hepatocytes628-631, and the Huh-7 cell line632; and can stimulate 
CD69 expression in human T cells633, 634. Initially we did see a reduction in CD69 
upregulation when hepatocytes were pre-treated with blocking anti-ICAM-1 antibodies (in 
3 of 4 donors), but this was not specific as isotype control antibodies produced the same 
effect (Fig. 4.3.5A). This was not due to a contamination of IMC, as the same result 
occurred in a new IMC batch from a different company (data not shown). Wondering 
whether the length of culture or pre-treatment time would affect the result, we included a 
short-term culture condition (4h), and did not wash off blocking antibodies before adding 
T cells to overnight (16h) co-cultures. None of these alterations affected the magnitude 
of the prevention of CD69 induction, and isotype controls for each produced the same 
effect as ICAM-1 blocking (Fig. 4.3.5B). Last, we targeted the T cell as well as the 
hepatocytes; blocking or stimulating components of LFA-1 (CD11a and CD18). We 
hypothesised that if ICAM-1 interactions were responsible for CD69 upregulation on CD4+ 
T cells, then blocking or stimulating CD4+ T cell LFA-1 components would dampen or 
enhance this process respectively. However, we saw no upregulation of CD69 on CD4+ 
T cells when CD11a or CD18 were stimulated; nor did we see a reduction in CD69% 
expression following T cell CD18 blocking (Fig. 4.3.5C). Additionally, coating plates with 
recombinant ICAM-1 antibody did not lead to appreciable CD69 induction. 
 
!',+!
!
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Figure344.3.3 - CD69 upregulation requires direct hepatocyte contact. Huh-7 cells were cultured in 24-
well plates before blood-derived CD4+ T cells were added either directly on top (direct contact), or on top 
of 0.4'm pore transwell inserts (indirect contact) so that only Huh-7 derived soluble mediators can interact 
with the T cells. Shown are the % of CD69-expressing CD4+ T cells following overnight co-culture in both 
conditions in 3 donors. 
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Figure354.3.4 - CD69 upregulation depends on active hepatocyte ligand engagement. Blood-derived 
CD4+ T cells were co-cultured overnight with live Huh-7 cells, or Huh-7 cells fixed by three different methods 
(Gluteraldehyde, Formaldehyde, or Methanol). Percentage CD69 expression shown (1 donor, 2 technical 
replicates, median + IQR shown). 
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Figure364.3.5 - ICAM-1 interactions may be involved in hepatocyte-induced CD69 upregulation. A - 
CD4+ T cells from 4 donors were put into overnight co-culture assays with Huh-7 cells; that had been pre-
treated with anti-ICAM-1 blocking antibodies (Ab), or IMC for 20 mins. B - This same experiment was 
carried out for different times - 4 hour co-culture, or overnight (16h co-culture). In one overnight iteration, 
the anti-ICAM-1 blocking antibody (or IMC) was not removed before CD4+ T cells were added. C - T cells 
were pre-treated for 20mins with stimulatory anti-CD11a antibodies, stimulatory anti-CD18 antibodies, or 
blocking anti-CD18 antibodies plus their respective controls; or Huh-7 cells were pre-treated with anti-
ICAM-1 blocking antibodies or IMC as before. Last, ICAM-1-coated culture plates (in the absence of Huh-
7) were used. T cells and Huh-7 cells were co-cultured together overnight to produce the conditions shown. 
All experiments in this figure show % CD69 expression (median + IQR). Parts B and C - n=1 (2 technical 
replicates). 
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Together these data show that CD69 induction by Huh-7 cells happens rapidly, and most 
efficiently to activated, memory CD4+ T cells. Direct cell-cell contact is key, and an active 
hepatocyte process is needed. We subsequently hypothesised that ICAM-1-LFA-1 
interactions could be responsible for CD69 upregulation, but were unable to confirm this 
so far. Thus, this chapter has disproved conventional T cell activation, and argued against 
regulatory function explaining hepatocyte-induced CD69 upregulation in CD4+ T cells, 
whilst contemporaneously beginning to unravel the mechanism behind this induction. 
 
4.5 Discussion 
 
In this chapter, we investigated the consequences of CD69 upregulation, as well as the 
mechanisms behind it. Our data first demonstrated that the process was independent of 
conventional T cell activation, before arguing against concomitant induction of regulatory 
T cell functions. Finally, we demonstrated that CD69 upregulation began very rapidly; 
was most efficient in activated memory CD4+ T cells; and the process was active, cell 
surface contact-dependent, and may involve ICAM-1-LFA-1 interactions (Box 4.1). 
 
 
 
Six separate lines of evidence pointed to Huh-7-induced CD69 being independent of 
conventional T cell activation. First the interaction is not antigen-dependent as Huh-7 cells 
Chapter 4 – Core Findings: 
 
• Contact with hepatic and non-hepatic epithelia induced an upregulation of CD69 
in peripheral blood CD4+ T cells 
• This upregulation was independent of activation as shown by intermediate 
expression levels, no correlation with other activation markers and no associated 
proliferation 
• This phenomenon also did not represent acquisition of a regulatory phenotype 
• The mechanism behind CD69 induction involved cell-surface contact with an 
actively expressed molecular determinant, potentially involving ICAM-1 
Box 4 Box 4.1 – Core findings from chapter 4. 
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do not express MHC class II (data not shown). The purity of CD4+ T cells we were isolating 
averages at over 98%, so there was no possibility that the high percentage of CD69 
expression seen (minimum 11.4%) was due to CD8+ T cell contaminants recognising 
antigen-MHC class I complexes. Second, no other activation markers were upregulated 
across the 7-day co-culture period, in stark contrast to when conventional activation 
stimuli were used. CD25 and CD38 act as intermediate markers of activation, while HLA-
DR is classified as late25, 635. Within the time period allowed, all markers should have 
sufficient time to upregulate following conventional activation, so it is telling that they were 
unaltered. Third, CD69 was only induced to an intermediate level, as opposed to the 
normal high level seen with conventional activation stimuli. We believe this is particularly 
significant not only in separating these cells from activated phenotypes, but in matching 
these cells with their intrahepatic CD69INT counterparts, discussed in chapter 5. Fourth, 
once induced by the Huh-7 cells, CD69 expression persisted for days, even following 
separation from the stimulus. Although we did not formerly demonstrate that removing 
the conventional activation stimuli would lead to a more transient CD69 expression 
profile, this well-studied aspect of CD69 biology can be strongly inferred27. Fifth, Huh-7-
induced CD69 did not associate with any real increase in activation-induced proliferation. 
We are confident that the small number of lymphocytes seen in the divided gate were not 
truly divided as they were shifted far towards the negative end of the scale. Instead these 
cells, that were only present in Huh-7 co-cultures, could represent Huh-7 contamination 
in the lymphocyte gate, or other artefacts of the co-culture. Sixth and finally, apoptosis 
rates were no higher in the CD69+ T cells than the CD69-. This reaffirms the other data, 
showing activation-induced apoptosis was not occurring preferentially in either subset565. 
Therefore, together it is clear that although contact with Huh-7 cells induced CD69, this 
was not reflective of an activation event. 
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In future, it would be worth formerly proving that removal of activation stimulus causes a 
rapid decline in CD69 expression, while removal of Huh-7 cells does not. We also ran an 
interesting supplementary experiment where Huh-7 co-culture and different conventional 
activation stimuli were combined. Combining activation stimuli and hepatocytes together 
generally reduced the % upregulation of CD69, CD25 and CD38. It could be that some 
of the stimuli are also triggering phenotypic changes in the hepatocytes in our system, 
and these altered hepatocytes cannot induce CD69 as well, or do not permit upregulation 
of the other activation markers as much636-639. Alternatively, the result could be due to 
some form of sequestration of the activation stimuli by the hepatocytes, or due the 
additional competition for stimulus that the hepatocytes provide. The fact that T-cell 
specific anti-CD3/CD28 beads have the smallest diminishing effect when combined with 
Huh-7 supports these hypotheses, as hepatocytes cannot be competing for this stimulus. 
In our experiments, the stimuli were added into the wells already containing both 
hepatocytes and T cells. Therefore, although the stimuli are acting at the same 
concentration, they are now acting on a much larger cell number compared to with T cells 
alone. Future experiments could control for this by carrying out a matched stimulation per 
total cells (T cells + hepatocytes), or by pre-treating the T cells before adding them to 
hepatocytes. Interestingly, HLA-DR% expression synergistically increased when stimuli 
were combined. Perhaps therefore Huh-7 cells contain co-stimulatory abilities that are 
only important and additive once a T cell has been appropriately stimulated. Dose-
dependent treatments with the conventional stimuli, and different sequential exposure of 
T cells to hepatocytes and the stimuli will help answer these questions. 
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CD69 upregulation was also caused by primary BEC. We had previously shown that 
CD69 upregulation occurred following contact with multiple epithelial cell lines from 
different tissues, but this finding showed for the first time that the induction was 
transferrable to primary hepatic epithelia. Additionally, the failure of primary HSEC to 
induce CD69 upregulation demonstrated the phenomenon does not happen following 
contact with any cell type. However, CD69 upregulation can occurr following co-culture 
with TNF-a-activated endothelial cells, as others have shown568, 633. BEC-induced CD69 
induction was delayed by 1-2 days compared to that seen with hepatocyte cell lines, 
perhaps reflective of the different properties of primary cells compared to tumour cell 
lines. Last, LX2 showed a very discrete, but definite induction of CD69 upregulation 
compared to other cell types. We have not followed this up here, but it would be 
interesting in future to determine if this was consistent with primary liver HSCs, and if so 
to compare liver epithelial and non-epithelial cell-mediated CD69 upregulation 
mechanisms, dynamics, and associated phenotypic changes. Additionally, the combined 
liver cell co-cultures made an interesting initial inroad into uncovering the influence of 
multiple cell types on CD69 upregulation. This tentatively shows LX2 cells inhibit the 
process, but ultimately a much more detailed approach is needed. As CD4+ T cells can 
contact all cells equally and in random orders in these simple mixed culture systems, liver 
chip systems (discussed in 3.6) that organise cell types into a more physiological ‘liver-
like’ arrangement would be perfect successor assays, allowing CD4+ T cells to interact 
with different liver cells in the order they would in vivo. 
 
We next turned our attention to the possibility of our generated CD69+ CD4+ T cells 
possessing regulatory capabilities. This hypothesis was fuelled by previous data showing 
CD69 marks an unconventional TREG subset with links to hepatic tumours620-623; as well 
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as our own data showing CD69 expression remains elevated long-term, an aspect linked 
to this regulatory subset29, 625. Therefore, we performed suppression assays to address 
this possibility. It would have been favourable to sort CD69+ hTCs, instead of just using 
total hTCs as our suppressor population, but we felt total hTCs were sufficient for 
preliminary experimentation. Any evidence of suppression and we would have moved 
onto cell sorting. Additionally, the use of purified conventional TREG cells as positive 
controls would be of interest, although technically challenging to achieve as a large 
amount of starting material was required. Instead we used potent inhibitory cytokine TGF-
b as a positive control640, with very limited success. Nevertheless, multiple experimental 
iterations failed to conclusively prove that hTCs were providing a suppressive effect. The 
standard assays where hTCs showed apparent suppression at ratios of 2 hTCs for every 
1 Tresp and above, but even if this was real suppression and not an artefact of 
competition for physical space or nutrients, these ratios were not likely something that 
would ever be reached in vivo. Furthermore, it is commonly thought harder to prove a 
suppressive effect in vivo than in vitro540. Such assays are thought to be highly sensitive 
to many variables627. One such variable is TCR-stimulation strength – too strong and no 
suppression would be visible, too weak and insufficient proliferation will be seen to reliably 
calculate percentage suppression. Although, we tested soluble anti-CD3/CD28 
antibodies, and anti-CD3/CD28 complexes, as well as anti-CD3/CD28 beads and found 
the latter to be optimum; this stimulation may have been slightly ‘too strong’. Another 
caveat of our suppression assays is the lack of a live/dead marker. While we took great 
care with our live lymphocyte gating, dead cells could still form a part of those gates. 
Overall, the lack of proliferative inhibition, and no alterations in cytokine potential or 
activation marker phenotype provide fairly comprehensive evidence that hTCs are not 
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suppressive. Any future suppression assay experiments should include live/dead stains, 
and ideally sorted CD69+ hTCs and positive control TREGS to confirm this. 
 
We attacked the question of the mechanism behind CD69 upregulation from two angles. 
The first investigated the CD4+ T cell. We were able to show that CD69 upregulation was 
more efficient in memory T cells, and likely better in more activated T cells as shown 
through transwell methodology. This gives early indication of the type of T cell able to 
upregulate CD69. Future experiments could delve further, sorting specific memory 
subtypes, sorting different T helper subsets, or sorting on different activation marker-
positive cells. As another example, KLRG-1-expressing and non-expressing T cells could 
be sorted and then added to Huh-7 co-cultures to see if CD69 is upregulated equally in 
both subsets. A bias towards KLRG-1- cells could indicate CD69 upregulation is related 
to a tissue-residence phenomenon110. Analyses of this sort may provide candidate 
molecules that would be involved in CD69 induction, with their partner molecules 
preferentially expressed on the more efficient CD69 upregulators. The second angle was 
from the hepatocyte side. We demonstrated the need for cell-cell contact with the 
hepatocyte, and the requirement of live, active hepatocytes for the interaction to be 
successful. Therefore, many cytokines that have been previously shown to upregulate 
CD69 in T cells such as type-1 IFNs, TNF-a and TGF-b can be ruled out30, 171. However, 
this does not preclude involvement of mTGF-b or IL-15 that can both function as cell 
surface ligands and are both linked to CD69 upregulation148, 641. Even so, the need for 
cell contact is interesting as we may have revealed a less recognised, or even novel 
upregulation mechanism here. This led us to target ICAM-1-LFA-1 interactions as the first 
candidate pathway as ICAM-1 has triggered CD69 upregulation in other settings633. 
Unfortunately, the IMC matched the downregulation observed by blocking ICAM-1, and 
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stimulating LFA-1 or culturing T cells on ICAM-1 coated plates did not produce a 
corresponding CD69 upregulation. In future, isotype matched antibodies against VCAM-
1 (that is not expressed by Huh-7 cells [Z. Stamataki – personal communication]) could 
be used instead of the non-specific IMC to verify if ICAM-1 is involved, and plate bound 
ICAM-1 presence could be verified by anti-ICAM-1 staining and appropriate visualisation. 
If required to look for other candidate molecules, we could use transcription and 
translation inhibitors such as actinomycin D and cycloheximide to determine at which 
stage of protein processing is more important. Other candidate molecules to target could 
be include ICAM-3, another LFA-1 partner, that has also been held responsible for T cell 
CD69 upregulation by others642; and CD58 (LFA-3), that binds to the costimulatory 
receptor CD2 (LFA-2) on T cells, and, like ICAM-1, is known to be expressed on 
hepatocytes, especially during inflammation643. Alternatively, we could back-track and 
perform comparative transcriptomic analyses of CD69+- and CD69- hTCs, allowing us to 
then target preferentially-expressed surface receptors that could be involved in CD69 
induction. 
 
While CD69 upregulation was influenced by primary and cancer cell hepatic epithelia 
alike, it is interesting to briefly consider the impact on anti-tumour responses. It has been 
proposed that all TILs are in fact a form of TRM, and the generation of which is better 
associated with tumour eradication23, 644, 645, substantiating their importance. We were 
unable to show induction of associated regulatory phenotypes through hepatoma contact 
like others have623; but we did show consistent CD69 upregulation amongst many 
different tumour cell lines, and propose this represents a form of tumour-residence23, 645. 
How the tumour cells could be altering the resident T cells in other ways is a potential 
avenue for future work. 
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In conclusion, we have proved CD69 induction by hepatomas likely represents neither 
activation, nor formation of a regulatory subset. If so what does this drastic change in 
CD69 represent for the T cell? Some have pointed to the ‘dimmer switch hypothesis’ 
using CD69 to explain a poised, intermediate activatory state590. While feasible, we prefer 
a different explanation that links these cells to tissue residence. Other arms of our 
investigation have now connected this CD69+ phenotype to an analogous CD69INT 
phenotype seen in the liver. This finding will be discussed in depth in the next chapter.  It 
is important to continue to elucidate the mechanism behind this change as it may be 
important in TRM precursor formation, and/or short-term maintenance of CD4+ T cells in 
the liver.  
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Chapter 5 - CD69 expression separates two distinct 
intrahepatic CD4+ T cell lineages: CD69HI tissue resident 
cells, and a novel CD69INT subset 
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5.1 Introduction – Resident memory T cells and the Liver 
 
Resident memory T cells have rapidly emerged as key constituents of systemic immunity. 
These cells embody scientific intelligent design – strategically placed at sites of 
reinfection, they respond rapidly to clear the pathogen directly, alert other arms of the 
immune system to its presence, and persist indefinitely224, 238. We already know that these 
cells provide superior protection to local infections versus circulating T cells, and 
contribute to a number of human inflammatory diseases23, 84. Given the intimate 
relationship of the liver and the immune system, and the potency of liver tolerance, it is 
of great importance that the field combine these aspects to investigate liver TRM biology. 
 
Until recently the best insights we had into liver TRM biology came from the identification 
of liver-resident CD8+ T cells in mouse models123, and from resident human NK cells395, 
646-650. In mice, CD8+ TRM that were generated in response to malaria sporozoite infection, 
were critical for clearance and depended on CXCR6 expression for their maintenance123, 
128, 393. Atypically, they principally resided in the liver vasculature – unlike TRM from any 
other organ108, 128, and recent data showed a dependence on LFA-1 for their 
maintenance651. Three studies to date have characterised human liver TRM82, 148, 149. All 
three have investigated CD8+ TRM, with Wong et al. also studying CD4+ TRM. Pallett et al. 
provides the most comprehensive study of this population, demonstrating tissue-resident 
CD8+ T cells in the human liver with a distinct CD69+CD103+CXCR6+ CXCR3+PD-1+ 
phenotype, and markedly elevated IL-2 production following stimulation. The authors 
were also able to induce a matching TRM phenotype in circulating CD8+ T cells in culture 
by the sequential addition of IL-15/anti-CD3 and then TGF-b. Interestingly, the order of 
signals provided appeared to be non-negotiable; with CD69 and homing receptor 
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expression imprinted by the first (IL-15/anti-CD3), and retention signals through CD103 
imprinted by the second (TGF-b). This study also demonstrated a key role for liver TRM in 
controlling HBV infection, the first direct evidence of TRM involvement in human liver 
disease148. The study by Stelma et al. was published soon after, and supports the work 
of Pallett et al.. They too showed resident CD8+ T cells in the liver largely express CD103 
and CXCR6, and added low KLF-2 and S1PR1 gene expression to this phenotype149. 
The analysis in Wong et al. is part of a multi-organ high-dimensional mass spectrometry 
approach to analyse T cell compartments throughout the human body. As such it lacks 
liver-specific hypothesis-driven data, unlike the other studies. However, this work 
provided an excellent framework for the expression of homing receptors and 
activation/inhibitory markers in CD8+ and CD4+ T cells in the liver that express CD69, 
CD103, or both. According to this work, CD69+CD4+ T cells express more CXCR3, 
CXCR6, CCR5, CCR6, and PD-1 (amongst others) than CD69- cells, a trend that was 
also seen amongst the intrahepatic CD8+ T cell pool, matching up well with the other two 
studies82. 
 
CD4+ TRM have been comparatively understudied next to CD8+ TRM. This is despite the 
key role CD4+ T cells have in enhancing many aspects of the immune response, including 
B cell help, allowing CD8+ T cell memory formation, and providing regulatory assistance 
to inflammatory environments652-655. All evidence to date points to TRM acting as super-
charged versions of their circulating counterparts, regardless of helper or killer 
designation, whether through providing superior cytokine production, or in some cases 
superior killing ability23, 108, 186. CD4+ TRM have already been shown to be important in the 
clearance of infections of the FRT, lungs, and skin of mice99, 102, 112, 124, 199; and outnumber 
CD8+ TRM in many body sites in mouse and man as revealed by recent multi-organ T cell 
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mapping studies82, 87, 88, 90, 91. In this chapter, we aimed to identify the hepatic CD4+ TRM 
cell type, and perform a thorough and detailed characterisation of this population’s 
phenotype and function. We sought to place our cells in the ever-expanding human TRM 
matrix, using other CD4+ TRM studies, and the liver CD8+ TRM studies as comparative 
axes. Furthermore, given our earlier evidence of a CD69INT population generated through 
contact with hepatic epithelia (chapter 4), we asked whether an analogous population 
was present in liver, and if so, what their properties would be. 
 
5.2 Identification of CD69HI TRM and CD69INT CD4+ T cells in human liver 
 
First, we analysed CD69 expression amongst intrahepatic CD4+ T cells in human livers. 
In this chapter, we utilised both healthy and chronic end-stage diseased livers from a 
variety of aetiologies (for patient donor information see table 2.2). Liver explant slices 
were diced and washed thoroughly to minimise blood cell contamination and digested 
mechanically. The LIMCs isolated from the resulting homogenate were then subjected to 
surface protein expression analysis by flow cytometry. 
 
Combining all liver donors, we first gated on singlet lymphocytes. Any NK cells, NKT cells, 
and gd-T cells were then excluded with CD56 and gd-TCR staining; allowing downstream 
investigations to focus on the conventional ab-TCR-expressing CD4+ T cell population 
(Fig. 5.1.1A), that will henceforth simply be referred to as CD4+ T cells. CD69 has been 
repeatedly described as the key discriminator of human TRM91, 186, and has been used for 
this purpose in multiple studies82, 88, 90, 136. Therefore, we first analysed CD69 expression 
in order to identify resident T cell subsets. Within the CD4+ T cell compartment, three 
distinct populations were observed based on CD69 expression: CD69-, CD69INT, and  
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Figure375.1.1 – Identification of CD69INT and CD69HI CD4+ T cells in the human liver. A – Gating 
strategy used. First live lymphocytes were gated on, then single cells, then CD4+ lymphocytes that did not 
express CD56 (excluding NK and NKT cells) or the "$- T cell receptor (excluding "$-T cells). The remaining 
CD4+ T cell population was split into three populations based on CD69 expression – CD69-, CD69INT and 
CD69HI cells (left plot). Negative gates were set according to isotype matched control (right plot). B – 
Percentage of CD69-, CD69INT and CD69HI  intrahepatic CD4+ T cells in combined healthy and diseased 
livers (n=54). Lines show median values. Groups compared statistically with a Friedman test with Dunn’s 
multiple comparisons test. 
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CD69HI (Fig. 5.1.1B). CD69INT cells were clearly elevated above IMC background, and 
we were confident we were not gating on the tail of another population, or seeing a 
fluorescence shift artefact as we have previously observed a similar intermediate CD69 
level in T cells in culture with hepatic epithelia. Importantly, although the CD69- and 
CD69HI populations were consistently larger (medians of 42% & 39% respectively); 
CD69INT cells were ever-present. 
 
Having found two CD69-expressing populations where other studies have only reported 
one, we delved deeper into tissue residence properties in order to address the question 
as to which population represented the true TRM cell type. Using matched patient blood 
and liver samples we were able to ascertain that both CD69INT and CD69HI CD4+ T cells 
were only appreciably present in liver tissue, not peripheral blood (Fig. 5.1.2A). Second, 
using classical memory and naïve T cell markers CCR7 and CD45RA656, we noticed the 
first divergence between the two populations. While all populations from both diseased 
and healthy livers showed mostly a TEM phenotype (CD45RA-CCR7-), CD69HI cells 
showed an especially strong, statistically significant preference for this subset – a 
phenotype shared with TRM71 (Fig. 5.1.2 B-D). When compared to the other two 
populations, CD69HI cells showed a corresponding underrepresentation of naïve, TCM, 
and TEMRA cells. In contrast, CD69INT cells were not different from the CD69- putatively 
non-resident CD4+ T cells in any naïve or memory population, in either healthy or 
diseased livers. Third, we determined the expression of other tissue-residence associated 
markers across CD69-, CD69INT, and CD69HI CD4+ T cells. Assessing data from the more 
numerous diseased livers first, percentage of CD49a positive cells was progressively 
increased with CD69 expression, although CD49a+ MFI of CD69HI cells was no higher 
than in the CD69INT pool (Fig. 5.1.3). CD103 expression was low amongst intrahepatic  
!'-.!
!
Figure385.1.2 CD69HI cells are not present in peripheral blood and display increased effector memory 
phenotype representation. A - CD69INT and CD69HI cells in liver compared to matched patient peripheral 
blood (n=6). B-D –Percentages of CD69-, CD69INT and CD69HI cells that made up each naïve and memory 
subset (TN – naïve; TCM – central memory; TEM – effector memory). B – Representative flow cytometry plots 
for each CD69-population. C – Combined data from all chronic liver disease donors (n=51). D – Combined 
data from all healthy liver donors (n=7). Median and IQR shown. 
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CD4+ T cells in general as previously described23, 91, 186, but a modestly higher fraction of 
both CD69INT and CD69HI cells were positive for this marker. However, only CD69HI cells 
had a higher expression level by MFI. We next assessed expression of tissue egress 
receptor S1PR1, which turned out to be a key factor in distinguishing CD69INT and CD69HI 
cells. A very small frequency of CD69HI cells expressed S1PR1, and of those that did they 
only expressed low levels. By contrast, around a quarter of CD69INT cells expressed 
S1PR1 on average (25.2%), comparable to CD69- cells. Lastly, we established the 
expression of CXCR6 in the three populations as this chemokine receptor has been 
heavily associated with tissue retention in the liver148, 180, 393, 395. Compared to CD69- cells, 
CD69INT had slightly higher percentage of CXCR6+ cells, but the highest CXCR6+ 
proportion were found in CD69HI cells. The healthy donor liver cells showed very similar 
CD49a, CD103, S1PR1, and CXCR6 differential expression patterns to the diseased 
donors, albeit with less observed statistical significance, likely due to smaller sample 
numbers (Fig. 5.1.4). Together these data point to CD69HI cells representing the CD4+ 
TRM population of the liver. While both populations were only found in liver tissue and not 
the periphery, the CD69HI CD4+ T cell population expressed more TRM-associated 
molecules, and crucially only CD69HI cells did not express appreciable S1PR1, making 
these cells insensitive to tissue egress signals and promoting retention in the liver. 
 
Next, we asked if we could pinpoint an even clearer TRM phenotype using additional 
residence-associated markers. High expression of CD69 alone acted as our gold-
standard control. We compared these cells to CD69HICXCR6+, CD69HICD103+, and 
CD69HICD49a+ cells in the context of CXCR6, CD103, and CD49a expression (using the 
other two proteins not already defined in the population – see Fig. 5.1.5A). To compare 
the new populations to CD69HI control, the % expression of each protein in the three new  
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populations was normalised to expression in control CD69HI cells (i.e. % protein 
expression in new population/% protein expression in CD69HI control population). These 
normalised differences were then summed, and plotted to give a rank difference (Fig. 
5.1.5B). This revealed each new population had a higher rank than CD69HI cells. With the 
highest rank, the population with most promise was CD69HICXCR6+. Although CD103 
showed a similar median difference this antigen expression was low on CD69HI cells and 
is not a good marker of CD4+ TRM; while CD69HICD49a+ cells showed the smallest rank 
difference. To investigate the possibility of CD69HICXCR6+ T cells representing the most 
likely liver TRM, we compared CD69HI cells with and without CXCR6 expression for 
CD103, CD49a, S1PR1, and for a TEM phenotype (Fig. 5.1.5C). Only CD103 expression 
was significantly elevated in this population, with none of the other phenotypes 
differentially expressed. Furthermore, back analysis on the rank difference data (in Fig. 
5.1.4B) revealed that most of the differences between CD69HICXCR6+ and CD69HI cells 
were due to this elevation in CD103 that was large in fold change, but small in absolute 
%. Therefore, based on this data combined, we decided that total CD69HI cells represent 
the likeliest liver TRM cell phenotypically. While CXCR6 was a good additional qualifier, 
the real shifts in other TRM-associated markers were not convincing enough to switch to 
this phenotype. Importantly, remaining with CD69 alone as our sole TRM discriminator, 
allowed for more rigorous analysis as no trends could be missed that were only present 
within the CXCR6 negative gate. 
 
Expression of the transcription factor Hobit is part of the core tissue residence signature 
in mice174, but its involvement in human T cell tissue residence is thought to be non-
essential134, 135, 148. We performed preliminary stains for Hobit expression in intrahepatic 
liver T cells. In 3 of 5 livers, no Hobit protein expression was observed above IMC  
!'-,!
!
!
!
Figure415.1.5 – Determining the best Tissue Resident population. A – The intrahepatic CD4+ CD69HI T 
cells were compared with the CD69HICXCR6+, CD69+CD103+, & CD69HICD49a+ sub-populations in terms 
of expression of the other residence markers (CXCR6, CD103 and CD49a). B – 6 donor liver populations 
were analysed (from mixed aetiologies). For each donor the percentage expression of each residence 
marker was analysed (CXCR6, CD103 and CD49a) within each subpopulation. This expression was then 
normalised to that of the control CD69HI population. Finally, the differences found were summed within each 
population to allow a simple comparison to the control population, 0. Median average used. C – Comparison 
of residence factors, CD103, CD49a, S1PR1 and effector memory (TEM – CD45RA
-CCR7-) in 
CD69HICXCR6- cells (red) and CD69HICXCR6+ cells (green). CD69- (black) populations are included as 
controls. Box and whisker plots show min. to max. (n=6-9). 
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background in CD4+ or CD4- T cells (Fig. 5.1.6A). Naïve/memory cell 
compartmentalisation analysis dispelled any doubts that high IMC background was hiding 
true Hobit staining in CD4+ T cells as naïve T cells showed the highest fluorescence in 
the channel occupied by Hobit staining (Fig. 5.1.6B). This is unlikely to be a true result as 
it is known that Hobit is specifically upregulated in effector T cell populations in humans190. 
However, the Hobit staining protocol did work, at least in part, as evidenced by positive 
Hobit expression in the remaining two livers (Fig. 5.1.6C). Interestingly, looking at CD4+ 
T cells in the donor with the largest Hobit expression, there was a slight preference for 
Hobit expression in CD69INT cells, but no change in the more phenotypically resident 
CD69HI population (Fig. 5.1.6D). Thus, preliminary data pointed to no strong association 
of Hobit with CD69HI TRM, with intrahepatic T cells from most livers seemingly lacking this 
transcription factor. 
 
Next, we asked whether CD69HI TRM cells, or the newly identified CD69INT CD4+ T cell 
population were enriched in any specific liver disease aetiology. We saw no such 
enrichment in either population when comparing donors with dietary (ALD, NASH), or 
autoimmune end stage liver diseases (PBC, PSC) with healthy controls, although more 
donors may be needed to truly confirm this (Fig. 5.1.7). These results suggest neither 
CD69HI nor CD69INT frequencies are associated with non-viral liver disease, and instead 
are universally present, consistent components of human liver immunity. 
 
In sum, these results identify two distinct intrahepatic CD4+ T cell populations based on 
CD69 expression levels. CD69HI cells likely represent the true tissue resident cells of the 
liver due to their absence in the circulation, lack of S1PR1 expression, and the highest 
expression of other TRM associated markers; while CD69INT present with a semi-resident  
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Figure425.1.6 – Hobit expression in intrahepatic CD4+ T cell populations. A,B – Hobit Negative liver T 
cells. A – In 3/5 livers no clear Hobit expression was detected (representative flow cytometry plots shown). 
CD4+ and CD4- T cells were investigated. In each population the expression of Hobit was investigated in 
the context of CD69 allowing both Hobit+ and Hobit- gating in conjuction with gating on CD69-, CD69INT and 
CD69HI cells. B - Representative Hobit and CD69 co-expression in the four canonical naïve/memory 
subsets from the livers that showed no clear Hobit expression (naïve, green; central memory, blue; effector 
memory, red; & TEMRA, orange). C,D – Hobit positive liver T cells. C – Hobit expression in CD4+ T cells 
(black) and CD4- T cells (brown) from the two livers where Hobit positivity was detected above isotype 
matched control (grey). Percentages of Hobit+ cells are given in the legend. D – Percentage of cells in the 
CD69-, CD69INT, and CD69HI  CD4+ T cell pools within both the Hobit-, and Hobit+ gates from liver 9 (where 
CD4+ Hobit expression > CD8+ Hobit expression).  
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Figure435.1.7 – CD69-, CD69INT or CD69HI populations are not enriched in different liver diseases. 
Proportion of intrahepatic CD4+ T cells that are CD69-, CD69INT or CD69HI from different chronic end-stage 
disease liver donors. Donor (n=7), ALD (n=16), NASH (n=8), PBC (n=6), PSC (n=8). Averages displayed 
are medians. 
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phenotype, also absent from the blood, and intermediary TRM marker expression, but with 
clear S1PR1 expression. Neither population appeared to express Hobit, and neither were 
clearly associated with pathology. Future mentions of CD69HI and CD69INT cells here 
pertain to intrahepatic CD4+ T cells. 
 
5.3 CD69HI TRM display a more restricted homing receptor profile than CD69INT 
cells 
 
Next, we moved on to the analysis of further homing receptor expression patterns in order 
to ascertain migratory potential of the different populations in vivo. Chemokine receptors 
CCR5 and CXCR3 are involved in T cell recruitment to portal and sinusoidal 
endothelium362, while CXCR6, CCR6, CCR10 and CX3CR1 are associated with bile duct 
infiltration388, 389, and CXCR1 expression on a T cell allows migration towards inflamed 
hepatocytes396. In addition to maintenance in the liver, CXCR6 expression is important 
for a T cell to access the bile ducts, and liver parenchyma391. Of the three populations, 
CD69HI T cells only had the highest expression of CCR5, showed increased CCR6 from 
CD69- cells, and negligible expression of CX3CR1 (Fig 5.2.1). By stark contrast, CD69INT 
cells had the highest expression of CXCR1 and CXCR3, matched CD69HI expression of 
CCR6, retained consistent expression of CX3CR1, and had an intermediate expression 
of CCR5. CCR10 expression was not differentially expressed between the subsets. 
Furthermore, CD69INT cells expressed the most gut-homing chemokine receptor CCR9, 
and a significantly higher percentage of gut-homing integrin a4b7 than CD69HI cells (Fig. 
5.2.2). These data suggest that CD69HI TRM cells have migration patterns largely 
restricted to the portal areas, bile ducts and parenchyma through elevated CCR5, CCR6 
and CXCR6 expression. Contrastingly, CD69INT cells may have more of a free reign over 
the liver through their wider array of expressed chemokine receptors, and may be able to  
!'*.!
 
 
 
 
 
  
02040608010
0
***
*
***
**
02040608010
0
***
*
***
*
02040608010
0
***
*
**
02040608010
0
10
1
10
2
10
3
***
*
***
*
10
1
10
2
*
***
10
1
10
2
10
1
10
2
10
3
***
*
**
***
*
!!
"#
!!
"$
!%
!"
&
!%
!"
'
!!
"&
(
!%
'!
"&
)
*
+,
)
*
+,
)
*
+,
)
*
+,
)
*
+,
)
*
+,
!"
#$%
!"
#$&'
(
!"
#$)
&
020406080
***
***
*
!"
#$%
!"
#$&'
(
!"
#$)
&
020406080
***
***
!"
#$%
!"
#$&'
(
!"
#$)
&
10
1
10
2
10
3
***
***
*
10
1
10
2
*
***
!"
#$%
!"
#$&'
(
!"
#$)
&
10
1
10
2
10
3
***
*
Fi
gu
re
44
5.2
.1 
– 
CD
69
HI
ce
lls
 s
ho
w 
in
cr
ea
se
d 
CC
R5
 a
nd
 C
CR
6 
ex
pr
es
sio
n,
 w
hi
le 
CD
69
IN
T  c
ell
s 
sh
ow
 m
or
e 
va
rie
d 
ch
em
ok
in
e e
xp
re
ss
io
n 
pa
tte
rn
s. 
Si
x d
iffe
re
nt
 ch
em
ok
ine
 re
ce
pt
or
s a
re
 sh
ow
n.
 A
s i
n 5
.1
.3
, fo
r e
ac
h t
rip
le 
re
pr
es
en
ta
tiv
e f
low
 
cy
to
m
et
ry
 p
lot
s, 
co
m
bin
ed
 p
er
ce
nt
ag
e 
m
ar
ke
r 
ex
pr
es
sio
n,
 a
nd
 c
om
bin
ed
 M
FI
 o
f t
he
 m
ar
ke
r-p
os
itiv
e 
ce
lls
 a
re
 s
ho
wn
. 
Co
m
bin
ed
 h
ea
lth
y a
nd
 d
ise
as
e 
do
no
rs
 sh
ow
n.
 L
ine
s r
ep
re
se
nt
 m
ed
ian
 va
lue
s, 
er
ro
r b
ar
s s
ho
w 
10
-9
0%
 d
at
a 
ra
ng
e.
 
!'*'!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
Figure455.2.2 – CD69INT cells have increased expression of the gut-homing markers CCR9 and 
Integrin #4"7. A – Combined expression of CCR9 (% and MFI) in the three liver CD4+ populations. B – 
Integrin #4 and Integrin $7 co-expression representative staining (left) and combined percentage 
expression data (right) in the three liver CD4+ populations. For both parts all healthy and diseased liver 
donors shown. Lines represent medians, error bars show 10-90% data range. 
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migrate to the gut through CCR9 and integrin a4b7. These patterns are in keeping with 
our model of CD69HI cells acting as a tissue-resident population, restricted in tissue 
niches; while also suggesting CD69INT cells are less confined, arguing against their 
placement into a bona fide TRM category. 
 
In an attempt to support these conclusions, we performed immunofluorescence staining 
of liver sections with the aim of identifying the positions of CD69HI and CD69INT cells in 
the liver. Unlike flow cytometry, this staining is not sensitive enough to differentiate cells 
expressing intermediate levels of CD69 from those expressing high levels. Instead, we 
stained for CXCR6 and CX3CR1 alongside CD69 to differentiate CD69HI and CD69INT 
cells respectively as we have already seen these receptors are largely population-specific 
(Fig. 5.1.3A; Fig 5.2.1). We combined these with stains for CD4 and NKp46 (in order to 
rule out contaminating NK or NKT cells, B cells and CD8+ T cells). Unfortunately, we were 
forced to limit our conclusions as both CD4 and CD69 staining was unsuccessful in these 
experiments. However, CXCR6 and CX3CR1 staining worked well, allowing us to perform 
simple assessments of these chemokine receptor localisation patterns across the liver 
architecture. CXCR6 was detected heavily in the liver parenchyma and around bile ducts, 
but scarcely in the fibrotic tracts (Figs. 5.2.3; 5.2.4). CX3CR1 was detected in the 
parenchyma and in sinusoids, but not in fibrotic tracts or around bile ducts. So, although 
we could not detect specific lymphocyte subsets, these preliminary data largely agree 
with flow cytometry staining patterns – CXCR6-expressing cells may favour the 
parenchyma and bile ducts, whereas CX3CR1-expressing cells may additionally be found 
in sinusoids, but do not preferentially associate with biliary cells. 
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(Legend cont. on next page)
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Figure475.2.4 – CXCR6 and CX3CR1 staining in fibrotic tract and bile ducts of diseased human liver. 
Merged immunofluorescence images from both fibrotic tract areas and bile ducts for both panels and IMC. 
Representative images from n=4 combined chronic liver disease donors. 
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Figure465.2.3 – CXCR6 and CX3CR1 staining of human liver parenchyma. Displayed are the individual 
and merged immunofluorescence staining patterns for panel 1, panel 2 and IMC (top to bottom 
respectively). These data show the parenchymal regions. Representative staining from n=4 combined 
chronic liver disease donors.                (cont. from previous page)   
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5.4 CD69HI and CD69INT cells possess distinct activation profiles and 
differentiation states 
 
Continuing deeper into the characterisation of the three intrahepatic CD4+ T cell 
populations, we analysed activation marker expression patterns, beginning with 
commonly used activation markers CD25, CD38, and HLA-DR24-26. In combined end-
stage disease livers, CD69HI cells displayed the highest % of CD25 expression, but the 
expression level per cell was no higher than in the other two populations (Fig. 5.3.1A,B). 
CD38 expression was highest in CD69INT cells, both at a population and per-cell level. 
Percentage HLA-DR expression was also highest in the CD69INT cells, and CD69HI cells 
had significantly lower expression levels compared to the other two subsets. In healthy 
donors, patterns were harder to interpret due to low donor numbers. However, it appeared 
that % CD25 expression correlated with CD69 expression, just like in the diseased donors 
(Fig 5.3.1C). CD38 and HLA-DR expression directional trends appeared to match those 
in the diseased donors as well. Additionally, analysis of proliferation marker Ki-67 
demonstrated that CD69INT cells were the most actively dividing, a statistically significant 
increase from CD69HI cells (Fig. 5.3.2). Overall, CD69INT appeared to be the most 
activated subset, displaying more CD38 and HLA-DR molecules, and contain a greater 
cycling fraction in the absence of artificial stimulation. 
 
Human TRM have been associated with elevated inhibitory receptors, such as PD-1 and 
CTLA-491, 134, 135, 148. Similarly, in our study we noted a strong association of CD69HI TRM 
with PD-1 expression in both healthy and diseased livers, although no increases in CTLA-
4 expression were seen compared to the CD69- control cells (Fig. 5.3.3). The fraction of 
CD69INT cells expressing PD-1 was midway between the other two subsets, and CTLA- 
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Figure485.3.1 – CD69INT represent the most activated intrahepatic CD4+ T cell population. A – 
Representative flow cytometry staining examples from diseased liver  explants showing activation markers 
CD25, CD38 and HLA-DR in the context of CD69. B – Combined diseased liver explant data showing these 
activation markers as % of liver CD4+ T cells (top graph), and as MFI of marker-positive cells (bottom 
graph).                (Legend cont. on next page) 
:;), 
:;+* 
C7DE;F 
7"
#8
9!
:;
(<
!1
!=
8>
>?
!@A
B 
B 
!"
#$%
!"
#$
&'(
!"
#$
)&
101
102
103
!"
#$%
!"
#$
&'(
!"
#$
)&
100
101
102
103
!"
#$%
!"
#$
&'(
!"
#$
)&
101
102
0
20
40
60
80
0
20
40
60
80
100
**
0
20
40
60
80
100
4
50
 
7"
#8
9!
:;
(<
!1
!=
8>
>?
!@A
B 
:;
%&
 
C 
9 
I"B#:K 
:!GHBGH: 
IHB"%IJ 
!"#$%
!"#$&'(
!"#$)&
0
20
40
60
80
****
****
**
***
**
* ****
CD
25
CD
38
HL
A-D
R
101
102
103
** **
***
******
!'*-!
C – Combined healthy liver explant data of these activation markers - % (top panel) and MFI of marker-
positive cells (bottom panel). For all chart types median averages are used, error bars show 1—90% data 
range. 
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Figure495.3.2 – Proliferation is highest among the CD69INT CD4+  Liver T cell population. 
Representative flow cytometry staining (left) and combined percentage expression data from all healthy 
and diseased donors for proliferation marker Ki-67. All three liver CD69 populations shown. Ki-67 was 
detected by intracellular staining without stimulation directly following isolation from liver explants. Lines 
represent median values.
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Figure505.3.3 – Inhibitory marker expression is greatest amongst CD69HI liver CD4+ T cells. A - 
Expression of inhibitory markers PD-1, Fas, and CTLA-4 in CD69-, CD69INT and CD69HI cells from diseased 
liver donors. From top to bottom: representative staining in each CD69 population, expression (%) and 
expression (MFI + cells). B – As part A, but only PD-1 expression shown in healthy donor liver populations. 
Median used as average value, error bars show 10-90% data range. 
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4+ cells made up a moderately higher fraction of the CD69INT subset than the CD69- cells. 
We also analysed expression of the death receptor Fas and saw that in most livers, nearly 
all intrahepatic CD4+ T cells expressed this receptor, regardless of CD69 expression. 
Although there was a statistically significant difference between CD69- and CD69HI cells 
for % Fas expression (p=0.042), the absolute difference was minute and so unlikely 
physiologically relevant. 
 
We next used three key proteins to determine the differentiation status of our three CD69-
subsets: CD27, KLRG-1, and CD127. CD27 is a key costimulatory receptor, loss of which 
is a mark of a more differentiated memory cell type19, 657-659. Interestingly, the CD69INT 
population contained the greatest frequency and expression levels of CD27 in diseased 
livers; and at least the frequency data was matched in healthy livers (Fig. 5.3.4). KLRG-
1 expression shows antigen experience, and advanced, late-stage differentiation192, 193, 
488, 660. We noticed that for both diseased and healthy livers CD69HI TRM cells had the 
lowest % expression of KLRG-1, while the other two subsets were similar. 
Correspondingly, CD127 expression, which marks a resting state258, was at its highest 
level in both CD69INT and CD69HI cells; although in percentage terms, no statistical 
increase was seen in CD69HI cells from the CD69- subset (p=0.061), and these trends 
were not apparent in healthy liver donors. 
 
The most information on differentiation status and antigen exposure history can be 
uncovered by using KLRG-1 and CD127 in combination. This strategy has been inspired 
by the work of Donna Farber’s lab, who employed a very similar strategy using CD28 and 
CD127 to define four distinct stages of activation and homeostasis90. As KLRG-1 denotes 
antigen experience, and CD127 downregulation occurs both upon antigen recognition  
!'&.!
  
Fi
gu
re
51
5.3
.4 
– D
ist
in
ct
 d
iff
er
en
tia
tio
n p
ro
fil
es
 o
f C
D6
9IN
T  a
nd
 C
D6
9H
I  in
tra
he
pa
tic
 C
D4
+ T
 ce
lls
. E
xp
re
ss
ion
 pa
tte
rn
s o
f d
iffe
re
nt
iat
ion
 m
ar
ke
rs
 
CD
27
, K
LR
G-
1 
an
d 
CD
12
7 
am
on
gs
t t
he
 C
D6
9-
, C
D6
9IN
T , 
an
d 
CD
69
HI
 in
tra
he
pa
tic
 p
op
ula
tio
ns
. F
ro
m
 le
ft 
to
 ri
gh
t: 
re
pr
es
en
ta
tiv
e 
flo
w 
cy
to
m
et
ry
 
sta
ini
ng
, %
 o
f li
ve
r C
D4
+  T
 ce
ll e
xp
re
ss
ion
 in
 d
ise
as
ed
 liv
er
 d
on
or
s, 
M
FI
 (o
f m
ar
ke
r-p
os
itiv
e 
ce
lls
) i
n 
dis
ea
se
d 
do
no
rs
, %
 o
f C
D4
+  T
 ce
ll e
xp
re
ss
ion
 
in 
he
alt
hy
 liv
er
 d
on
or
s, 
an
d 
M
FI
 (o
f m
ar
ke
r-p
os
itiv
e 
ce
lls
) i
n 
he
alt
hy
 d
on
or
s. 
Av
er
ag
e 
va
lue
s u
se
d 
ar
e 
m
ed
ian
s,
 fo
r M
FI
 p
lot
s e
rro
r b
ar
s s
ho
w 
10
-
90
%
 d
at
a 
ra
ng
e.
 
02040608010
0
10
1
10
2
**
***
*
10
1
10
2
10
3
10
1
10
2
10
3
02040608010
0
***
*
02040608010
0
02040608010
0
***
*
***
Q
"K
T
#S
U 
9:
S$
MU
 
9:
$M
U 
10
1
10
2
10
3
:;%& 
:;
)-
 
2
/!
 
>
 
:
!G
HB
GH
:
 
I
HB
"%
I
J 
CD
69-
CD
69IN
T
CD
69H
I
02040608010
0
*
CD
69-
CD
69IN
T
CD
69H
I
02040608010
0
CD
69-
CD
69IN
T
CD
69H
I
10
1
10
2
10
3
*
CD
69-
CD
69IN
T
CD
69H
I
10
1
10
2
10
3
***
*
***
*
 191 
and ligation with common-g chain cytokines and IL-6258, we defined these four stages as 
follows: KLRG-1-CD127+ - resting/unstimulated, KLRG-1-CD127- - cytokine-stimulated, 
KLRG-1+CD127- - antigen-driven effector, KLRG-1+CD127+ - previously responded to 
antigen. When comparing the three CD69-defined subsets in healthy and diseased livers, 
CD69HI cells had a strong preference for resting (KLRG-1-CD127+) cells (Fig. 5.3.5). By 
contrast, the previously activated (KLRG-1+CD127+) phenotype was favoured by CD69INT 
cells over both other subsets in disease, and seemingly over CD69HI cells in healthy 
donors. Activated/effector (KLRG-1+CD127-) and cytokine-stimulated (KLRG-1- CD127-) 
cells were similar in frequency across the three subsets. Together, these results show a 
strong dichotomy of a non-terminally differentiated resting CD69HI TRM cell type, 
compared to a more differentiated previously activated CD69INT cell population. 
 
Finally, no CD69-subset contained a greater fraction of conventional regulatory cells 
(CD25HICD127LO), and no subset strongly favoured FoxP3 expression (Fig. 5.3.6). We 
also performed a preliminary assessment of expression of components of the CD28 
costimulatory pathway – CD28, CD80, and CD86. In the one donor tested (a PSC 
patient), we noted highest % expression of CD28 in the CD69HI compartment (Fig. 5.3.7). 
This fits with previous data that argues CD69HI cells are largely not terminally 
differentiated, as loss of CD28 correlates with late-stage differentiation of memory 
cells659. T cell expression of CD80 and CD86 is not well understood, but both could 
enhance survival and are likely involved in T cell - T cell antigen presentation661, 662. Here, 
CD80 was progressively and steadily increased with higher CD69 expression, but CD86 
was markedly absent on CD69HI TRM cells. 
 
  
!'&)!
!
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Figure525.3.5 – KLRG-1 and CD127 co-expression patterns reveal CD69HI and CD69INT favour resting 
and previously activated phenotypes respectively. A – Representative flow cytometry staining in CD69-
, CD69INT, and CD69HI cells (from a diseased liver) showing co-expression patterns of differentiation and 
homeostasis markers KLRG-1 and CD127. Using these markers allows the divergence of populations into 
four subtypes as shown: resting (KLRG-1-CD127+), cytokine-stimulated (KLRG-1-CD127-), 
activated/effector (KLRG-1+CD127-), and previously activated (KLRG-1+CD127+). B - Heat-map showing 
combined % co-expression of the four aforementioned subsets. Central numbers in each cell represent 
median % expression, while values in parentheses represent the interquartile range. Asterisks in a cell 
denote the minimum statistically significant value when compared to both other values in the row (in each 
case highest p value used). Healthy donor, n=6; diseased donor, n=35. 
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Figure535.3.6 – Conventional regulatory cells are not markedly enriched across the different 
intrahepatic CD69-expressing populations. A – Percentage of conventional TREG in CD69
-, CD69INT, and 
CD69HI populations as representative staining (upper) and combined % in healthy and diseased donors 
(lower). B – Expression of FoxP3 in the three populations as representative staining and combined % 
expression for all diseased donors. Populations are indicated next to the histograms with the % expression 
for this example experiment listed in parentheses. For all scatter plots, lines represent median values. 
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Figure545.3.7 – Preliminary CD28, CD80, and CD86 staining in intrahepatic CD69 T cell subsets. Flow 
cytometry histograms of CD28, CD80, and CD86 expression in CD69- (dark grey), CD69INT (blue), and 
CD69HI (red) cells, as well as IMC controls (light grey – dashed). Percentage positive expression given in 
parentheses to the right of the plots. LIMCs isolated from a PSC liver explant. All histograms gated on CD4+ 
T cells. 
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Collating all the phenotypic data so far, we have identified two distinct CD4+ T cell 
populations in the liver. The first is a CD69HI TRM-like cell that matched numerous 
residence characteristics including elevated residence-associated markers, elevated PD-
1, and diminished KLRG-1. This cell type had a restricted chemokine receptor profile, and 
favoured a resting state. The second subset was a novel, more heterogeneous CD69INT 
cell type. This subset possessed a semi-resident phenotype, a wide array of homing 
receptors and contained a greater proportion of activated and previously activated cells. 
These differences are summarised in Fig. 5.3.8. Thus, we can conclude with some 
confidence that CD69HI cells are the CD4+ TRM of the human liver, whereas the role of 
CD69INT cells requires further investigation. 
  
!'&%!
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Figure555.3.8 – In depth flow cytometric profiling of CD69-, CD69INT and CD69HI CD4+ intrahepatic 
CD4+ T cells. Summary heat-maps showing median % expression of (A) TRM markers, (B) Homing 
receptors, and (C) Activation/differentiation markers across CD69-, CD69INT and CD69HI cells. / in the box 
represents a statistically significant difference (p<0.05) in that population compared to CD69HI cells, while 
\ demonstrates a statistically significant change to CD69- cells. Total combined disease and healthy liver 
donors used for all plots.  
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5.5 Characterisation of CD69-expressing populations in blood and lymph nodes 
 
Human studies on T cells have largely focussed on peripheral blood populations, and as 
such the roles and expression patterns of key T cell molecular determinants are mainly 
derived from these studies. We have used a plethora of surface antigens thus far to 
dissect the roles of our liver-infiltrating populations. To gain a better understanding of first 
what it means to be a T cell in the liver, and then to go deeper to examine how intrahepatic 
CD69-expressing subsets are distinct to blood T cells, we performed multi-parameter 
analyses on liver patient matched peripheral blood CD4+ T cells. We have already shown 
that blood T cells did not appreciably express CD69 (Fig. 5.1.2A) and so all comparisons 
were made with blood CD69- CD4+ T cells. 
 
Blood CD4+ T cells showed negligible expression of CD103 and CXCR6, and only a small 
fraction of CD49a+ cells that was lower than all liver populations (Fig. 5.4.1A). S1PR1 
expression was also extremely low, comparable to CD69HI cells in liver. As previously 
documented, we found blood contained much larger naïve and TCM populations, and 
diminished TEM cells compared to all liver populations (Fig. 5.4.1B)314. Although homing 
receptors CCR6 and integrin a4b7 showed no change from the liver populations, % CCR5 
and CXCR3 expression appeared lower in blood than the liver populations, CXCR1 was 
low – comparable to liver CD69HI cells, CCR9 was not expressed, and CX3CR1 was 
highly variable between donors (Fig. 5.4.1C). Activation and co-inhibitory markers CD25, 
CD38 and PD-1 were very similar in % expression to the CD69- liver cells, while HLA-
DR+ and Ki-67+ fractions were low – more akin to the liver CD69HI population (Fig. 5.4.1D). 
There was a trend towards a higher TREG representation in blood vs liver (p=0.041 vs. 
liver CD69INT cells), while CD27 appeared higher in blood populations (p=0.022 vs. liver 
CD69HI cells) (Fig. 5.4.1E). The most revealing differences on state of activation was seen  
!'&*!
!
!
Figure565.4.1 – Phenotype of matched blood and liver CD4+ T cells. Bar charts show median (+IQR) % 
expression of different phenotypic markers in peripheral blood CD69- CD4+ T cells (black); and liver CD69-
, CD69INT, and CD69HI  CD4+ T cells (white, blue, and red bars respectively. TRM (A), homing (C), activation 
(D) and differentiation (E) associated-markers are shown. B, F – Pie charts showing median proportion of 
each cell subset from liver and blood that fall into either different naïve and memory categories (B), or 
KLRG-1/CD127 delineations (F).             (Legend cont. on next page) 
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For all bar charts, liver populations were all statistically compared to the blood CD69- population only. 
Asterisks above the bar indicate a statistical difference in that population to the control blood population. 
Similarly, for the pie charts liver populations were compared to the blood CD69- population only. Statistical 
differences in a population are listed below the corresponding pie chart. All data shown combination of 6 
donors except naïve/memory, KLRG-1/CD127, S1PR1, CD25, CD127 (all n=5); TREG (n=4), CX3CR1 (n=3); 
and CTLA-4, Ki-67 (both n=2). 
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using KLRG-1 and CD127 staining combinations, where interestingly blood CD69- cells 
seemed to most closely resemble the liver CD69HI subset, favouring a resting state for 
CD69HI liver cells (Fig. 5.4.1E). Together, although still preliminary observations, these 
data allow us to put our findings in liver in the context of blood CD4+ T cells, and reveal 
that while blood CD69- CD4+ T cells are most like their liver CD69- counterparts in terms 
of low intrinsic activation, they are also akin to CD69HI cells for resting homeostatic states. 
 
Comparison with blood may have allowed us to examine how tissue T cells are distinct 
from their peripheral counterparts, but this falls short of demonstrating a liver-specific 
effect on T cell biology. To combat this, we were fortunate to gain access to limited human 
hepatic lymph node tissue. This not only provides another tissue environment to compare 
with blood, but also presents us with the opportunity to study lymphoid versus non-
lymphoid organ tissue resident phenotypes. Unlike blood, but similar to liver, lymph nodes 
contained CD69HI and CD69INT CD4+ T cells, as well as CD69- T cells (Fig. 5.4.2A). 
Although difficult to accurately assess due to low donor numbers and high patient-patient 
variation, it may be that CD69INT cells were more frequent in hepatic lymph nodes than 
liver. Naïve/memory profiles were completely distinct in the two organs (Fig. 5.4.2B). 
Lymph node CD69- and CD69INT cells were similarly massively skewed towards naïve T 
cells, as anticipated due to the role of LNs in recirculation of naïve T cells. LN CD69HI 
cells showed a much greater preference for TEM cells, closer to their liver CD69HI 
counterparts, but still retained a substantial TCM and naïve component. 
 
Focussing just on any differential expression between LN and liver populations with the 
same CD69 designation, CD49a % expression was consistently higher in Liver vs. LN 
(Fig. 5.4.2C). The same pattern was observed for CCR5, KLRG-1, HLA-DR, and PD-1;  
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Figure575.4.2 – Phenotype of matched lymph node and liver CD4+ T cells. A – Representative flow 
cytometry plots showing CD69 expression among CD4+ T cells from liver and lymph node. Combined data 
(n=4) represented in a bar chart (median + IQR shown). B – Pie charts showing median composition of CD4+ 
CD69-, CD69INT, and CD69HI T cells from liver and lymph node, in terms of their naïve and memory cell 
subsets. C – Series of TRM, homing, differentiation, and activation % marker expression in liver and lymph 
node populations: liver CD69- (black open bars), LN CD69- (black closed bars), liver CD69INT (blue open 
bars), LN CD69INT (blue closed bars), liver CD69HI (red open bars), LN CD69HI (red closed bars). D – Pie 
charts showing median composition of KLRG-1/CD127 populations amongst liver and lymph node CD69-, 
CD69INT, and CD69HI subsets. Unless otherwise stated, all data from this figure is a summary of 3 donors 
with the following exceptions: CD49a, CD103, and naïve/memory populations (all n=4); S1PR1, CCR9, 
integrin α4β7, CD38, CTLA-4, Ki-67, and CD27 (all n=2); and CX3CR1 (n=1). 
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while the inverse was seen for CXCR3, CD27, and potentially TREGS for the CD69-
expressing subsets. Like liver populations, as CD69 expression increased so did the 
expression of TRM markers (↑CD49a, ↑CXCR6, ↓S1PR1); and certain activation/co-
inhibitory markers (↑CD25, ↑PD-1). Just like for liver cells, the marked expression of 
S1PR1 and CX3CR1 in LN CD69INT cells was not observed in the LN CD69HI population. 
Also, analogous to liver patterns, CCR9 expression was highest in LN CD69INT cells. 
Finally, based on KLRG-1 and CD127 co-expression patterns, LN cells are strikingly more 
resting and less activated/previously activated (Fig. 5.4.2D). CD69HI LN cells were most 
like CD69HI liver cells for these markers, but contained a far greater cytokine-stimulated 
population, hinting at differential requirements for CD69HI CD4+ TRM maintenance across 
different organs. Overall, despite differences in proportional expression magnitudes 
between liver and LN, relative expression levels across the three CD69-defined subsets 
of the two organs matched remarkably well. We therefore propose that CD69HI cells also 
represent the tissue resident cells of the lymph node, and point out a liver-analogous 
CD69INT population in the LN that shares major characteristics with its putatively non-
resident CD69INT liver counterpart. 
 
5.6 Liver CD69HI and CD69INT cells favour TH1 and TH2 cytokine responses 
respectively 
 
In order to determine the cytokine secretion potential of the three CD69-defined 
populations in the liver, isolated LIMCs were subjected to a pre-stain for CD69, before 
stimulation with PMA/Ionomycin, anti-CD3/CD28, or PHA for 2 or 5 hours (Fig. 5.5.1A). 
Intracellular stains for various cytokines were then carried out, and cells and analysed by 
flow cytometry. Preliminary work demonstrated that the intensity of CD69 staining was  
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Figure585.5.1 – LIMC cytokine staining protocol and CD69 expression confirmation experiment. A – 
Protocol used for investigating cytokine production in the different CD69-expressing liver CD4+ T cell 
populations. Liver was first mechanically digested and the LIMCs harvested. LIMCs were pre-stained with 
an anti-CD69 antibody before being added into culture with various stimuli (PMA & Ionomycin, PMA/Iono; 
anti-CD3/CD28 beads; PHA; or untreated, UT) for either 2h or 5h in the presence of golgi stop Brefeldin A. 
Cells were then harvested; surface stained for CD4, CD56, and "(-TCR; fixed and permeabilised; then 
stained for cytokines ready for flow cytometric analysis. B –  Maintenance of CD69 expression over time in 
culture. LIMCs were stained for CD69 then left in culture for 0, 1, 2, or 3 hours and then CD69 expression 
analysed. Plots show CD69 expression on CD4+CD56- "(-TCR- populations after indicated time points. 
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barely lost over time in culture, giving credence to our chosen methodology (Fig. 5.5.1B). 
We first Looked at the 5h time-point, where cells have had a greater chance to reveal 
their cytokine potential. 
 
The first main observation from these experiments was that CD69HI cells favoured IL-2, 
TNF-a, IFN-g, and IL-17A production (Fig. 5.5.2). This was most evident with the potent 
stimulants PMA and Ionomycin where consistent statistical increases were seen from 
CD69- cells. Statistical significance was not reached when comparing CD69HI and 
CD69INT cells, but a higher median percentage positivity was seen for every cytokine in 
the CD69HI subset. The other stimuli were less potent at inducing robust cytokine 
production in cells from both liver and blood, making interpretations harder. However, the 
proportion of IFN-g+ cells was highest in CD69HI cells following anti-CD3/CD28, and PHA 
stimulation; and even in unstimulated controls. Interestingly, both CD3/CD28 and PHA 
stimulation appeared to reveal the highest median IL-2 and TNF-a % production was in 
the CD69INT population, although this was not statistically significant versus the CD69HI 
cells. Differences in IL-17A production were not apparent across the other stimuli. 
 
CD69INT cells appeared to show better IL-4 and IL-10 responses (Fig. 5.5.3). For IL-4, 
this was clearly demonstrated following CD3/CD28, and PHA stimulation, as well as in 
unstimulated cells; though not in PMA/Ionomycin treated cells. For IL-10, the opposite 
effect was seen – CD69INT cells clearly contained the highest IL-10+ % following 
PMA/Ionomycin stimulation, but this pattern was less obvious with the other stimuli and 
unstimulated cells. Additionally, TGF-b and IL-6 were analysed. TGF-b production 
potential from the three subsets seemed to differ based on stimuli used. With CD3/CD28 
and PHA stimulation, CD69HI cells possessed the highest percentage of TGF-b+ cells, a  
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Figure595.5.2 – CD69HI cells favour TH1 and TH17 cytokine production in response to stimuli. 
Shown are cytokine production profiles (by intracellular cytokine capture) for IL-2, TNF-#, IFN-" and 
IL-17 (top to bottom rows) in various stimulation conditions (PMA/Ionomycin, CD3/CD28, PHA, and 
unstimulated – left to right). All stimulations were for 5 hours. Box and whisker plots show all 
combined % expression data for blood CD69- cells; and liver CD69-, CD69INT, and CD69HI cells 
(error bars show min-max points). Example histogram overlays show the same populations plus 
liver IMC following PMA/Ionomycin stimulation. 
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Figure605.5.3 – CD69INT cells are the best producers of IL-4 and IL-10 following stimulation. 
Figure layout exactly as in Fig. 5.5.2, but for the cytokines IL-4, IL-10, TGF- $, and IL-6. 5 hour 
stimulations shown, histograms are representative of PMA and Ionomycin stimulations. 
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trend that was not observed in the other two conditions. However, IL-6 % were highest 
on average in the CD69INT cells, the exception being following PHA stimulation where 
CD69INT and CD69HI cells were approximately equal. 
 
Overall, we saw substantial functional differences between CD69INT and CD69HI subsets. 
Following the most efficient PMA/Ionomycin stimulation method, CD69HI cells favoured 
TH1 and TH17 production, and CD69INT cells were better at generating IL-10. Additional 
stimulations revealed a further preference for IL-4, and to a lesser degree IL-6 production 
in these CD69INT cells. 
 
Using the additional 2-hour time-point allowed us to make preliminary observations about 
how cytokine production in these subsets changed over time. Only PMA/Ionomycin 
stimulation was studied in these experiments as it produced the greatest responses. 
CD69HI cells’ production of IL-2, TNF-a, IFN-g, and IL-17 was increased over time, 
whereas intriguingly the proportion of CD69INT cells making the same cytokines was the 
same at 2 hours as it was 5 hours post-stimulation (Fig. 5.5.4). IL-4-producing cells 
increased with stimulation time, regardless of the population studied. However, in the two 
CD69-expressing populations, TGF-b-secreting cells were actually at higher frequencies 
following 2 hours of stimulation, compared to 5 hours. Lastly, IL-6 production was 
independent of stimulation time in CD69HI cells, but CD69INT IL-6 production frequency 
was greatly enhanced at the later 5-hour time-point. Together, these data reveal intrinsic 
differences in the responsiveness of CD69HI and CD69INT cells to stimulation. 
 
Multifunctional TH1 cells are able to produce combinations of IL-2, TNF-a, and IFN-g, and 
show superior immune protection compared to single cytokine-producing cells241-243. Like  
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Figure615.5.4 – Cytokine expression in liver CD69 populations over time. Bar charts show cytokine 
production in blood CD69- cells (light grey), liver CD69- cells (dark grey), liver CD69INT cells (blue) and liver 
CD69HI cells (red) post 2-, and 5-hour stimulations with PMA/Ionomycin. Bar heights show median and 
error bars IQR. N=5 for all liver data except for IL-10 and IL-17 (n=4). N=4 for all blood data except for IL-
10 (n=3). 
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other similar studies on human tissue residence82, 88, 131, 144, we calculated the proportions 
of liver CD69HI TRM cells that could make multiple cytokines, compared to liver CD69- and 
CD69INT cells, and blood CD4+ T cells following PMA/Ionomycin stimulation. CD69HI cells 
contained the highest proportion of IL-2+TNF-a+IFN-g+ cells, IL-2+IFN-g+ cells, and TNF-
a+ cells (Fig. 5.5.5). All these differences were statistically different compared to CD69- 
cells. CD69INT cells on the other hand, fell in between the two liver populations, but were 
much closer aligned to CD69- cells. Interestingly, blood CD4+ T cell responses were 
distinct from all liver CD4+ T cell populations, showing far greater fractions of T cells 
making IL-2 alone, and IL-2 with TNF-a. In these investigations, we also looked for IL-4 
and IL-10 dual producers, but were unable to locate any double positives in any liver 
studied (data not shown). 
 
These data demonstrate stark functional distinctions between CD69INT and CD69HI cells 
in terms of the type(s) of cytokines produced, and the speed of responses. CD69HI favour 
TH1 and TH17 profiles, with the highest type-1 multifunctionality. Conversely, CD69INT 
cells favoured IL-4 and IL-10, and generally reached their peak cytokine production faster 
than their CD69HI counterparts. 
 
5.7 Co-culture with hepatic cell lines imprints blood CD4+ T cells with a partial 
liver CD69INT phenotype, while culture with intact liver slices may induce CD69HI 
generation 
 
We previously observed that co-culture of blood-derived CD4+ T cells with both hepatic 
and non-hepatic epithelia led to an upregulation of CD69 to an intermediate level (chapter 
4). We showed this upregulation did not represent activation, nor did it indicate the  
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Figure625.5.5 – The CD69HI liver population contain the most multifunctional IL-2+TNF-#+IFN-!+ cells. 
Stack charts display multifunctional responses in terms of single, dual, and triple IL-2, TNF-#, and IFN-" 
responses to 5 hour PMA/Ionomycin stimulation. As in previous figures, blood CD69-, liver CD69-, liver 
CD69INT, and liver CD69HI CD4+ T cell responses are shown. Stack chart heights represent median % of 
each cytokine expression pattern as shown. Accompanying table shows population key, statistical 
comparison between the three liver populations and interquartile range values (liver, n=7; blood n=5). 
  
CD69- CD69INT CD69HIBLOOD !"#$%&'(") *+, -(.)(/(0&)'1 2345678
9 :;<52=> 9 :;<5?2 2=>5:;<5?2 9 2=> ?2
!"#$%&'(#)%!('#*% +, --- +, ./. 0/1 .1
&'(#)%!('#*% +, +, +, ./0 ./2 3/3
!"#$%!('#*% +, - +, ./2 $/2 $/4
!"#$%&'(#)% +, +, +, 0/0 4/1 0/5
!('#*% +, +, +, 0/3 $/5 3/6
&'(#)% +, -- +, $/2 3/5 ./2
!"#$% +, +, +, 0/$ 0/2 $/3
!"#$#&'(#)#!('#*# +, - +, .1 $5 .5
 212 
generation of a novel regulatory phenotype. Based on our discovery of a CD69INT CD4+ 
T cell type in the liver, we hypothesised that the CD69INT phenotype we generated from 
blood CD4+ T cells would phenotypically resemble their intrahepatic CD69INT 
counterparts. 
 
To test this, we performed a comparative analysis of the CD69INT blood CD4+ T cells that 
were the product of Huh-7 co-culture (CD69INT hTCs). We asked first if CD69INT hTCs are 
imprinted with a partial residence phenotype, like that displayed by liver CD69INT cells. 
CD69INT hTCs showed an upregulation of CD49a at day 1 following co-culture that 
remained consistent throughout the course of the 7-day co-culture period (Fig. 5.6.1). 
This difference was observed relative to the co-cultured CD4+ T cells that did not 
upregulate CD69 (CD69- hTCs), but was also apparent when compared to T cells cultured 
alone (virtually all CD69-) proving the effect a genuine upregulation. CD103 and CXCR6 
were only expressed on very few CD4+ T cells, but the CD69INT hTC cells contained a 
few more CD103+ and CXCR6+ cells than the CD69- hTC pool. S1PR1 was upregulated 
on all T cells following culture with Huh-7 cells, but this effect was greatest in magnitude, 
and longest lasting in CD69INT hTCs. Therefore, CD69INT hTCs seemed to recapitulate 
the partial residence phenotype of intrahepatic CD69INT cells, most notably through 
elevated S1PR1 expression. 
 
Another key feature of liver CD69INT cells was relative increases in the percentages 
expressing KLRG-1 and CD127. KLRG-1 expression was higher among the CD69INT 
hTCs too, with CD69- hTCs more resembling T cell only controls (Fig. 5.6.2A). CD69INT 
hTCs also maintained CD127 expression well across the 7-day culture period, similar to 
the T cells alone. In stark contrast, CD69- hTCs drastically lost over 56% of their CD127  
!)'+!
!
!
Figure635.6.1 – Huh7 exposure induces blood-derived CD4+ T cells to express a partial residence 
phenotype akin to liver CD69INT cells. Shown are blood-derived CD4+ T cell expression patterns of the 
tissue residence markers CD49a, CD103, CXCR6, and S1PR1, both with and without Huh-7 co-culture. 
Representative flow plots show expression of each marker against CD69 in both T cells only, and co-
cultured cells after day 3 in culture. Graphs display change in % expression over time for T cells only (black), 
co-cultured CD69- cells (green), and co-cultured CD69+ cells (blue). Points are medians, while error bars 
show IQR (all n=6 bar S1PR1 where n=5). Statistical analyses in this figure compare CD69- and CD69+ co-
cultured cells. 
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expression (Fig. 5.6.2B). Analysing combinatorial KLRG-1 and CD127 expression, T cell 
only controls were mostly resting, followed by smaller clusters of cytokine-stimulated, and 
previously activated cells, and very few activated/effector cells (Fig. 5.6.2C). In 
comparison, from day 3 onwards, many CD69- hTCs appeared to forgo their resting 
phenotype primarily becoming cytokine stimulated. These cells were much more 
susceptible to cytokine stimulation than CD69INT hTCs, which seemed to diverge into 
three main populations. First many more of these cells retained a resting phenotype. 
Second, some became cytokine stimulated, like their non CD69-expressing counterparts. 
Third, some of these cells presented with a previously activated phenotype. Of course, 
this last phenotype cannot be induced straight from resting cells, so instead it was inferred 
that the cells that upregulated CD69 through co-culture with hepatic cell lines were 
enriched for the existing previously activated population. This last feature was similar to 
liver CD69INT cells that were enriched for the previously activated phenotype. 
 
We next sought to discover whether these findings held true in other hepatic cell lines, 
and primary liver epithelia. Preliminary data demonstrated HepG2 and Hep3B cells, as 
well as primary BEC cells were just as good as Huh-7 at inducing CD49a, CD103, CXCR6 
and S1PR1 within the CD69INT gate when compared with the CD69- cells following co-
culture (Fig. 5.6.3A). Additionally, KLRG-1 and CD127 upregulations among the different 
co-cultured CD69INT cells was fairly consistent (Fig. 5.6.3B). Following this, we looked at 
the KLRG-1 and CD127 co-staining patterns among the CD69INT cells in each co-culture 
condition (Fig. 5.6.3C). At day 1, we found that T cells co-cultured with all cell types 
showed similar division amongst the four activation and differentiation subsets. By day 3, 
those cultured with the hepatocyte cell lines remained similar, whereas BEC-cultured T 
cells showed a heavier naïve/resting bias by day 3. At day 7, with HepG2 there was also  
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Figure655.6.3 – The phenotype of CD69+ cells induced by co-culture is similar regardless of inducing 
cell. A – Blood-derived CD4+ T cells co-cultured with hepatocyte cell lines Huh-7, HepG2, or Hep3B; or 
primary biliary epithelial cells (BEC); for either 1, 3, or 7 days. Resulting difference in CD69+ cell marker 
expression was shown as the median fold change compared to control CD69- cells. This was done for the 
TRM markers CD49a, CD103, CXCR6, and S1PR1. B – As part A, but for differentiation markers KLRG-1 
and CD127. For both parts: light blue – Huh-7, mid-blue – HepG2, dark blue – Hep3B, purple – BEC; plots 
show median + IQR. C – KLRG-1/CD127 co-staining patterns (%) in the generated CD69+ cells in each 
condition. Results shown as 3 heat-maps – 1 for each time point. Numbers in each cell denote median % 
expression in the CD69+ cells. Resting – KLRG-1-CD127+, cytokine-stimulated – KLRG-1-CD127-, 
activated/effector - KLRG-1+CD127-, previously activated – KLRG-1+CD127+. For all parts of this figure, 
donor numbers as follows – Huh7 – 6, HepG2/Hep3B – 2, BEC – 3. 
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a higher resting cell proportion in expense of the cytokine-stimulated cells, distribution in 
BEC co-culture remained as at day 3, and Hep3B showed a constant population spread, 
similar to Huh-7 controls. Thus, the key partial TRM and differentiation features seen 
following Huh-7 culture was largely consistent with different hepatic cell lines, and primary 
biliary epithelia. 
 
Other key differences between CD69INT and CD69- hTCs included those amongst 
inhibitory and chemokine receptors. Both PD-1 and Fas expression was significantly 
more frequent in the CD69INT population at all time points (Fig. 5.6.4A). The proportion of 
CCR6-expressing cells fell sharply in the CD69- population, but this effect was delayed in 
the CD69INT (Fig. 5.6.4B). On the other hand, CXCR3+ cells were clearly diminished in 
both co-cultured populations compared to T cells cultured alone, but CD69INT hTCs lost 
this chemokine receptor more effectively than CD69- hTCs. Last, after an initial delay, co-
culture induced an CX3CR1 upregulation that was similar amongst CD69-expressing and 
non-expressing cells. These findings again show similarities to the CD69INT liver cells, 
with higher PD-1 and CCR6 than their CD69- counterparts; although unlike the liver cells, 
CXCR3 was lost, and CX3CR1 similarly upregulated in both populations in vitro. 
 
To help determine whether the in vitro-generated CD69INT cells possessed the same 
cytokine biases as the earlier described liver CD69INT cells, we cultured blood-derived 
CD4+ T cells with and without Huh-7 cells, before stimulation and intracellular cytokine 
staining. Only three donors were used for these experiments making definite conclusions 
difficult, but it appeared that a higher frequency of co-cultured T cells secreted IL-4 
following PMA/Ionomycin, and especially CD3/CD28, stimulation (Fig. 5.6.5). The other 
cytokines were largely similar, but subtle distinctions may become significant with more  
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Figure665.6.4 – Inhibitory receptor and chemokine receptor expression on hTCs. A – Representative 
flow cytometry plots showing PD-1, and Fas vs. CD69 expression in T cells only and T cells co-cultured 
with Huh-7  cells for 3 days. Percentage expression data from all donors in the different culture conditions 
(both n=6) is shown in the graph on the right. B – CCR6 (n=6), CXCR3 (n=6), and CX3CR1 (n=2) % 
expression over time following co-culture. For all graphs, T cells only, CD69- co-cultured cells, and CD69+ 
co-cultured cells are shown in black, green, and blue respectively. Statistical comparisons tested the two 
co-culture populations only. 
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Figure675.6.5 – CD69INT cells generated through contact with Huh-7 cells show more pronounced IL-
4 production than T cells cultured alone, similar to their liver CD69INT counterparts. CD4+ T cells from 
peripheral blood were co-cultured with Huh-7 cells overnight, stimulated with PMA and Ionomycin, or anti-
CD3/CD28 (both with golgi stop Brefeldin A), and stained for the same cytokines studied in liver CD4+ T 
cells (Figs 5.5). Bar charts show median (+IQR) percentage cytokine expression in T cells only (white bars) 
and co-culture (blue bars). N=3. 
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experimental repeats. Thus, similar to liver CD69INT cells, hTCs upregulate IL-4 better 
than cells not exposed to Huh-7 cells in culture, but other cytokine distinctions seen in the 
liver counterparts were not seen in co-culture models. 
 
Several key questions still remained in the generation of CD69INT cells from blood. Would 
T cells adopt the same phenotype in coculture with primary hepatocytes, and if so what 
would be the time frame needed? How is the effect different within the complexities of the 
liver microenvironment and is this process different in diseased versus healthy patients? 
To begin to answer these questions, we cut 2mm slices of liver from patients with liver 
disease (n=2), and cultured them with autologous PBMCs for 5 hours. Although fairly 
crude experiments, determining whether intact liver slices induce a CD69INT phenotype 
will show us a more physiological generation pathway, and allow us to unpick specific cell 
type(s) and cytokines responsible later down the line. Additionally, it will answer whether 
the CD69HI TRM-like phenotype can be induced under these conditions. 
 
Like the healthy donor T cells, many blood CD4+ T cells from patients with liver disease 
also adopted the CD69INT phenotype following Huh-7 contact, although curiously almost 
as many T cells alone gained this phenotype (Fig. 5.6.6A). This was observed in both 
donors, and CD69 positivity was low in T cells immediately following isolation. 
Importantly, a clear differentiation into CD69INT cells was seen in the liver slice cultures. 
This was supplemented by a small, but distinct induction of CD69HI cells. 
 
First comparing CD69HI cells from liver and slice culture, we noted many markers showed 
similar differential expression (Fig. 5.6.6B). Relative to their individual CD69- controls, 
both populations showed similar changes in TRM markers (↑CD49a, ↑CD103,  
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Figure685.6.6 – Contact with autologous liver slices may imprint CD69HI and CD69INT phenotypes 
analogous to that seen in human liver. Liver slices from diseased livers were cut to a thickness of 2mm 
and cultured with autologous PBMCs for 5 hours before harvesting and staining for flow cytometry. 
Live/Dead stains were included to eliminate dead cells. A - Stack charts showing median % representation 
of the three CD69 populations in blood, liver, and the three different culture conditions listed (T cells alone, 
T cells with Huh-7 cells – ‘In Vitro’, and T cells with 2mm liver slices – ‘Ex Vivo’). For the ex vivo liver slice 
culture, a representative flow cytometry plot is shown. The remainder of the figure focusses on CD69HI 
cells (B), and CD69INT cells (C) where expression of multiple markers are compared in the liver, ex vivo, 
and in vitro Huh-7 co-culture conditions (T cells in the in vitro/Huh-7 co-culture are excluded from the 
CD69HI analyses as no appreciable induction of CD69HI cells was observed). Percentage marker 
expression displayed as a difference from CD69- cells in each case (median + 95% CI). In the heat-maps 
below, median percentage expression in these three conditions was analysed in the four populations 
defined by KLRG-1 and CD127 coexpression patterns (as previously defined – see Fig. 5.3.5). All data in 
this figure derived from 2 donors (both NASH patients). 
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↑CXCR6), chemokine receptors (↑CCR5, ↑CCR6, ↑CXCR3 ↑CCR9), and 
activation/inhibitory markers (↑PD-1). However, while both tissue egress receptor 
S1PR1 and chemokine receptor CX3CR1 were strongly diminished amongst the liver 
CD69HI cells, they were unaffected in the liver slice culture CD69HI population. 
Additionally, in slice models, CCR9 expression was much higher and HLA-DR expression 
was not repressed, unlike in true liver CD69HI cells. Both CD69HI cell types favoured a 
resting (KLRG-1-CD127+), followed by previously activated (KLRG-1+CD127+), activated 
(KLRG-1+CD127-), and finally cytokine-stimulated (KLRG-1-CD127-). 
 
CD69INT cells from the liver, liver slice cultures, and Huh-7 cultures were also mostly 
similar phenotypically. In all three, the four TRM associated markers (CD49a, CD103, 
CXCR6, S1PR1) were increased in percentage from their CD69- counterparts; alongside 
increases in CCR6, CXCR1, CXCR3, and CCR9 (Fig. 5.6.6C). KLRG-1 and CD127 co-
expression patterns were largely similar amongst the three CD69INT cell groups, although 
liver cells seemed to be more skewed towards cytokine-stimulated cells at the expense 
of resting cells. 
 
Therefore, preliminary data shows it is possible to generate both CD69INT and CD69HI 
CD4+ T cells from short-term liver slice culture, and these have similar, though not 
identical, expression profiles to their liver-isolated counterparts. 
 
 
 
 
5.8 Discussion 
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5.8.1 Summary of findings 
 
The liver can be considered an immune organ in its own right, mediating direct activation 
of naive T cells and providing powerful immune tolerance mechanisms. As TRM are key 
in immune homeostasis and memory immune responses, liver TRM are expected to be of 
great importance in hepatic immunity. Although the CD8+ TRM compartment has been well 
described148, CD4+ TRM are an unknown quantity. The aim of the research in this chapter 
was to address this gap in the literature and provide a thorough and detailed catalogue 
of their phenotype and function. On top of this, we asked whether a CD69INT population, 
analogous to that previously observed in hepatic co-culture systems could be identified 
in the liver, and if so what were its properties. 
 
We demonstrated that both CD69HI and CD69INT CD4+ T cells can be found in the human 
liver, appearing to be very distinct lineages (for summary see Fig. 5.7.1). CD69HI cells 
were true TRM with restricted homing receptor expressions and preferences for resting 
phenotypes. Following stimulation these cells were the best producers of TH1-cytokines. 
Conversely CD69INT did not appear fully resident phenotypically, expressed a wide range 
of homing receptors and mixed activation states, and were the highest IL-4 and IL-10 
producers following stimulation. Phenotypically similar CD69INT cells were induced in vitro 
following hepatic cell co-culture, and it is possible we saw the development of CD69HI-
like cells following contact with intact liver slices (Box 5.1). 
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Figure695.7.1 – Summary of phenotypic and functional differences between CD69HI and CD69INT 
CD4+ liver T cells.  Diagram shows first the significant differential expression of surface antigens between 
the two subsets (p<0.05). Two bars denotes a higher level of expression, while x means negligible 
expression of the corresponding marker. Markers highlighted in red or blue show subset-specific 
expression. Cytokines deemed differentially expressed following stimulation are shown below the cells. 
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Chapter 5 – Core Findings:
 
•! Intrahepatic CD4+ T cells subdivided into three populations based on CD69 
expression: CD69-, CD69INT & CD69HI
•! CD69HI: 
o! Represented the CD4+ TRM of the liver through absence in blood and 
strong co-expression of tissue-residency markers 
o! Expressed chemokine receptors predictive of restriction to portal and 
biliary areas 
o! Favoured a predominantly resting (KLRG-1-CD127+) state and high co-
inhibitory marker expression 
o! Evoked robust multifunctional TH1, and TH17 response best following 
stimulation 
•! CD69INT: 
o! Displayed a semi-resident profile, with elevations of some residency 
markers, but also high expression of tissue egress receptor S1PR1 
o! Were very heterogenous for homing receptors, suggestive of the ability 
to home to multiple liver niches as well as the gut 
o! Were a more activated cell type than their CD69HI counterparts (based 
on CD38, HLA-DR, Ki-67, and CD127/KLRG-1 designations) 
o! Were capable of producing IL-4 and IL-10 most efficiently 
•! Phenotypically similar CD69INT and CD69HI cells were generated from co-
culture with hepatic epithelia and intact human liver slices respectively 
Box 5 Box 5.1 – Core findings from chapter 5 
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5.8.2 Experimental justifications 
 
When assaying phenotype and function, all CD4+ T cell populations were pre-gated on 
CD56-gd-TCR- singlet lymphocyte populations. This ensured that only conventional T 
cells were studied, not NK cells, NKT cells, or gd T cells that can be substantial hepatic 
populations281. This gating strategy also largely excludes MAIT cells that can make up 
between 20-50% of liver T cells, as MAIT cells from are predominantly CD56+, and only 
a small proportion of MAIT cells express CD4663, 664. Next, although some panels 
contained a CD8 marker, there was not space in the 9-colour panels for this marker in all, 
so there is a possibility that some of our cells are CD4+CD8+ (double positive) T cells that 
have been described as a low frequency cell type in the human liver275. However, many 
of the livers we analysed did not contain appreciable amounts of these cells (data not 
shown). While we did not include a dead cell marker for the experiments where liver cells 
were immediately stained and fixed following their isolation (previous work in our lab has 
shown extremely low cell death in live lymphocytes in such experiments as LIMCs were 
obtained and stained immediately following density gradient centrifugation), live/dead 
dyes  were always used to exclude dead cells in cytokine detection, and liver slice culture 
experiments that included prolonged culture periods and/or cell stimulation. 
 
We used CD69 alone as the key discriminator of tissue-residence. The logic behind this 
was as follows. First, many other investigators of human tissue residence used this 
marker, enabling fair intra-study comparisons82, 88, 90, 135, 136, 146. Second, CD69 has shown 
repeatedly to be the best marker of human TRM91, 186. CD69 expression completely 
segregates TRM and non-TRM phenotypically91, has been demonstrated on every human 
TRM type studied186, and other TRM-associated markers such as CD103 and CD49a are 
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only suitable for particular T cell subsets, tissues, or tissue niches146, 152, 187, 188. 
Furthermore, CD69 expression is strongly correlated with repression of the tissue egress 
phenotype through downregulation of S1PR1153. This process is allowed by KLF-2 
downregulation that itself is downstream of other key TRM inducers84. Thus, CD69 
promotes tissue residence in a multitude of ways. Some murine studies have argued 
CD69 is an imperfect marker of tissue-residence, with some resident cells CD69- 87, 
expressing it while recirculating130, or differentially modulating it as they travel through 
NLTs213. However, in humans the story is likely different as nicely illustrated by Beura et 
al. who showed ‘dirty’ pet shop mice possessed much greater CD69 expression in tissue-
resident cells compared to specific pathogen free controls214. This provides a model 
closer to us ‘dirty’ humans214. Paradoxically, we argue both for and against CD69 as a 
true human TRM discriminator. We believe that while binary CD69 expression is not 
enough to discriminate TRM from non-TRM, high expression of this molecule is an excellent 
marker of true TRM cells. 
 
An essential prerequisite to comparing and contrasting the CD69INT and CD69HI cells, is 
to prove they are truly distinct subsets. We have done this in a multitude of ways. First, 
both isotype-matched controls and our previous data on CD69 upregulation to an 
intermediate level in co-culture convinced us the CD69INT population was real and not 
just a fluorescence shift. Although staining in some livers clearly showed three distinct 
populations based on CD69 expression, some stains were less distinct, with the CD69INT 
cells closely positioned to the CD69- population. Thus, predictably, some have argued 
that CD69INT cells were simply a tail of the CD69- population. We can show this is not the 
case through our second, third, and fourth arguments – that CD69INT and CD69HI cells 
are phenotypically, and functionally distinct, and not all phenotypic markers show simple 
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linear correlations with CD69 expression. Multiple phenotypic distinctions separated the 
two subsets, including stark differences in CX3CR1, CXCR6, PD-1, and KLRG-1. These 
cells were also functionally distinct as only CD69INT cells were able to appreciably make 
IL-4 and IL-10. Lastly, and most importantly, many markers that were differentially 
modulated in one direction from CD69- to CD69INT, were reversed in direction from 
CD69INT to CD69HI. Examples include CXCR3, CD27, CCR9 and HLA-DR. This goes 
against what we would expect if the CD69INT were only a population tail where only linear 
changes with CD69 expression would be seen. Therefore, we have provided multiple 
lines of evidence that CD69INT cells are a true distinct population, and not an artefact of 
staining. It is interesting that we are the first to report this cell type when many others 
have investigated human tissue resident T cells. The CD69INT phenotype could of course 
be liver, or CD4+ T cell specific, explaining away the vast majority of studies that look at 
CD8+ T cells. Alternatively, this population may have been overlooked by researchers 
who were not aiming to find it. We ourselves may have missed the CD69INT cells we had 
not been specifically looking for an intermediate population thanks to our co-culture data, 
and also had the advantage of staining for CD69 with an antibody conjugated to the 
fluorochrome PE-Dazzle594, a very bright dye. 
 
Finally, many of our literature comparisons have been made with CD8+ TRM as this reflects 
the availability of data in humans. Despite the clear differences between circulating CD4+ 
and CD8+ T cell biology, these differences may be largely diminished amongst TRM 
subsets. This was meticulously demonstrated in the human lung recently135. Thus, it 
appears that tissue-specific factors are the most important regulators of TRM identity, 
regardless of helper or killer designation. 
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5.8.3 Phenotypic and functional comparison of liver CD69-defined populations  
 
We showed that high expression of CD69 marks the tissue-resident CD4+ T cell 
population of the human liver. CD69HI cells were only present in liver not blood, were 
heavily skewed towards the TEM phenotype, and showed the strongest association with 
TRM markers (positive association with CD103, CD49a, CXCR6, PD-1; negative 
association with CCR7, S1PR1 and KLRG-1). These marker profiles were extremely 
similar to CD8+ TRM described in the liver148, 149, skin151, and lungs131, 134; as well as CD4+ 
TRM from the stomach, lungs, skin, and colon82, 135, 136. Comparing our results directly with 
the study by Wong et al. that also looked at liver CD4+ TRM, all of these markers (except 
for the lowly expressed CD103) showed the directional change in both studies (S1PR1 
and KLRG-1 not studied by Wong et al.). Interestingly though, their study only found 
around 4% of liver CD4+ T cells expressed CD69 compared to our average of 39%, and 
also reported no CD69INT cells. This could be partly due to methodology – we used 
digestion, whereas Wong et al. opted for portal flush82. 
 
CD4+ TRM were universally present in all livers, independent of disease aetiology, 
supporting a role for these cells in general immune homeostasis that supersedes any 
underlying inflammatory climates23. While we did not analyse differences in viral liver 
diseases here, intrahepatic CD4+ TRM are also thought to be unaltered in HCV infection384, 
although CD8+ TRM are elevated in patients with chronic HBV148. In support of other 
human data, our cells did not appreciably express Hobit134, 135, 148. Although CD103 
expression is generally not a good TRM marker among CD4+ T cells84, 88, 665, CXCR6 
expression in the CD69HI compartment was especially important. CXCR6 expression is 
thought to be vital for retention in the liver180, 391, 393, and accordingly has been reported 
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on human liver-resident NK cells, as well as liver-resident T cells148, 149, 384, 395, 646. 
However, it should be noted that CXCR6 may be a more generic TRM discriminator, as 
lung TRM appear to rely on this receptor also134, 135, 666. 
 
Aside from CXCR6, other homing receptors with the strongest association with CD69HI 
cells were CCR5 and CCR6, suggestive of preferences for portal and bile duct areas. 
These chemokine receptor preferences not only exactly match previous findings on CD8+, 
but also CD4+ TRM in the liver in lungs at both mRNA and protein levels82, 134, 135, 384. Our 
preliminary immunofluorescence data largely supported these conclusions showing 
CXCR6-expressing cells in the hepatic parenchyma and bile ducts. The two main 
limitations of these experiments were first we were not able to specifically stain CD4+ T 
cells, and second a small proportion of CD69INT cells also expressed CXCR6. We 
reasoned the majority of CXCR6 cells observed that were also CD4+ would be CD69HI 
cells as backed up by previous flow cytometry data, thus allowing the small discrepancy 
as acceptable error. Within the liver, CXCR6 is only expressed on lymphocyte populations 
(T cells, NK cells and NKT cells), except for in liver cancer where tumour cells can express 
this molecule667. As none of the livers used for staining had any information on file about 
liver cancer, again we deemed this latter scenario unlikely. Therefore, although we cannot 
pin down a specific lymphocyte subset from our immunofluorescence stains, we can 
argue that CXCR6 staining in these experiments at least limits the possibilities of where 
CD4+ CD69HI cells can be. 
 
Interestingly, we saw no association with sinusoidal homing receptor CXCR3 expression, 
and this was corroborated by little sinusoidal localisation patterns of CXCR6+ cells by 
immunofluorescence. This was in obvious contrast to previous studies on CD8+ and CD4+ 
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TRM from the liver and lungs82, 134, 135, 148; but agreed with studies on CD69+ intrahepatic 
CD4+ T cells in HCV patients384. Perhaps these discrepancies stem from the other authors 
looking at only total CD69-expressing cells – our CD69INT did contain a greater CXCR3+ 
population. As CXCR3 is used to enter the tissue through the sinusoids, it is possible that 
once a cell settles into a life of residency this receptor is no longer required and so 
downregulated. Perhaps this points to differences in the liver tissue niches of CD8+ and 
CD4+ TRM; as the former have been suggested to reside in the sinusoids in mouse modes, 
and now too in human livers128, 148, while our data supports the latter favour portal and 
biliary areas. This point brings us back to the low percentages of CD69-expressing 
intrahepatic CD4+ T cells found by Wong et al., as perhaps only CD8+ TRM can be reliably 
isolated by portal flush methodology (CD8+ TRM frequencies in their study were 
comparatively far higher)82. 
 
As opposed to the CD69HI population, CD69INT cells are likely non-resident. Despite their 
negligible presence in blood, there was no TEM phenotype enrichment within this subset 
compared to CD69- controls. CD69INT cells presented with a partial residence phenotype 
– expressing TRM-associated markers CD49a, CD103, and CXCR6 more than CD69- 
cells, but not to the same degree as the truly resident CD69HI cells. CD69INT cells 
expressed S1PR1, and this was actually at a higher median percentage than S1PR1 
expression in the CD69- cells. This was a key finding as possession of this receptor would 
allow CD69INT cells to leave the tissue. To our knowledge, our study is the first to report 
this association, with all others to date showing only negative associations between CD69 
and S1PR1153, 158, 668. Our result indicates there could be a threshold for CD69 expression 
needed, before which S1PR1 is not appreciably out-competed and thus downregulation 
does not occur. As CD69 is thought to be upregulated early in the tissue residence 
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formation process158, the S1PR1+ CD69INT cells may be very recently formed tissue-
residents that have not yet shut down the tissue-egress programme. Therefore, like 
others have suggested, it is conceivable that cells expressing CD69 could still return to 
the circulation before the TRM programme is set, as exemplified in the skin where multiple 
resident and recirculating populations exist152, 158, 213. 
 
Homing molecule expression profiling provided additional evidence for the non-resident 
nature of the CD69INT population. When compared to CD69- controls, CD69INT possessed 
greater CCR5, CCR6, CXCR1, CXCR3 and CX3CR1 percentage expression. This broad 
homing receptor profile suggested CD69INT cells had not found a tissue niche within the 
liver in which to settle, in contrast to the CD69HI cells which had a more restricted pattern. 
This is important as TRM from both mouse and man have often been described as residing 
in particular tissue niches133, 152, 218, 256, 261. This was the first demonstration of the relative 
heterogeneity of CD69INT cells versus CD69HI cells in our study, an aspect of their biology 
we will return to later. This point is important when attempting to assign roles to this newly 
discovered subset. For homing receptor expressions, further research with the use of 
bioinformatic tools should investigate whether the fractions of the CD69INT cells 
expressing different homing-receptors cluster together (i.e. are the CXCR3+ cells the 
same cells as those expressing CCR6 for example). Knowledge of these different 
receptors’ roles in homing to different areas of the liver suggest CD69INT cells would likely 
segregate, but it is important to test this hypothesis formally. 
 
CX3CR1 was key in discriminating CD69INT from CD69HI cells. While the CD69HI subset 
barely expressed this receptor, CX3CR1 expression in CD69INT cells was clear. CX3CR1 
is the receptor for fractalkine (CX3CL1), as well as CCL26 in humans354, 669. In the liver, 
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fractalkine can be expressed on inflamed bile ducts398, 399, and perhaps may attract TH1 
cells on which CX3CR1 is traditionally expressed353. Data on CCL26 expression in the 
liver is scarce, but expression has been documented on human umbilical vein endothelial 
cells, raising the possibility of expression on liver endothelium670. Very little CX3CR1 
expression in the CD69HI TRM compartment fits well with the literature, as many have 
reported similar decreases in TRM, and recently Kumar et al. even included its 
downregulation in the core human TRM signature91, 134, 135, 384. Conversely, CX3CR1-
expressing CD69INT cells could allow access to the bile ducts as part of the wide-ranging 
capabilities of this cell type. Further, CX3CR1 has been used to separate three distinct 
CD8+ subsets in mice. High and low expressors represented TEM and TCM respectively, 
whilst intermediate expressors were more plastic, able to form both other populations, 
and were the predominant NLT-recirculating subset671. Perhaps this argues for the 
CX3CR1+ CD69INT cells being a CD69HI TRM precursor, as will be discussed in more detail 
in section 6.1. 
 
We used CX3CR1 expression to identify the CD69INT cells by immunofluorescence. 
Unfortunately, we could not get around the same limitations posed by using CXCR6 to 
identify CD69HI cells for this subset. This was as CX3CR1 was comparably expressed by 
CD69- cells, and CX3CR1 expression is not limited to lymphocytes in the liver, but also 
BEC, vasculature, HSEC and the fibrotic septa398, 399, 672. Therefore, we limited our 
conclusions to state that CX3CR1 expression was seen in the parenchyma, sinusoids, 
and fibrotic septa, but not bile ducts in our hands. Future work will aim to successfully 
combine the stain for CX3CR1 with CD69 and CD4 to allow us to see exactly where our 
desired cell type is located. 
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CD69INT cells also expressed the most gut-homing receptors CCR9 and integrin a4b7. 
This is suggestive of the ability of CD69INT cells to travel to and from the gut. This 
compliments the other homing receptor data as now we can suggest that not only are 
CD69INT not restricted to one tissue niche within the liver, they are not restricted to the 
liver either. This is an interesting prospect, as it could be the recirculation of CD69INT cells 
that contributes to sharing of immunological data between the gut and liver, either 
promoting tolerance, or immunity. The gut and liver have an intimate immune relationship 
– demonstrated best by antigen sharing via the portal vein, and the continuous nature of 
the intestinal and biliary epithelia276, 673. Consequently, all major liver autoimmune 
disorders show strong associations with bowel disease414, the most apparent being 
between PSC and IBD673, where CCR9+ gut-tropic lymphocytes can be greatly enriched 
in PSC patient livers404. Thus, discovering whether CCR9+ CD69INT cells are similarly 
enriched in the liver or the gut of PSC patients, and if so discerning their roles in 
pathology, would be an interesting angle to take in the better understanding of these cells. 
 
Some of the most important differences in CD69INT and CD69HI cells lay within their 
activation and differentiation states. Activation markers CD25, CD38 and HLA-DR were 
more frequently expressed in CD69INT cells, and these cells proliferated the most of the 
three CD4+ T cell subsets. CD69HI cells were comparatively less activated. While CD25 
expression was still elevated in the population compared to CD69- cells, there was no 
increase in proliferation. Additionally, HLA-DR and KLRG-1 were both decreased. A 
similar KLRG-1 decrease was seen in lung CD8+ TRM134, but in other liver studies, both 
CD4+ and CD8+ TRM expressed higher HLA-DR levels82, 148. However, this was not 
consistent with other human NLTs, with HLA-DR levels low among TRM isolated from 
these91. These differences could again be explained by the increased HLA-DR 
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expression among our distinguished CD69INT cells, and/or by differences in CD8+ TRM 
activation potential or the liver immune environment. TRM cells in mice are thought to 
develop preferentially from KLRG-1- precursors110, a cell type also responsible for long-
lived CD8+ TCM193. Our findings, combined with other human data, may hint at a similar 
mechanism in the human CD4+ lineage134. Importantly, CD69HI TRM were biased towards 
a resting (KLRG-1-CD127+) phenotype. Thome et al. used a similar marker set (CD28 
and CD127) to demonstrate that lung and gut tissue CD4+ T cells were also predominantly 
resting, whereas interestingly, CD8+ T cells from these sites were mostly cytokine 
responsive90. Our CD69INT population by contrast was once again more heterogenous. 
However, the significant change from the other two subsets was in the previously 
activated (KLRG-1+CD127+) phenotype, in agreement with our earlier activation marker 
data. Following this logic, at least some of the intrahepatic CD69INT cells are not 
permanently resident, and/or perhaps too far differentiated to become resident through 
virtue of their KLRG-1 expression. 
 
On the subject of differentiation status, CD27 and CD28 expression patterns were 
different among the two CD69-expressing subsets. CD27 and CD28 are both 
costimulatory receptors that are downregulated with advanced effector memory cell 
differentiation659, 674. In CD4+ T cells, CD27 is usually lost first, followed by CD28 as 
differentiation progresses488, 659. Our data shows CD69HI cells have relatively low %CD27 
expression, but high CD28, suggesting that TRM occupy a specific intermediate-late 
differentiation stage. However, it is difficult to apply the same logic to CD69INT cells that 
have the highest CD27 expression, but lower CD28. As well as pointing out that CD28 
stains were only performed on one donor to date, we suggest that assessing precise 
differentiation stages further would inevitably involve combining both these markers into 
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panels to compensate for cellular heterogeneity. Indeed, Larbi et al. state only five key 
markers (CD28, CD27, CD57, KLRG-1, PD-1) are necessary to encapsulate the entire 
spectrum of T cell differentiation, exhaustion, and senescence; four of which we have 
already studied659. Of interest, human lung CD4+ TRM contained the highest CD28 
expression also135, validating our results. Last, CD80 expression was marginally 
increased amongst CD69HI cells, but CD86 expression was markedly absent in this 
population (n=1). This could be a PSC-specific phenomenon, but other explanations are 
scarce due to the lack of knowledge of the implications for CD80/CD86 expression on T 
cells.  
 
Analysis of the functional responsiveness of the three intrahepatic CD4+ subsets revealed 
a greater propensity for CD69HI and CD69INT to produce TH1 and TH2 cytokines 
respectively. We decided to use multiple stimuli to test cytokine production. This provided 
a robust approach as no one stimulus was optimum for all cytokines (for example IFN-g 
and IL-10 have been reported to be better stimulated by PMA/Ionomycin, and anti-
CD3/CD28 respectively675); but also allowed better comparison with human TRM studies 
who use both PMA/Ionomcyin82, 88, and anti-CD3/CD28 stimulation135, 136, 148, and a 
combination of the two91, 131. 
 
Our assay design involved a pre-stain of CD69 before stimulation and subsequent 
cytokine staining. This was similar to that employed by Wong et al. who stained for 
homing receptors prior to stimulation and cytokine staining82. In our case this pre-staining 
step ensured the process of stimulation did not mean we detected false CD69-positives. 
We also verified CD69 does not appreciably downregulate in culture for up to 3 hours, 
increasing confidence in our CD69 stain endurance. 
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Human CD4+ T cells in the liver, like most other NLTs, have been show to favour TH1 
cytokine production the most82, 88, and CD4+ TRM from the lungs also follow this pattern135. 
This lines up well with our findings – a consistent upregulation of IFN-g with all stimulation 
methods, and IL-2 and TNF-a with PMA/Ionomycin in CD69HI TRM cells. Also like TRM 
from other studies135, 136, the CD69HI cells in our study were the most type-1 
multifunctional. It is well established that multifunctional cells are the most potent in 
multiple contexts241, 243, and this finding also indicates that our cells are largely not 
functionally exhausted564, 676. Besides this, we found our TRM were the best at producing 
IL-17 following PMA/Ionomycin stimulation, akin to CD4+ TRM in the stomach and lungs91, 
136. These strong pro-inflammatory capabilities following stimulation suggest at a key role 
for the CD69HI TRM in immune protection and pathology. There is also weaker evidence 
that CD69HI cells are the best TGF-b-producers, meaning these cells could also be self-
regulating, and/or be contributing to fibrosis677. 
 
The word heterogenous must once again be used when describing the CD69INT cells. 
Although these cells appeared better than CD69- cells at making IL-2 and TNF-a 
(although not statistically significant) with PMA/Ionomycin stimulation, they did not make 
any more IFN-g or IL-17, and neither are they any more type-1 multifunctional than the 
control CD69- cells. Instead, they make the highest IL-10 and IL-4, offering type-2 and 
regulatory responses that CD69HI cells cannot. Similar IL-4 and IL-10 findings were also 
observed with the other stimulation methods, but of course this is only the story at 5 hours 
or less. Once additional ways of extending the lives of LIMCs can be found, longer 
stimulations can be carried out. Interestingly though, CD69INT cells showed no clear 
enrichment of conventional regulatory T cells (CD25HICD127LO), meaning if there is any 
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regulatory bias within the CD69INT population, it must be within an unconventional subset. 
Lastly, IL-6+-cells were most frequent within the CD69INT gate. This could reflect a role of 
these cells in pro-inflammatory responses, maintenance of liver metabolic function, 
and/or hepatocyte proliferation depending on the levels and persistence of IL-6 
secretion678. 
 
Increased expression of inhibitory markers such as PD-1 and CTLA-4 have been noted 
in many human TRM studies134, 135, 148, and PD-1 is now considered to be a TRM core 
signature marker91. In agreement, we found PD-1 to be markedly upregulated in the 
CD69HI population, but less so in CD69INT. Contrastingly, CTLA-4 was not increased in 
CD69HI cells, but was marginally elevated in the CD69INT subset. Like others have put 
forward, we believe that the high inhibitory marker expression on TRM cells serves to 
restrain this population’s potent activatory capabilities134, 135, 148. The CD69HI TRM in this 
study likely behave similarly as they are mostly resting (KLRG-1-CD127+), and self-
inhibitory (PD-1+), but can potently produce type-1 and -17 cytokines upon stimulation, 
consistent with a key immunosurveillance role. It will be interesting to discern whether our 
CD69HI cells have the highest levels of preformed cytokine mRNA, as is seen for resident 
CD8+ T cells in the lungs, although interestingly possession of pre-formed IFN-g mRNA 
did not notably contribute to the rapidity of the response in some studies134, 135. CD69INT 
cells by contrast are more activated as a population, and perhaps their smaller inhibition 
by lower surface PD-1 levels means they are less restrained than their CD69HI 
counterparts. This hypothesis is supported by the time-course experiments that revealed 
that for many cytokines, CD69INT had already reached their maximum % responsiveness 
at 2h post-stimulation; whereas CD69HI cells generally produced more at the 5-hour time-
point. Curiously, 5h anti-CD3/CD28 stimulation brought about the best IL-2 and TNF-a 
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responses in CD69INT cells, whereas PMA/Ionomycin stimulation showed CD69HI cells 
were the best at generating these cytokines. This again hints at potential differences 
responsiveness to stimulation signal types/strength, also supportive of a more restrained 
CD69HI TRM cell type. 
 
5.8.4 Phenotypic comparison with blood and lymphoid organs 
 
Many of the phenotypic markers studied in the liver were also analysed in blood and 
hepatic lymph nodes. Although the numbers of these samples obtained was much smaller 
as matched patient blood and lymph nodes were much more difficult to obtain, preliminary 
analyses into these populations allowed us to understand what is truly a liver-resident 
versus general tissue-resident phenotype. Many excellent human tissue atlas studies 
have been published in recent years, where multiple cell types across multiple human 
body tissues are studied82, 88, 90, 91. We used these studies as benchmarks wherever 
possible to verify our findings and to better understand the biology of both blood, and 
lymph node cells compared to the liver populations. 
 
We found blood T cells contained many more naïve and TCM cells, and as expected, 
displayed diminished expression of residency-associated markers compared to liver. This 
is in agreement with other studies88, 90. Levels of activation markers were often 
comparable to liver CD69- cells, and displayed a predominantly resting (KLRG-1-CD127+) 
phenotype. Thome et al. also reported blood CD4+ T cells favour a resting 
(CD28+CD127+) phenotype, but in their study cytokine-stimulated cells comprised the 
second largest population, especially in the TEM compartment. By contrast, in our cells, 
the previously activated cell type was the second largest fraction. These differences could 
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be down to disease status as all our donors were patients with chronic liver disease, 
whereas in the study by Thome et al., donors used were free of apparent immune-
mediated disease90. 
 
Interestingly, human lymph nodes did not only contain CD69HI cells, but a substantial 
proportion of CD69INT cells as well. LN CD69HI cells appeared most phenotypically 
resident, with notable increases in CD49a, CXCR6, and PD-1; and decreases in S1PR1, 
and KLRG-1 expression from LN CD69- cells. CX3CR1 was also very lowly expressed in 
LN CD69HI cells. Therefore, Liver and LN CD69HI CD4+ T cells were remarkably similar 
and likely both represent tissue-resident cells. Distinctions between the two exist 
however, and give us an idea about subtle differences in their biology. For example, LN 
CD69HI have much greater % CXCR3 expression, but less CCR5 and CD49a; indicating 
differing reliance for these molecules for their maintenance. Additionally, CD69HI LN cells 
have a much greater cytokine-stimulated component. This is largely similar to findings 
made by Thome et al. where CD4+ TEM from various lymph nodes trend towards a higher 
cytokine-stimulated fraction than TEM equivalents in gut tissues90. This indicates that 
compared to liver, LN CD4+ TRM are much more reliant on common g-chain cytokines for 
their survival. 
 
As for CD69INT cells, intriguingly this population in LN may have even been a larger 
constituent than in liver. Like in liver, they display a partial residence phenotype, but retain 
S1PR1. CD69INT LN cells were also the best CCR9-expressors suggestive of gut-homing 
ability. A key difference however was that no LN population seemed to express CX3CR1 
(n=1). This finding seems consistent with human lymphoid tissue82. KLRG-1/CD127 co-
expression also revealed the majority of LN CD69INT are resting, compared to the much 
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larger expansion of previously activated cells in the liver. This highlights the ability of the 
liver to retain activated T cells341, and suggests that while liver and LN CD69HI cells seem 
similar, the heterogeneous CD69INT populations differ substantially in activation state 
even if it turns out they fulfil similar roles. 
 
5.8.5 Insights into the generation of liver CD69INT and CD69HI cells 
 
Finally, we carried out preliminary investigations into the generation of liver CD69INT cells. 
Using blood-derived CD4+ T cells cultured with hepatic epithelia, we managed to recreate 
a partial CD69INT phenotype. Alongside moderate increases in CD49a and CXCR6, 
S1PR1 was induced, indicating contact with the hepatic cell lines was not mimicking TRM 
induction. This phenomenon was not solely due to tumour effects, as a similar S1PR1 
upregulation was seen following contact with primary BEC cells. CD69INT hTC contained 
higher KLRG-1 proportions than CD69- hTCs, and maintained CD127 expression far 
better. Together, these markers suggested that generation of CD69INT cells from blood 
was slightly more efficient in both resting cells and previously activated cells than those 
currently activated or cytokine-stimulated. In particular, cytokine stimulated cells were far 
higher in the CD69- hTC cells, backing up earlier observations that soluble cytokines are 
less important in the generation of the CD69INT phenotype than direct surface cell contact 
(section 4.4). On top of this, co-culture revealed increases in % of inhibitory markers PD-
1 and Fas in the CD69INT cells, the significance of which is unknown. However, depletions 
of CCR6 and CXCR3 expression in co-culture were seen, unlike the liver CD69INT cells. 
These could be artefacts of the tumour co-culture system679, or novel signatures imprinted 
by hepatocytes that restrict migration to other areas of the liver. 
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The above observations were largely consistent regardless of hepatic cell line used, but 
interestingly also seen when using primary BEC, now allowing us to say that a CD69INT 
phenotype largely reminiscent of liver CD69INT cells can be induced with contact with 
primary liver epithelial cells. The only stark change in BEC-induced CD69INT cells from 
their liver counterparts, was a much greater preference for the resting (KLRG-1-CD127+) 
phenotype in the former. Surprisingly, co-culture with Huh-7 cells was enough to alter the 
cytokine production potential of these cells – IL-4 was preferably produced after co-
culture, much the same as the liver CD69INT cells. However, total alignment was not seen 
as there were no other clear changes in cytokine potential. 
 
So, in sum it appears that co-culture of blood CD4+ T cells with a hepatic cell line is 
enough to induce a reasonably accurate replica of a liver CD69INT cell. This suggests that 
CD69INT cells in the liver form following direct contact with either hepatocytes or BEC. 
While not all markers matched, and not all cytokines were skewed the same way, this is 
to be expected as simple cell line systems cannot hope to recapitulate the full 
complexities of the liver microenvironment. However, as culture with BEC induced a 
similar phenotype, we gained confidence that most of the observations were not simply 
down to the use of a tumour cell line. Next steps would include the use of PHH alongside 
larger donor numbers, but even at this stage our data provide important clues to how 
these phenotypes might arise in vivo. 
 
This data was supplemented by liver slice models which revealed that phenotypically 
similar CD69INT cells could be generated by contact with intact liver slices. Crucially, it 
appears that slices could also generate modest numbers of CD69HI cells too. These cells 
also showed well-matched phenotypes with liver-isolated CD69HI T cells. Although also 
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at an early stage, this data suggests that additional signals from other cell types in the 
liver, and/or exposure to the cytokine and antigenic milieu is enough to drive generation 
of resident T cells in the liver. As Pallett et al. show that CD8+ TRM can be similarly induced 
with IL-15 (or antigen) and TGF-b148, perhaps similar signals in the context of the liver 
stroma are what is generating the CD4+ CD69HI TRM cells, a concept we are eager to put 
to the test. 
 
Together these data suggest CD69INT cells develop from direct contact with hepatic 
epithelia in the liver, and additional signals may cause the development of CD69HI cells. 
 
5.8.6 Conclusions & future work 
 
In conclusion, we have found two phenotypically and functionally distinct liver CD4+ 
populations based on differential CD69 expression. Our data strongly suggest that the 
CD69HI cells are the resident population in the liver. Profiling of residence-associated 
markers, chemokine receptors, differentiation markers, and coinhibitory molecules 
revealed significant alignments of our CD69HI cells with both CD4+ TRM from other 
organs88, 90, 91, 135, and CD8+ TRM from the liver148, 149, allowing us to place these cells in 
the matrix of human TRM with confidence. The biggest key question that remains is what 
are the roles of the newly identified CD69INT cells, a question made more difficult to 
answer by the heterogeneous nature of this population. Based on our data, and excerpts 
from the data from others, we have proposed three linked hypotheses (Fig. 6.1). The first 
proposes that CD69INT cells are a transitional population, en route to becoming full-
fledged CD69HI resident cells. This is supported by many residency-associated 
phenotypic markers being partially expressed on CD69INT cells, and their apparent need 
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for contact with hepatic epithelia in order to develop. Perhaps further signals are needed 
in order to drive high CD69 expression and the associated full residence phenotype, as 
supported by our preliminary liver slice findings. The second hypothesis postulates that 
CD69INT cells represent a short-term, or transiently resident population that remain in the 
liver longer than recirculating CD69- cells, but do not persist long-term like CD69HI cells. 
Partial residence marker expression would also argue for this, as well as some evidence 
from the literature of modulation of CD69 upon tissue egress213, and recirculation of cells 
expressing intermediate CD69 levels in mice153. It follows that if this were the case, 
CD69INT cells would lose CD69 expression before leaving the liver. Of course, these 
hypotheses are not mutually exclusive.  It is conceivable that a third possibility exists 
where CD69INT could be  short-term resident cells that can undergo bidirectional 
differentiation to either a CD69HI TRM cell, or a CD69- non-resident cell, in a signal-
dependent manner. Just like in SLOs where CD69 is expressed for sufficient time to allow 
naive T cells chance to receive appropriate activation signals31, CD69INT cells could 
remain in the liver for a limited time and if no appropriate signals (antigenic or otherwise) 
are received, the cells downregulate CD69 and return to the circulation. The expanded 
rationales behind all three hypotheses, and possible ways to test them will be discussed 
in greater detail in chapter 6. 
 
Through this work we have delved deep into the biology of intrahepatic CD4+ T cell 
populations in order to understand how these cells might work in inflammation and 
homeostasis. We have now built a platform on which to investigate both hepatic CD4+ 
CD69HI TRM and CD69INT cells, including their roles in specific diseases, and uncovering 
their preferred tissue niches and migration patterns. We can use this knowledge to further 
understand the generation requirements for both cell types, and in turn use this to uncover 
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the true roles of CD69INT cells in the liver. Answering these questions will aid the field in 
understanding of immune tolerance, and hepatic immune memory; as well as ultimately 
helping us combat liver pathology.  
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Chapter 6 - Discussion 
  
 248 
6.1 Summary of findings 
 
6.1.1 Modelling CD4+ T cell transmigration into the liver parenchyma 
 
The data presented in chapter 3 puts forward the idea that transwell migration through 
hepatic epithelia may be used as a tool for isolating CD4+ T cell populations. Migrated 
populations were able to better produce TNF-a, IFN-g and IL-4; were enriched for TEM 
and TEMRA phenotypes, and presented with a distinct activated profile. Most significantly, 
CD4+ T cells from different chronic liver disease origins revealed intrinsic, disease-
specific dispositions, that were only identifiable through the use of these migration 
assays. Whether we have accurately replicated transmigration into the parenchyma 
remains to be seen, but the strong possibility remains that migration assays reveal 
populations important in disease processes, and may also be able to act as a disease 
profiling mechanism. 
 
While it is tempting to propose that transwell assays could be used for diagnostic 
purposes, only needing blood samples and with the ability to screen for multiple liver 
diseases at once, the reality is that there are more effective tools for this purpose. Liver 
biopsy is often no longer necessary for diagnosing PBC or HCV680, 681, and the presence 
of specific auto-antibodies or anti-HCV antibodies in the serum is undoubtedly more 
accurate than monitoring directional cytokine changes in CD4+ T cells. Instead, we 
believe the greatest potential in this work lies in understanding disease mechanisms by 
studying the phenotypic and functional properties of CD4+ T cells likely best able to 
migrate into the heart of the diseased parenchyma. 
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Discovering the meaning behind the distinctions in cytokine profiles across different 
diseases will be of great importance. If the changes to the population we have shown 
following migration through hepatoma cell lines (the transmigration effect) is accurately 
recapitulated using primary hepatocytes, we can start to gather a wealth of information 
on what happens to a T cell after migration through HSEC, but before re-entry to the 
circulation, a topic that has been grossly understudied. We can also determine whether 
the differences seen in PBC and HCV are linked to disease pathology. Additionally, 
coupling this work to our other studies, we now know migration through hepatocytes is 
not enough to trigger induction of CD69INT or CD69HI TRM phenotypes. Instead a period 
of contact is needed, although this may not necessarily be long – 2h was sufficient to see 
a modest upregulation of CD69 in culture (see section 4.4). Therefore, the most activated, 
migration-capable cells may not be the same precursors that form TRM, as supported by 
CD69HI TRM favouring resting, non-activated phenotypes (section 5.4). Instead, rapidly 
migrating cells may not have long enough contact time with hepatocytes for their 
phenotype to be largely altered. It will be fascinating in the future to determine the different 
roles of migratory recirculating cells, and TRM in the liver in both immune homeostasis and 
disease. 
 
6.1.2 Implications of CD69 upregulation on CD4+ T cells with hepatocyte contact 
 
Co-culture of peripheral blood-derived CD4+ T cells with hepatocyte cell lines and primary 
BEC led to a robust upregulation of CD69. This phenotypic change was not only 
independent of activation (showing CD69 upregulation to an intermediate level, and no 
associated changes in other activation markers, or proliferative status compared to 
conventional activation stimuli), but also did not reflect a switch to a novel regulatory 
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phenotype as demonstrated through in vitro suppression assays. Instead, in chapter 5 
we suggested that the CD69 upregulation is modelling differentiation into a phenotypically 
similar CD69INT phenotype seen in the liver. Furthermore, we began to investigate the 
mechanism behind the phenomenon, proving an active and rapid, contact-dependent 
process with potential, yet inconclusive, ICAM-1 involvement.  
 
While we have not yet elucidated the key molecular determinants of CD69 induction, our 
current data prepares us well. First, we know that CD69 upregulation can happen to a 
wide variety of cells, but is more efficient in activated memory cell types. This tells us the 
molecules involved must be fairly T cell ubiquitous, making ICAM-1 and CD58 good 
candidate molecules as their receptors LFA-1 and CD2 are expressed on all T cells, and 
ICAM-1 increases in expression and changes to a more active confirmation on activated 
and memory T cells [refs 682-685  and my own unpublished data]. Second, we know the T 
cell requires cell contact with the hepatocyte, making these same target ligands possible. 
Third, we know the process is active from the hepatocyte standpoint, and begins rapidly 
following cell-contact. ICAM-1 expression on endothelial cells and hepatocyte cell lines 
could be induced rapidly (by 4 hours)643, 686, supporting the possibility of its involvement. 
Fourth, we know that both ICAM-1 and CD58 are costimulatory ligands and therefore can 
increase activation in conjunction with TCR stimulation683, 687, and for ICAM-1 at least, 
CD69 expression can be triggered in the absence of antigen recognition633. Therefore, 
ICAM-1 and CD58, known to be expressed on human hepatocytes643, are good candidate 
molecules for us to continue our investigation in many different ways. An alternative 
approach would be to utilise RNA sequencing to assay the Huh-7 cells, CD69+ hTCs, and 
CD69- hTCs. This would allow for the screening of differentially expressed receptors 
between the two T cell subsets, and allow alignment with any potential ligands expressed 
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on the Huh-7 cells. Expression of any candidate molecules could then be confirmed at 
the protein level, before they are blocked with antibodies or silenced genetically so CD69 
upregulation in T cells can be monitored. Any candidates could then be tested in primary 
cells, first BEC, then PHH in the future. 
 
Next, we must consider how determining the mechanism behind CD69 induction would 
benefit the field. We are currently hypothesising that liver CD69INT CD4+ T cells represent 
either a short-term resident population and/or a transitionary precursor of CD69HI ‘true’ 
TRM cells (see 6.1.3). Based on current evidence, the co-culture-induced CD69+ CD4+ T 
cells appear to mimic these CD69INT liver cells. Therefore, if translatable to primary cells, 
determining the mechanism behind CD69 induction would for the first time show how 
CD4+ T cells begin to acquire residence properties in the liver. CD69 is key in initial 
residence formation in CD8+ T cells158, and important for multiple arms of the residence 
cascade, explaining why it is the central molecule in human TRM-programmes30, 91. 
Strikingly, LFA-1 – ICAM-1 interactions were necessary for the maintenance of murine 
liver CD8+ TRM in the sinusoids651. Perhaps then a similar mechanism is at play for human 
hepatic CD4+ TRM. ICAM-1 and CD58 are both increased in expression on hepatocytes 
after stimulation or in pro-inflammatory environments628, 630, 631. Conceivably, interaction 
with these molecules in the liver, either alone or in combination with antigen, provides 
cues to differentiate into either CD69INT or CD69HI TRM phenotypes. It may be, as Pallett 
et al. suggest, that following these cell-surface signals, cytokines or antigen are required 
to push T cells into the full CD69HI TRM phenotype, a possibility we are excited to 
investigate148. If ICAM-1-LFA-1 interactions do turn out to be responsible, this represents 
a key step in understanding the settlement of these vital immune cells. In conclusion, we 
believe cell-surface ligands ICAM-1 and CD58 are two high potential molecules to 
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investigate in the CD69 upregulation mechanism, the revealing of which could have 
crucial implications for understanding the initiation of T cell retention in the liver, and 
ultimately the triggering of highly potent, disease relevant CD69HI TRM cells. 
 
6.1.3 In vivo CD69INT and CD69HI population relationships 
 
Moving on to look at intrahepatic T cells, we isolated and defined three CD4+ T cell 
populations based on CD69 expression – CD69-, CD69INT, and CD69HI. CD69HI were 
deemed tissue-resident based on universal liver presence, and phenotypic and functional 
expression patterns allowing us to comfortably place them amongst other human tissue 
resident T cell types previously described. CD69INT were more difficult to define due to 
their previously undescribed nature, large heterogeneity, partial residence expression 
patterns and possession of a wide range of homing receptors. Moreover, a phenotype 
remarkably similar to liver CD69INT cells could be generated from blood CD4+ T cells 
through simple co-culture with hepatic epithelia, hinting at similar generation pathways in 
the liver. 
 
The next important question to answer is what are the roles of CD69INT cells in the human 
liver. Based on our data and from others, we devised three hypotheses to test (Fig. 6.1): 
 
i. CD69INT are a transitional population, a precursor of CD69HI cells 
ii. CD69INT are a short-term resident population, able to convert to CD69- cells 
upon liver exit 
!),+!
iii.! Both the above are true. CD69INT cells contain both short-term residents able 
to convert to CD69- and exit liver, and differentiate into CD69HI to become long-
term residents.
 
 
 
!
 
Figure706.1 – Hypothesised roles of liver CD4+ CD69INT cells. The diagram represents the liver 
vasculature and liver parenchyma as two separate compartments. We believe CD69- CD4+ T cells 
differentiate into CD69INT cells following contact with liver parenchymal cells (Hepatocytes, BEC), based on 
our hepatic cell co-culture and liver slice culture data. From here we believe one or both of two hypotheses 
is likely true. In the first situation (i – red arrow), CD69INT cells can become long-lived CD69HI TRM cells upon 
receiving yet undefined signals, most likely cytokine and/or antigenic in nature (represented with red 
lightning bolt). In the second situation (ii – blue arrows), CD69INT cells spend a short period of time in the 
liver, before downregulating CD69 expression and returning the circulation. Number of clock symbols 
represent relative dwell time: 1 - short-term, 2 - long term. 
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To our knowledge, ours is the first description of a distinct CD69INT phenotype in T cells 
in humans. Using parabiotic mice, Skon et al. described a rare population of CD8+ cells 
that also expressed CD69 and KLF-2 at intermediate levels. These cells were 
recirculating, not resident, reaching NLTs of the parabiont mouse. The authors could not 
answer whether such cells were in the process of joining the TRM population, or ready to 
re-join the circulation, lending equal support to all of our hypotheses153. Assumedly, 
partial KLF-2 downregulation would lead to incomplete S1PR1 reduction, as seen in our 
liver CD69INT cells. Thome et al. have reported the most activated human T cell 
populations re-enter the circulation, which matches the CD69INT population in our study90. 
Additionally, the ‘migratory memory’ (TMM) cells in human skin grafts described by 
Watanabe et al. also share features with our liver CD69INT cells152. Although no data on 
CD69 expression levels per cell in this population was shown, the authors state that 
approximately a third of these cells expressed CD69, and some data indicated their 
slower migration through skin than TCM. These cells made up the predominant skin-tropic 
population in the blood, and interestingly (like our liver CD69INT) were good IL-4 producers 
following stimulation, although these comparisons were done using blood, not tissue 
populations. However, a major difference between these cells and ours was the TMM cells 
were of the central memory lineage152. Nonetheless, the authors also suggest their TMM 
cells may be in a transitional residency state, much like we have proposed for our CD69INT 
cells152. Gerlach et al. showed that CD8+ T cells expressing CX3CR1 at an intermediate 
level were the major population entering NLTs of mice671. As our CD69INT cells were the 
highest CX3CR1-expressing cells amongst liver CD4+ T cells, this study provides an 
argument for these cells being a TRM precursor. Another study has demonstrated the up-
, and down-regulation of CD69 on CD4+ T cells upon respective entry and exit to the skin 
in mice213, heavily supportive of a short-term resident population that could be analogous 
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to ours. Others have also reported the shorter tissue-dwell times of CD4+ T cells 
compared to CD8+ 218, and perhaps some of this difference is down to the CD69INT CD4+ 
population that has not been found in CD8+ T cells. Finally, Sakai et al. describe a 
CX3CR1+KLRG-1HI lung-vasculature resident CD4+ T cell population in mice that semi-
parallels our CD69INT cells. Although this population did not express CD69 appreciably, 
they were able to lose their residence properties and migrate to multiple locations 
following adoptive transfer, unlike the CD69+ lung-parenchymal resident cells that 
preferentially migrated back to the lungs112. This argues for a less committed resident 
role, that could support either a more short-term dwell time, as well as a TRM precursor 
population. 
 
Thus, using the literature alone cannot provide enough evidence to skew us towards 
either hypothesis, largely due to the lack of strongly applicable data. Lessons from our 
own data will help to shape our future research more. Expression of many of our 
phenotypic markers correlated directly with CD69 expression, supporting a transitional 
phenotype as cells transform from CD69- to resident CD69HI. Also in support of our first 
hypothesis, culturing with liver slices allowed for the generation of CD69HI cells, building 
on the CD69INT generation seen with hepatic epithelia culture. This suggests that 
additional signals provided by the liver microenvironment may drive CD69INT cells towards 
a CD69HI phenotype. However, some of our data argues against this hypothesis as not 
all markers followed simple correlations with CD69. Lack of KLRG-1 appears important 
in the generation of TRM cells110, yet our CD69INT cells have much higher KLRG-1 
expression than CD69HI cells. Functionally, the TH2 cytokine-favouring CD69INT cells 
would also have to lose this cytokine production ability to become a more TH1-skewed 
CD69HI population if the first hypothesis was correct, a switch that is possible, but perhaps 
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unlikely. On the other hand, given the heterogeneity of the CD69INT pool, perhaps only 
some cells are able to convert, countering above arguments on non-linear surface antigen 
relationships, KLRG-1 preferences and cytokine switching. 
 
In favour of the second hypothesis, our CD69INT cells express a partial residence profile, 
but still retain S1PR1 expression. This latter feature means that they are unlikely to be 
resident by traditional definition (long-term), but none have yet described features of a 
transient/short-term population. Perhaps when researchers see discrepancies such as 
CD69- resident cells87, or modulations in CD69 expression upon entry and exit213, this is 
actually reflective of short-term residence. It is very plausible that tissue-residence is a 
continuum, instead of a binary situation that many are treating it as. The liver CD69INT 
cells we describe are the most activated subset, and it is the most activated cells that 
have been shown to be able to recirculate90. Additionally, they possess the widest homing 
receptor profiles, suggesting they have not settled in a liver niche, and can presumably 
migrate to the gut through CCR9 expression. In terms of naïve/memory profiles, CD69INT 
were most similar phenotypically to CD69- cells so perhaps interconversion with this 
phenotype was easier than with the more distinct CD69HI cells (although this would be 
best tested with analysis of transcription factor profiles). 
 
Of course, the third hypothesis (that CD69INT cells contain both short-term resident cells 
and subsets able to differentiate into CD69HI TRM) could also be true. A lot of arguments 
from the literature suggest both possibilities. From our data, it could be that the CD69INT 
pool contains both precursors able to convert to CD69HI TRM, and cells that can move 
back towards CD69- cells after a short residency period. While we cannot favour one 
hypothesis at the current time, we can devise experiments to test them all. Extended 
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monitoring of CD69INT hTCs would allow us to see whether additional signals such as 
cytokines or antigen stimulation would push these cells to a CD69HI phenotype. Parallel 
experiments could dissect the components involved in the generation of CD69HI in liver 
slice culture, perhaps by blocking certain cytokines or cellular interactions, before setting 
up simpler cultures with individual liver cell types. Further, we could culture liver-isolated 
CD69INT cells under different stimulatory conditions, in the hope of generating CD69HI 
cells, although feasibility would depend on the survival times of these cells in culture. 
Better determining where both CD4+ CD69INT and CD4+ CD69HI cells are located in the 
liver may give us additional clues about what liver parenchymal or stromal cells are 
involved in their maintenance and potential interconversion. Ascertaining whether 
analogous populations exist in mouse livers would allow tracking experiments, genetic 
manipulations and precise time-course experiments to monitor any differentiation and 
residency periods of CD69INT cells. Lastly, full transcriptomic analyses of the different cell 
types would allow us to compare thousands of genes between CD69INT and CD69HI, 
answering whether they are genetically related, and thus more likely to possess a 
precursor-product relationship. 
 
6.2 Limitations of studies 
 
The major limitation of the transwell migration assays used in chapter 3 and the static co-
culture assays used in chapters 4 and 5 were the use of tumour cell lines instead of 
primary cells. Cell lines are much more robust, and with careful culturing are in ample 
supply. The Huh-7 cells that we used for the majority of our experiments have also been 
particularly well studied688. While it is imperative we compare our findings to primary 
hepatocytes in the future, we believe that Huh-7 cell lines have given us a good platform 
to build on, allowing us to collect data reproducibly. Furthermore, analogous results with 
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BEC and liver slices in co-culture experiments increase our confidence that we were not 
observing a tumour-related effect in CD69 induction and associated phenotypic changes.  
 
For the ex vivo liver characterisation work, the use of CD69 could represent another 
limitation. As discussed, some have argued that CD69 is not a perfect marker of TRM 
cells87, 213, although no evidence points to this in humans91, 214. Ideally, tissue-residence 
would be proved by demonstrating a clear lack of recirculation of these cells as done by 
using parabiotic mice, but these type experiments clearly cannot be performed in 
humans. The closest substitute others have used are antibodies to deplete circulating 
cells150, human skin grafting into mice152, or the study of repeated organ transplant 
recipients646. The feasibility of using the latter example to extend our studies will be 
discussed in the next section. Nonetheless, most, if not all, human TRM studies have used 
CD69 as their primary residency marker allowing us easy intra-study comparisons. Thus, 
while CD69 may not be a completely perfect marker, we believe its use here can be more 
than justified. 
 
Flow cytometry was the predominantly used end-result assay in these studies. 
Undoubtedly a powerful technique, there are obvious limitations with background 
fluorescence, fluorescence overlap, and undetectable antibody binding that we have 
done our utmost to minimise through the use of proper fluorescence minus one/isotype-
matched controls, thorough compensation, and proper antibody screening and titration 
respectively. Panel size was occasionally an issue as with a 9-colour limit we were 
sometimes unable to look for all the marker associations we wanted to (pertinent for the 
ex vivo characterisation), or include important controls such as a live/dead marker 
(pertinent for suppression assays in chapter 4). This also relates to the use of flow 
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cytometry-linked bioinformatics that would have been extremely helpful in picking up 
marker associations in certain populations that we might have missed or were not 
realistically feasible to assess by repeated manual gating. Mass cytometry allows for over 
30 parameters to be detected simultaneously, however it is laborious to analyse and 
unrealistic to perform for over fifty livers tested in this work within the given time frame. 
However, multi-parametric flow cytometry allowed the characterisation of 35 phenotypic 
markers and 8 intracellular cytokines in this study, the most comprehensive 
characterisation of human liver CD4+ T cells to date.  
 
The poor survival of LIMCs in culture limited our study of their long-term responsiveness 
to stimuli. NLT immune cells are known to be particularly susceptible to death in culture71, 
170, presumably due to their removal from key tissue-rich survival factors they require. 
Until better culture methods are developed that allow LIMC survival without drastically 
altering their phenotype, this limitation will be difficult to overcome. More advanced culture 
systems such as liver microchips573 may prove useful in this, while in themselves 
providing us better and more physiological models to study migration, allowing us to 
overcome the limitations of the relatively simple transwell migration assays. 
 
Finally, as with all human studies, patient variability, sample size, and disease staging 
and management all play a role in shaping the results. In these studies, we have used 
mostly HFE patient blood as healthy controls. Our department has used this material with 
minimum resistance from the field for many years, as the immune cells are thought to be 
largely unaffected by liver pathology in this disease. However, this may not be a fool proof 
assessment, as some alterations in CD8+ (though not CD4+) T cell numbers and 
phenotypes have been reported689, 690. For liver samples, we have compared the 
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frequencies of CD69-, CD69INT, and CD69HI CD4+ T cells in various end stage diseases, 
finding no proportional differences. This is not unexpected, given that end stage diseases 
share features of chronic inflammation that has led to fibrosis and cirrhosis. Antigen-
driven autoimmune disorders such as AIH, PBC and PSC can resemble metabolic injuries 
such as high alcohol or high fat diet from an immunological perspective, as liver damage 
can result in neoantigen expression and local autoinflammatory injury. Of note, in the 8 
livers with NASH tested, we did not observe a reduction in CD4+ T cell numbers 
compared to other diseases, as reported in one study453; and nor did we see large 
elevations in TREG frequencies in HCV livers like others have reported, albeit only with 
n=2 here518. We have therefore grouped all chronic liver diseases together and so effects 
of different treatment regimens, disease stages, and patient demographics would have 
had a smaller impact than if investigating a disease-specific effect more susceptible to 
these compounding factors. This impact is decreased further by our relatively large 
sample sizes for the liver. Number of healthy donor livers is a bigger influence on our 
interpretations. Many of the donor livers used had been rejected for transplantation based 
on being too steatotic or due to surgical logistic reasons. Both of these factors could affect 
the cells’ viability and phenotypes. Furthermore, donor tissue is much more infrequently 
available, yet ideally more ‘healthy’ donor data would be needed in our study to provide 
statistically significant data that back up the trends seen that match the diseased liver 
groups. Alternative sources of ‘healthy’ donor tissue have been suggested to come from 
tumour-free areas of liver cancer patients that undergo resection surgery, or patients with 
colorectal metastases in the liver; or from cyst-free areas of polycystic liver patients. None 
of these solutions are ideal however, as the impact of these diseases on T cell biology is 
largely unknown. Last, patient variability means that true differences are sometimes 
masked, and while with large sample numbers the true differences emerge through 
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statistical analysis, sufficient sample sizes have only been reached with most, not all of 
my data. 
 
6.3 Future work 
 
Our main future focusses in modelling transmigration of CD4+ T cells into the liver are in 
expanding the diseases tested, determining disease relevance and expanding these data 
to more physiological systems. Determining the post-migrated cytokine potential of CD4+ 
from other liver diseases such as HBV and PSC would allow for the expansion of our 
portfolio, in the hope of strengthening the transwell migration model. This would be most 
beneficial if disease relevance could be proved. We hypothesise that the more activated, 
more pro-inflammatory CD4+ T cells separated out by migration are similar to the cells 
that would migrate into the hepatic parenchyma, and so by extension may participate in 
disease pathology and tissue damage. Downstream assays we could use to test these 
suspicions include antigen-presentation assays (with disease-specific antigens), further 
assessment of activation and exhaustion markers post-migration, or even transfer of 
these populations to humanised mouse models of liver disease. Lastly, the future use of 
more physiologically representative models of the human liver, such as the increasingly 
popular aforementioned liver chip system, will help translate these findings to human 
disease mechanisms. 
 
The most pressing issue when studying CD69 upregulation in vitro is to uncover the 
mechanism behind this process, as discussed in depth above (sections 4.5, 6.1.2). This 
could either involve short term approaches of interfering with ICAM-1 - LFA-1, and/or 
CD58 – CD2 interactions; or more detailed whole transcriptome analyses to pick up likely 
candidate molecules from both hepatocyte and induced T cell perspectives. Another facet 
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of this overall project that might be worth studying is to address the issue of CD69+ cell-
associated suppression. We concluded that suppression was unlikely in these cells, but 
results were occasionally contradictory and confusing. What is likely needed here is 
robust comparisons with isolated conventional TREG if possible, cell-sorted CD69+ and 
CD69- hTC populations, upscaling of the plate well size so to remove competition for 
space as an issue, and the exclusion of dead cells with appropriate markers. 
 
Key expansions in the hepatic CD4+ T cells project would include first full transcriptomic 
analyses of the three intrahepatic CD4+ T cell populations. This would involve the use of 
RNA sequencing or microarray technologies, similar to other human TRM studies we have 
compared our data with91, 134, 135. Thousands of transcripts would be compared, hopefully 
identifying many more key differences between the populations. This would not only 
further inform us on how the liver CD69HI TRM differ from described TRM in different organs, 
but also how they differ from the liver CD69INT cells that could give more information on 
their specific roles. Further any shared transcriptional regulators between the populations 
would point to potential for subset interconversion. Thanks to other transcriptomic 
analyses in the literature, this need not be entirely a fishing exercise. Some have pointed 
to glucose deprivation and hypoxia signatures in lung TRM134, 135  that would be of interest 
to study in the liver. We could also look at chemokine production by liver TRM, allowing 
their implication in auxiliary immune cell recruitment134, 135. Likewise, determining whether 
Notch-1 or any related pathway components are upregulated in liver CD4+ TRM, as seen 
in lung TRM, would be key in helping to establish whether Notch-1 is a universal regulator 
of human TRM maintenance134, 135. This would be a particularly exciting scenario, as many 
pharmaceutical Notch inhibitors have been developed, offering the possibility to 
specifically target TRM691. 
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We would also like to investigate the generation of both CD69-expressing subsets in in 
vitro systems more, as discussed in sections 5.8.5 and 6.1.3. It is inferred that in addition 
to undefined cell-surface signals that trigger development of the CD69INT phenotype, 
specific cytokine or antigenic signals are required to push further development into 
CD69HI TRM-like cells. We would carry out parallel work to investigate both these steps, 
investigating both the initial CD69 upregulation mechanism that may be ICAM-1-, or 
CD58-dependent, before aiming to define the additional signals needed for CD69HI cell 
generation. For this latter part, we would start with sequential addition of IL-15, then TGF-
b in a similar manner to Pallett et al.148. Transcriptomic analyses may also be of use in 
generation studies too, informing us of differentially expressed transcripts in CD69INT and 
CD69HI cells, isolated both ex vivo and generated in vitro, that would allow a targeted 
approach. 
 
Differentially expressed transcripts would need confirming at protein level, and this could 
be done by more flow cytometry, or higher-parameter mass cytometry, as performed by 
Wong et al in their multi-organ approach82. The inclusion of more parameters would allow 
us to look at other populations in the liver, starting with conventional CD8+ T cells. 
Although others have performed comprehensive studies on liver CD8+ TRM148, none have 
specifically looked for CD69INT CD8+ T cells, and there is great value in comparing 
populations from the same livers too. 
 
I previously alluded to the benefits of incorporating bioinformatics into multi-parameter 
flow cytometry analyses. The example given was to see if the variety of homing receptors 
expressed by the CD69INT pool clustered together or formed separate subsets. Many 
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similar questions could be answered by clustering analyses such as t-distributed 
stochastic neighbour embedding (t-SNE), where all parameters are compared against all 
others and visualised in two dimensions, as many groups are performing now. For 
example, we could assess whether CD69HI and CD69INT cells with different cytokine 
preferences have different homing receptor preferences, or favoured a different KLRG-
1/CD127 designation. The dangers of these are the loss of hypothesis-driven directions 
in the research, but on the plus side many unknown antigen co-localisation patterns could 
be uncovered. The heterogeneity of human cells compared to mouse, both within 
individuals and donor groups, strengthen the need for this type of research. 
 
We, like many others, have used CD69 as the principal marker of tissue residence here. 
However, our data argue that CD69INT cells can recirculate, whereas CD69HI cells were 
the most likely resident type. We therefore discourage the use of CD69 as a binary marker 
of tissue residence and instead suggest the high expression of CD69 is an even better 
indicator. Despite the strength of this marker, it would of course be beneficial to formally 
prove our CD69HI CD4+ T cells do not recirculate. The most feasible way to do this would 
be to mimic the approach of Cuff et al. who proved long-term residence in NK cells in 
patients with multiple liver transplants. By monitoring patients with HLA-mismatched 
transplants, the authors were able to prove the putative resident NK donor cells remained 
in the livers up to 13 years after transplant646. This would work just as well for our CD69HI 
TRM, and short-term residence could be proved without the need to wait for a second 
transplant by taking blood both pre- and post-transplant and comparing it with liver 
perfusate. The presence of CD69HI cells in the perfusate, but their absence in post-
transplant blood would indicate their true-resident status, although modulation of CD69 
expression on liver egress could not be ruled out. Also, unless CD4+ TRM were similarly 
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present in the liver perfusate when compared to digested liver tissue, (like the NK cells 
described646), donor liver tissue biopsies would also be required. 
 
Additionally, we would seek to extend our imaging of the different CD4+ T cell subsets in 
the human liver. The preliminary data we have at present could be extended by finding 
reliable CD4 and CD69 immunofluorescence antibodies that fit in with CXCR6, CX3CR1 
and NkP46 in antibody panels. This would allow us to verify  the distribution of CD69INT 
and CD69HI cells in the liver.  
 
Cementing our TRM population in the human TRM matrix further, it would be fascinating to 
study the metabolism of these cells. One candidate method to do this would be the use 
of Seahorse analysers (Agilent technologies, UK) that efficiently measure both 
mitochondrial respiration and glycolysis in real-time. Murine TRM have recently been 
shown to adapt to consume free fatty acids that feed into oxidative phosphorylation 
pathways in order to survive for elongated periods in the skin114, 692. Determining whether 
liver CD4+ TRM are similar to this published study, and the contribution of glycolysis versus 
oxidative phosphorylation would be of great benefit to understanding the lives of these 
cells. These experiments would once again give us more ideas about the roles of CD69INT 
cells through their survival tactics. 
 
Finally, ascertaining whether either CD69-expressing population is disease relevant will 
be important. We have looked at relative frequencies in autoimmune liver diseases and 
dietary liver injury, but would like to extend this to viral liver disease as others have 
done148, 384. Given the importance of TRM cells in perpetuating, as well as controlling 
disease, we would expect CD69HI CD4+ TRM to be key in all liver pathologies. Therefore, 
 266 
collecting more donors will allow for comparison of activation states and cytokine 
production ability across the different disease groups as part of an extended phenotypic 
and functional characterisation. These data would give researchers an idea of the CD4+ 
T cell populations most important in the different diseases, along with indications on how 
to specifically target them therapeutically. 
 
6.4 Conclusions 
 
 
 
 
Here we have explored multiple aspects of hepatic CD4+ T cell biology, from the initial 
migration into the liver, to the short-term impact of hepatocytes on CD4+ T cell phenotype 
and function, to the adaptations of long-term liver resident CD4+ T cells (Box 6.1). 
Through modelling migration into the liver parenchyma, we found hepatocyte-selected 
migrated CD4+ T cells displayed intrinsic and disease-specific enhanced cytokine 
Chapter 6 – Core Findings and their Implications: 
 
• Modelling CD4+ T cell migration into the parenchyma revealed intrinsic chronic 
liver disease-specific differences in cytokine functionality, and may prove a 
useful way to study populations relevant to disease without the need to sample 
liver tissue 
• Co-culture of blood-derived CD4+ T cells with hepatic epithelia led to an 
activation-independent upregulation of CD69 that was also not linked to the 
acquisition of regulatory properties 
• CD69 was also an important discriminator of intrahepatic CD4+ T cells, allowing 
the divergence into CD69HI TRM that acquiesce with the field in terms of a resting, 
tissue restricted, but multifunctional cytokine-capable cell type; and a novel 
CD69INT population, distinct through their semi-residency-associated, activated 
profile and ability to make TH2 cytokines 
• Generation of phenotypically similar CD69INT and CD69HI CD4+ cells from blood 
through culture with hepatic epithelia, and intact liver slices respectively hints at 
untapped developmental pathways required for TRM generation 
• Together the data provide the first full characterisation of liver CD4+ TRM and 
identify CD69INT cells that are likely TRM precursors and/or short-term resident 
liver cells; both likely important in immune homeostasis and disease 
pathogenesis 
Box 6 Box 6.1 – Core findings from these studies combined and the implications for immunology. 
 267 
potential, that we postulated could be relevant to individual disease processes. The 
finding that simple co-culture with hepatocyte cell lines caused intermediate level CD69 
upregulation in CD4+ T cells that did not coincide with conventional T cell activation or 
acquired regulatory properties, gave us insights on how hepatocyte contact alters CD4+ 
T cell phenotypes. This led to detailed characterisation of the entire intrahepatic CD4+ T 
cell compartment and accompanied revelations that the pool contained two CD69-
expressing subsets. The first was a putative TRM cell type, high for CD69 expression, with 
the greatest association with residence-associated markers, restricted homing receptor 
profile, mostly resting profile, and a tendency towards multifunctional TH1, and TH17 
cytokine production. The second, CD69INT, subset seemed often diametrically opposed: 
thought non-resident with the potential for egress, with a wide-ranging predicted pattern 
of intra-and extra-hepatic movement, previously activated, and additionally able to 
produce TH2 cytokines.  Last, we demonstrated that modelling short-term hepatocyte 
contact was enough to mimic the generation of a phenotypically similar CD69INT cell type, 
while the more complex liver microenvironment additionally created CD69HI cells. 
Combined these findings document the powerful influence the liver microenvironment can 
have on the biology of a T cell and open multiple avenues to investigate how these 
alterations play roles in different liver disease processes. The properties of the novel 
CD69INT cells are of particular importance, and may represent a step in unravelling the 
generation and maintenance of human liver CD4+ TRM, or in understanding tissue 
residency as a dwell-time-dependent continuum. 
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